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ABSTRACT 
Background: Excess white adipose tissue (WAT) in humans is considered as a 
harmful health index. However, increased brown adipose tissue (BAT) and brown-like 
adipose tissue activity are associated with increased resting energy expenditure (REE) 
that may help to control body weight. Exercise may enhance browning formation of 
WAT and reduce WAT that may lead to health improvements. Aims: a) to examine 
the effects of physical activity on the link between peroxisome proliferator-activated 
receptor gamma co-activator 1-alpha (PGC-1α) and fibronectin type III domain-
containing protein 5 (FNDC5) genes in muscle, circulating Irisin and uncoupling protein 
one (UCP1) of WAT in humans (study 1); b) to examine the relationship between 
UCP1 mRNA and protein expression as well as PGC-1α, peroxisome proliferator-
activated receptor alpha (PPARα) and PPARγ genes with physical activity levels in 
WAT of healthy men (study 2); c) to examine the effects of different types of exercise 
and de-training on the UCP1 mRNA and protein expression (study 3), and d) on leptin 
mRNA in WAT of healthy men (study 4). Method: Study 1: A systematic review was 
conducted using the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses. Studies 2-4: The total of 46 healthy men subjected to measurements for 
physical activity levels, diet, anthropometry, body composition, REE, peak oxygen 
consumption, 1-repetition maximum and provided subcutaneous fat biopsies to 
determine mRNA and protein expression of six genes in one cross-sectional study and 
one randomized controlled trial. Results: Study 1: No link was found between PGC-
1α and FNDC5, circulating Irisin and UCP1 of WAT in response to physical activity. 
Study 2: The mRNA of, UCP1, PGC-1α, PPARα and PPARγ genes of WAT were not 
associated with physical activity levels. The UCP1 protein expression however, was 
negatively associated with physical activity levels. Studies 3-4: Different types of 
chronic exercise and de-training do not affect UCP1 mRNA and protein expression 
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and leptin mRNA in WAT. However, effect size analyses demonstrated increased 
UCP1 mRNA and protein expression, PPARγ and leptin in response to chronic 
exercise. Conclusions: There is no evidence to support the link between PGC-1α and 
FNDC5 in human muscle or the link between FNDC5 and circulating Irisin and UCP1 
in WAT in response to exercise. There are no effects of exercise and de-training on 
browning formation of WAT and no link between browning formation indices and REE, 
body weight as well as leptin mRNA in healthy men. Further research is required to 
elaborate the aforementioned phenomena.  
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1. CHAPTER 1: INTRODUCTION 
Excessive adipose tissue is defined as an obesity state in humans and has been 
recognized as a harmful health index [1]. Specifically, obesity can lead to compromises 
in health, such as cardiovascular disease, type 2 diabetes (T2D), and hypertension [2-
5]. About 700 million adults are obese worldwide, while ~20 million children and ~2.3 
billion adults are overweight [6]. Excessive adipose tissue may disrupt biological 
processes such as immune function, insulin sensitivity, and blood pressure [7, 8] 
increasing the risk for disease in humans. Therefore, by increasing our knowledge on 
how to reduce the excessive adipose tissue in humans, it may help to lessen the risk 
of weight gain and disease.  
Exercise regulates hormonal activity within adipose tissue [9-13] and may 
reduce adipose tissue mass [14], particularly when this is in combination with caloric 
restriction [15]. Exercise also significantly reduces total and abdominal fat in obese 
individuals with T2D [16] and minimizes the risk for cardiovascular disease [15, 17]. 
On the other hand, physical inactivity is a risk factor for developing T2D [18] and has 
been linked to greater risks of morbidity and mortality than increased adipose tissue 
mass [19]. It is essential, therefore, to identify the exercise mechanisms that can 
reduce adipose tissue mass. 
Researchers have observed two types of human adipose tissue: brown and 
white [20-22]. Both tissues store energy and are considered as endocrine organs, 
however, they display different functions [23]. The main difference is that white 
adipose tissue (WAT) produces energy in the form of adenosine triphosphate (ATP) 
[24], whereas brown adipose tissue (BAT) uses energy to produce heat and maintain 
body temperature [25]. In other words, WAT stores calories as a “stock energy room”, 
while BAT spends energy for thermogenesis [26]. It was believed however, that BAT 
is present only in infants [27]. In 2009 it was confirmed that BAT is also active in 
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healthy adults after 2-hour of exposure to 16°C [21, 22], while increased BAT activity 
was associated with elevated daily resting energy expenditure (REE) [21]. Also, 
increased BAT activity has been associated with reduced body mass index (BMI) [28], 
age [29], and fat mass [21]. Finally, a recent study has found a positive association of 
BAT activity with increased physical activity levels in humans [29]. 
Recent research suggests that a third type of adipose tissue – the brown-like 
or beige adipose tissue – can play a significant role in human metabolism by increasing 
REE [30], and that exercise can change WAT to function in a brown-like mode. This 
was attributed to a newly discovered protein called Irisin, which is a fragment protein 
released by skeletal muscle during exercise [30]. However, current research shows 
conflicting results [31-34] and more investigation is needed into the role of Irisin in the 
human body, as well as the role of exercise in the browning process of WAT. This is 
because the methods used for circulating Irisin identification were questioned [35]. 
Also, the role of exercise on browning formation of WAT has not been extensively 
investigated in humans. Given also that adipose tissue has a significant impact on 
human metabolism, more research is needed that could direct potential therapeutic 
pathways through exercise on humans’ health and wellbeing. In this light, the current 
PhD study includes the first systematic review to date to examine the role of exercise 
on the browning formation of WAT in humans. Also, this PhD includes the first 
randomized controlled trial (RCT) to date to examine the effects of exercise training 
on a part of the mechanism of the browning formation of WAT, while it examined a 
specific mechanism of WAT related to appetite levels in humans. Finally, this PhD 
study examined for the first time the effects of de-training on the browning formation 
of WAT in humans.     
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2. CHAPTER 2: REVIEW OF LITERATURE 
Parts of the review of literature have been published in the peer-reviewed journal ISRN 
Physiology, vol. 2014, Article ID 964627, 11 pages, 2014. doi:10.1155/2014/964627, 
(Appendix 8) where the author of this Thesis also appears as the leading author.  
 
2.1. APPROACH 
The current review of literature will offer an overview of the function and activation of 
human adipose tissue. First, it will describe the phenomenon of obesity and the effects 
of exercise, highlight the function of WAT and the role of leptin and adiponectin in 
metabolism as well as their relationship to exercise. This will also display the role of 
WAT in human health. Secondly, it will describe the function and activation of BAT and 
its link with exercise and nutrition while a description of the function of brown-like 
adipose tissue and the role of four genes that indicate a browning process of WAT will 
be given. Finally, the role of exercise in brown-like adipose tissue formation will be 
discussed.  
 
2.2. THE PHENOMENON OF OBESITY 
Obesity is characterized by the presence of excessive weight primarily in the form of 
excessive adipose tissue [36]. Clinical practise indicates that an individual is defined 
as obese when he/she displays a Body Mass Index (BMI) ≥ 30 kg/m2. Increased BMI 
is a major risk factor for heart disease, stroke, T2D, musculoskeletal disorders and 
endometrial, breast and colon cancers [37-40]. BMI is used to describe general body 
mass and to estimate adiposity. It generally displays small margin errors and is 
suitable for identifying trends within sedentary or overweight populations [41], by 
simply dividing weight (kg) by height (m) squared [6]. The BMI categories can be found 
in Table 1. 
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Table 1: Body mass index categories 
Category Value 
Underweight <19 kg/m2 
Normal weight 19-24.9 kg/m2 
Overweight 25-29.9 kg/m2 
Class I obese 30-34.9 kg/m2 
Class II obese >35 kg/m2 
kg:kilograms; m: meters 
Another index of increased fat accumulation in humans is the waist to hip ratio 
(WHR). This is defined as the ratio of the smallest diameter of the waist circumference 
and the largest diameter of the hip circumference. WHR >1 in men and >0.85 in 
women is considered a risk of abdominal obesity [42] and an independent risk factor 
for cardiovascular disease [43]. However, neither BMI nor WHR actually describe the 
composition of the human body and should be used with that limitation in mind. They 
are both useful for showing general correlations regarding obesity whereas it is BMI 
that has been used extensively by clinical practise and by the World Health 
Organization to record obesity statistics [44].  
In the absence of an underlying pathology, obesity is mainly caused by an 
energy imbalance between calories consumed and calories expended [45, 46]. It may 
also be the result of genetic predisposition [47], medical conditions, or psychiatric 
illness [48]. Research indicates that most of the obesity cases worldwide are due to 
increased consumption of high-fat foods in conjunction with decreased physical 
activity [49, 50]. In developed countries, some argue that access to plenty of food [51] 
and reliance on vehicles for transport [52, 53] contribute to the observed increased 
obesity trends. This raises the debate as to whether the increased obesity rates are 
due to physical inactivity or poor diet. Some support the latter given that physical 
activity rates have not been changed significantly in recent times [54]. For instance, 
excess sugar consumption increases by 11-fold the prevalence of T2D independent 
of physical activity levels [55]. Other evidence indicates that up to 40% of people with 
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a normal BMI will develop hypertension, dyslipidaemia, and cardiovascular disease, 
conditions associated with obesity [56, 57] while the “western diet”, stress and sleep 
deprivation increase insulin resistance, leading to increased food intake [58-60].  
Contrary to the above, it has been claimed that daily physical activity has 
declined over the last decades [61], due to the increase in sedentary jobs [62] and  
that there is no firm data that people eat more calories per day nowadays than in 
previous decades [63]. This view suggests that physical activity cannot be taken out 
of the equation as a cause of human obesity. Evidence suggests that obesity 
increases with age [64-66], with ~700 million adults being obese now [6]. The global 
obesity prevalence in adults in 2014 is displayed in Figure 1.  
Figure 1: Global obesity prevalence in adults in 2014 
 
Europe, North America, Australia and North Asia display high prevalence of obesity 
cases (20-20.9%) in adults, while the United States of America displays the highest 
prevalence in obesity cases in adults worldwide (>30%). Africa (<10%) and South Asia 
(<10%) display the lowest prevalence in obesity cases in adults worldwide. 
Figure retrieved from the World Health Organization website: 
http://gamapserver.who.int/mapLibrary/app/searchResults.aspx 
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Physical inactivity should be considered one of the main reasons of obesity [67] 
and the fourth highest risk factor for mortality worldwide [68]. In 2010, 23% of the adult 
and 80% of the adolescent population were physically inactive [68]. Insufficient 
physical activity levels may lead to cardiovascular disease, cancer and T2D [69]. 
Excessive body fat mass is associated with T2D in 64% of the cases in men and in 
77% of the cases in women [70]. Being physically active in combination with smoking 
cessation reduces the risk for coronary heart disease by 59%, the risk for mortality 
due to cardiovascular disease by 77% and the risk for all-cause mortality by 69% in 
men [71]. Increased fat mass is also associated with osteoarthritis, cancer, 
cardiovascular disease, non-alcoholic fatty liver disease [72-75], insulin resistance and 
pro-inflammatory [76] and pro-thrombotic states [77]. 
 
2.2.1. Physical activity, exercise and obesity 
Physical inactivity is defined as very low or no bodily movement that requires energy 
expenditure. On the other hand, physical activity is defined as the total of the daily 
movements produced by skeletal muscles causing energy expenditure including 
programmed exercise [78]. 
Overweight and obese individuals are usually recommended to eat less and be 
more physically active. These lifestyle changes are important as only ~25–30% of 
lifespan variation can be attributed to genetic factors [79, 80]. However, it remains 
difficult to prescribe an exact amount of exercise to prevent weight gain for obese and 
overweight populations. This is partly because each person requires an individual plan 
to maximize the benefits gained from exercise training. Nevertheless, evidence 
suggests that exercise has a dose-dependent relationship with health and that any 
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amount of exercise can be effective in weight management for overweight and obese 
individuals [81, 82].  
Exercise has also been shown to reduce adipose tissue mass and result in 
weight loss [83, 84]. Evidence suggests, however, that exercise-induced adaptations 
could occur independent of weight loss. Thirteen weeks of supervised aerobic exercise 
[60 minutes at 60% peak oxygen uptake (VO2peak)] significantly reduced total and 
abdominal fat in obese individuals with T2D [16], as well as minimized the presence 
of cardiovascular disease risk factors [17]. In addition, a 12-week exercise intervention 
[walking or light jogging on a treadmill, 5 times/week, 60% maximum oxygen uptake 
(VO2max), 60 min/session] reduced waist circumference in obese men with or without 
T2D [85]. 
A major concern for overweight and obese individuals is weight regain following 
a weight loss intervention. Hunter and colleagues [86] examined weight regain in 
healthy premenopausal overweight women after one year of following a dietary 
intervention in which the participants lost 12.3±2.5 kg. The results revealed that both 
aerobic and resistance training exercisers regained 3.5 kg after one year compared to 
6.4 kg of weight regained by the non-exercisers [86]. Thus, exercise has a critical role 
in the maintenance of body weight that should be included in lifestyle modification 
programmes. 
 
2.3. WHITE ADIPOSE TISSUE 
2.3.1. Function  
WAT stores energy in the form of lipids and provides insulation. It is also considered 
an endocrine organ [87, 88]. WAT has three main functions: a) lipids metabolism that 
includes storage of triglycerides and fatty acids, b) catabolism of triglycerides to 
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produce glycerol and fatty acids that are involved in glucose metabolism of several 
tissues and c) secretion of adipokines, including hormones that are involved in 
biological functions [89]. WAT also produces hormones and cytokines to regulate 
energy metabolism including, estrogen, resistin, tumor necrosis factor alpha (TNFα), 
leptin and adiponectin [87, 88, 90]. WAT is also involved in angiogenesis, 
adipogenesis, steroid metabolism, in haemostasis and the function of the immune 
system [91]. 
The size of white adipocytes is increased during positive energy balance 
(increased energy intake) and decreased when energy expenditure is more than the 
energy intake [87]. WAT can undergo hyperplasia mainly in the growth stage of an 
organism and also hypertrophy, which designates the regulation of the capacity of the 
adipocytes [92]. Subcutaneous adipose tissue (located underneath the skin) shows 
the different body composition of men and women and is mainly responsible for the 
thermal insulation [93]. Visceral adipose tissue (located between organs) maintains 
the integrity of organs [93]. These different locations designate its different functions. 
For instance, in the absence of a pathological condition in gluteal area, white 
adipocytes are larger in women than in men, which may indicate larger lipolysis rate 
in women [94, 95]. Under energy deprivation subcutaneous adipose tissue may be 
triggered faster than the visceral one, in order to release fatty acids for energy 
production [96]. However, excessive visceral and subcutaneous fat mass are 
associated with metabolic abnormalities: visceral mass and adipocyte size are 
positively correlated with insulin resistance [97, 98] while excessive subcutaneous 
adipose tissue may also be responsible for insulin resistance, hypertension and 
cardiovascular disease [99]. In humans, an overall percentage body fat of ≥ 25% in 
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men and ≥ 35% in women classifies obesity [100], which also strongly correlates with 
chronic inflammation that may lead to disease [101].  
 
2.3.2. White adipose tissue and inflammation 
Individuals suffer of chronic inflammation may experience macrophage infiltration of 
adipose tissue that leads to the production of cytokines, such as inteleukin-6 (IL-6) 
that activate the immune system, through the acute phase response [87, 102]. 
Additionally, chronically high levels of circulating inflammatory cytokines are 
associated with impaired insulin sensitivity that may indicate a high risk for T2D [76] 
as well as atherosclerosis [103]. Furthermore, increased levels of the pro-inflammatory 
biomarker TNFα appear to be associated with reduced circulating adiponectin 
concentrations that increase the risk for inflammation [104], while a potential 
mechanism for the increase in adiponectin is a reduction in circulating concentrations 
of TNFα [105]. A summary of the association of obesity with chronic inflammation can 
be found in Figure 2. 
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Figure 2: Obesity and chronic inflammation 
 
 
Abdominal obesity causes the production of tumor necrosis factor alpha (TNF-α) and 
interleukin 6 (IL-6), which may increase C-reactive protein (CRP) that enhances insulin 
resistance, hyperinsulinemia, hypertriglyceridemia and decreases high-density 
lipoprotein (HDL). This process may promote cardiovascular disease.  
 
During an inflammatory condition macrophages release IL-6 and other 
cytokines that trigger the acute phase response. Subsequently, the liver synthesizes 
and releases C-reactive protein (CRP) in the bloodstream. CRP is then overexpressed 
leading to further increase of cytokines [106]. A recent systematic review and meta-
analysis shows that exercise reduces CRP and IL-6 in T2D patients [107]. Regarding 
the acute effects of exercise, one study showed that after a single bout of exercise (on 
the treadmill at 55% of VO2max), IL-6 was significantly reduced in WAT in a group of 
obese men. However, there was no corresponding reduction in circulating IL-6, which 
may indicate a local adipose tissue anti-inflammatory response to acute exercise [17]. 
Evidence concerning the chronic effects of exercise shows a significant reduction in 
IL-6 in obese adolescent men following participation in a 12-week aerobic exercise 
programme [108]. Also, a 6-month aerobic exercise programme exerted anti-
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inflammatory effects in overweight individuals with T2D [109]. However, no changes 
in IL-6 and TNFα in overweight and obese post-menopausal women have been found 
following participation in 6 months of exercise training [110]. Broadly, IL-6 may be 
increased in response to exercise most likely because of the demand of energy from 
the muscle contraction and may act as a messenger for glucose production from the 
liver [111]. After exercise, however, IL-6 may have a suppressive effect on the immune 
system by triggering anti-inflammatory cytokines that may designate an anti-
inflammatory role of IL-6 [112].  
There is also evidence showing that a 6-month exercise programme reduced 
both CRP and fat mass in patients with rheumatoid arthritis [113]. This may indicate 
that the anti-inflammatory effects of exercise may also occur due to changes in body 
composition. Indeed, evidence showed that obese individuals reduced inflammatory 
markers, such as IL-6, TNFα and CRP, in response to long-term exercise [114]. 
Exercise may also improve endothelial dysfunction [112] that can produce IL-6 and 
promote inflammation [115]. These markers act peripherally and are positively 
correlated with the endothelial dysfunction [116]. In summary, exercise training 
appears to exert anti-inflammatory effects via the stimulation of anti-inflammatory 
cytokines (IL1Ra, sTNFr, IL-10) and the suppression of inflammatory cytokines (TNFα, 
IL1b) [117] that partly may be due to reductions in body weight, total body fat and 
visceral fat [118]. 
 
2.3.3. Leptin  
The understanding of the function of WAT changed when leptin (a protein mainly 
secreted by WAT) was discovered and its effects on central and peripheral organs 
were noted [47]. This helped determine the mechanisms of energy balance and 
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various physiological processes. Indeed, WAT is homeostatically controlled by leptin 
that regulates food intake and metabolism [119]. Leptin is an adipokine that is 
characterized as a satiety peptide because of its role in food intake regulation [120]. 
Leptin is formed by the ob gene that is thought to be responsible for the development 
of obesity [87, 121]. The mRNA of the ob gene reflects rates of leptin production [87], 
while the production of leptin in WAT is positively associated with the amount of body 
fat [122]. Fasting may inhibit the mRNA of ob gene in WAT that may lessen leptin 
concentrations in the bloodstream. This, however, is inversed in the re-feeding 
process [123, 124]. In order to regulate hunger, circulating leptin is detected by 
receptors in the hypothalamus, where it inhibits appetite [120]. Despite having greater 
concentrations of circulating leptin, obese individuals may experience a condition 
referred to as leptin resistance that leads to inadequate communication with the 
hypothalamus [120]. This may occur due to: a) general changes in leptin receptor 
signaling, b) alterations of leptin during the development phase, and c) changes in the 
way that leptin crosses the blood brain barrier that separates the circulating blood from 
the brain extracellular fluid [125]. Evidence suggests that leptin sensitivity affects 
lipolysis in adipose tissue and hepatic fatty acid uptake and oxidation [126]. Recent 
data, however, show that increased inflammatory cytokines and free fatty acid levels 
were associated with impaired leptin sensitivity in mice [127]. Indeed, circulating leptin 
in humans has been associated with greater levels of systemic inflammation and fat 
mass [120]. Thus, increased circulating leptin, potentially indicating leptin resistance, 
may be involved in enhancing adipose tissue accumulation [120].  
Leptin may also be involved in other physiological processes, such as the 
inhibition of insulin production by the pancreas, sugar transport and platelet 
aggregation [128-130]. Studies have shown that exposure to cold may reduce 
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circulating leptin via the suppression of the ob gene [123, 131-133]. While leptin is 
suppressed in response to cold exposure, which is accompanied by a reduction of fat 
mass [134], non-shivering thermogenesis (NST) is increased [134-136]. This shows 
an inverse relationship of leptin with NST that exclusively occurs in BAT. Cold 
exposure and excessive food intake activate the sympathetic nervous system (SNS) 
that, via norepinephrine, increases BAT activity [25]. The SNS is the main regulator of 
leptin (it reduces the production of the protein) [137] and norepinephrine suppresses 
leptin production [122, 123]. Overall, the interaction of SNS with leptin occurs when 
leptin stimulates SNS in WAT [138] and when there are signals from WAT to leptin 
sensors [139]. The Figure 3 summarizes leptin’s function. 
 
Figure 3: Leptin function 
 
 
In obesity state leptin develops resistance with its receptor in the hypothalamus, which 
lead to adiposity signals, inflammatory overactivity, food intake and decreased energy 
expenditure. This leads to insulin resistance.  
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The extent to which exercise may influence leptin concentrations depends on 
(a) the leptin circadian rhythm, (b) energy spent during an exercise session, (c) resting 
leptin levels, (d) gender, and (e) postprandial time prior to exercise [120]. Acute 
exercise (i.e. treadmill exercise at 90% VO2max for 5 min, or 100% VO2max for 2 min) 
does not modify circulating leptin concentrations in well-trained adult men (age: 28.71± 
2.91 years) [140]. Similarly, a VO2max test did not affect circulating leptin 
concentrations in healthy sedentary individuals [141]. Also, while acute exercise did 
not affect leptin concentrations immentiatelly after the exercise bout it reduced leptin 
concentrations 24 hours post exercise in healthy male who had negative energy 
balance (caloric restriction) [142]. The same study also showed that acute exercise 
increased leptin concentrations 24 hours post exercise when the participants had 
positive energy balance [142]. Furthermore, acute exercise at 95% VO2max in male 
adolescents showed that leptin concentrations did not change after 30 minutes of 
cycling, even though they had consumed a meal 2-3 hours prior to exercise [143]. 
Chronic exercise, may reduce circulating leptin particularly when exercise is 
accompanied by a reduction in fat mass [141, 144, 145]. When a chronic exercise 
programme did not reduce body weight, leptin concentrations did not change [146]. 
Caloric restriction in conjuction with a 2-month exercise programme showed 
decreased circulating leptin as opposed to either caloric intake restriction or exercise 
alone in obese adolescents [147]. In adolescent female athletes, however, leptin 
concentrations were increased at the fourth and seventh weeks of the chronic exercise 
programme, probably due to hemoconcentration that may have affected the protein 
concentrations [148]. Therefore, even though leptin concentrations are dependent on 
energy balance, exercise may play an important role in circulating leptin 
concentrations. Also, leptin may be increased in response to caloric consumption while 
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caloric intake restriction may disrupt leptin action independently of exercise [149].  
Overall, the evidence indicates that, particularly when accompanied by weight 
loss, exercise training reduces circulating leptin concentrations and enhance leptin 
sensitivity. It can be also suggested that caloric intake restriction in combination with 
exercise may be effective in decreasing circulating leptin concentrations. These 
findings are confirmed by a systematic review which concluded that chronic exercise 
decreases circulating leptin concentrations in obese individuals [150]. However, a 
more recent systematic review failed to accumulate available data of the effects of 
combined exercise and diet interventions on circulating leptin, due to the small number 
of available trials and limitations in the methodology of the existing trials [151].  Finally, 
leptin may be increased in 12 hours (short-term) and in 2-8 weeks after overfeeding 
[152, 153]. Leptin may not however, be regulated by short-term exercise (<60 minutes) 
while it might be decreased by long-term exercise (1-3 hours), yet this is dependent 
on the energy balance [154]. The effects of acute and chronic exercise on leptin in 
humans can be found in Table 2.   
 
Table 2: Effects of acute and chronic exercise on leptin 
Study Participants Exercise mode Outcome 
Pérusse et. 
al. 1997 
Healthy men 
and women 
20-wk, 3 days/wk, 30-50 
min/day, 55-75% of VO2max   
↓ Leptin   
Kraemer et. 
al. 2003 
Well-trained 
athletes 
VO2max test No changes in 
leptin 
van Aggel-
Leijssen et. 
al. 1999 
Healhty lean 
male  
50% of VO2max, 2h cycling in 
4X30 min intervals   
↓ Leptin 24h 
post- exercise 
with caloric 
intake restriction. 
↑ Leptin 24h 
post- exercise 
with caloric 
consumption 
Pomerants 
et. al. 2006 
Healthy non-
obese male 
adolescents 
30-minute cycling at 95% 
VO2max 
No changes in 
leptin 
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Halle et. al. 
1999 
Obese/type 2 
diabetic 
4-wk, 5 days/wk, 30 min/day, 
70% of VO2max   
↓ Leptin, ↓ body 
weight 
Kohrt et al. 
1996 
Sedentary, 
healthy women, 
aged 60-72 
years old 
2-month flexibility-exercise 
followed by a 9-month exercise 
program (walking, jogging, stair 
climbing) 
↓ Leptin, ↓ fat 
mass 
Kelly et al. 
2007 
Overweight 
children 
8-wk, 4 days/wk, 30-50 min/day, 
50-80% of VO2max   
No changes in 
leptin 
Elloumi et al. 
2009 
Obese 
adolescent 
2-month, 4 days/wk, 90 min of 
warm-up and games 
↓ Leptin with 
caloric 
restriction. No 
changes without 
caloric restriction 
Kraemer et 
al. 2001 
Adolescent 
female athletes 
7-wk interval training ↑ Leptin 
wk:Week; VO2max: Maximal oxygen consumption. 
 
2.3.4. Adiponectin 
Adiponectin, encoded by the ADIPOQ gene [155], it is an adipokine that affects energy 
homeostasis and insulin sensitivity. High levels of circulating adiponectin may reduce 
free fatty acids after a meal [156], while it reduces the blood glucose production by the 
liver that may affect insulin sensitivity [156]. Low levels of adiponectin have been 
associated with increased appetite and impaired insulin sensitivity [157]. In the 
presence of hyperinsulinemia and dyslipidaemia, adiponectin is decreased in skeletal 
muscle and this is thought to be associated with insulin resistance [158]. Increased 
adiponectin may increase fatty acid oxidation in skeletal muscle in the presence of 
hyperinsulinemia [159] while TNFα may decrease circulating adiponectin [104] due to 
TNFα and adiponectin may inhibit each other’s production in WAT [160]. However, 
when TNFα is inhibited adiponectin directly increases nitric oxide and adenosine 
monophosphate–activated kinase that may indirectly reduce CRP and IL-6 that 
indicates decreased inflammation [161]. Reduced circulating adiponectin is associated 
with the development of cardiovascular disease and metabolic syndrome [162], T2D 
and increased IL-6 [163]. The Figure 4 displays adiponectin’s function. 
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Figure 4: Adiponectin function 
 
Circulating adiponectin concentrations are negatively associated with body mass 
index and inflammatory status, cardiovascular disease, insulin resistance and type 2 
diabetes. Circulating adiponectin concentrations are positively associated however, 
with type 1 diabetes while it is expressed more in females than in males. 
 
Recent research suggests that a 120-minute aerobic exercise bout at 50% of 
VO2max did not affect circulating adiponectin concentrations immendiately after the 
exercise bout in healthy lean males [164]. Also, a 60-minute of aerobic exercise at 
65% of VO2max  did not alter circulating adiponectin concentrations immendiately after 
the exercise bout in healthy males and females [165]. Circulating adiponectin did not 
also change immendiatelly after a 75-minute brisk walking session in children with type 
1 diabetes [166]. Another study showed that 60 minutes of cycling at 50% of VO2max 
did not alter circulating adiponectin neither immendiately after the exercise bout nor 
30 minutes post-exercise in adult healthy men [167]. In contrast, 20 minutes of high 
intensity rowing significantly reduced circulating adiponectin immendiately and 30 
minutes after the exercise bout in athletes [12]. In general, acute exercise has been 
shown not to influence circulating adiponectin while evidence from a systematic review 
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shows that short-term high intensity resistance and aerobic exercise that changes 
body composition may increase adiponectin [161].  
The effects of chronic exercise on adiponectin however, seems to be different 
than the effects of acute exercise. Indeed, a chronic aerobic exercise intervention (7 
months cycling, 60-70% VO2max, 4-5 days/week) in obese Japanese individuals 
increased adiponectin concentrations that was relative to the amount of weight loss 
[13]. Similarly, circulating adiponectin was increased in response to a school-based 
exercise programme in “normal weight” American adolescents [168] and in obese 
adolescents boys after a 2-month exercise intervention in combination with caloric 
restriction [147]; the improvement in adiponectin concentrations was accompanied by 
an improvement in body composition, lipid oxidation and insulin sensitivity [147]. In 
obese adolescents girls, however, more training than in boys is needed to achieve 
similar responses for adiponectin [169]. Finally, a 12-week exercise programme did 
not increase circulating adiponectin in overweight and obese adolescent girls, even 
though an improvement in insulin sensitivity was found [170]. Overall, chronic exercise 
may increase circulating adiponectin that may be accompanied by increased insulin 
sensitivity and weight loss. The effects of acute and chronic exercise on adiponectin 
in humans can be found in Table 3. 
 
Table 3: Effects of acute and chronic exercise on adiponectin 
Study Participants Exercise mode Outcome 
Punyadeera 
et. al. 2005 
Healthy lean 
males 
120 min of aerobic 
exercise at 50% of 
VO2max   
No changes in 
adiponectin 
Ferguson et 
al. 2004 
Healthy males 
and females 
60 min of aerobic exercise 
at 65% of VO2max   
No changes in 
adiponectin 
DRCN group 
2008 
Children with 
type1 diabetes 
75 min of brisk walking No changes in 
adiponectin 
Numao et. 
al. 2008 
Adult healthy 
men 
60 min of cycling at 50% 
of VO2max 
No changes in 
adiponectin 
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Jürimäe et 
al. 2005 
Athletes rowers  20 min at maximum 
intensity 
↑ adiponectin 
Kondo et. al. 
2006 
Obese 
Japanese 
7 months cycling, 60-70% 
VO2max, 60 min/day, 4-5 
days/week 
↑ adiponectin 
Carrel et al. 
2009 
American 
adolescents 
School-based exercise 
programme 
↑ adiponectin 
Elloumi et al. 
2009 
Obese 
adolescent 
2-month, 4 days/wk, 90 
min of warm-up and 
games 
↑ adiponectin with 
caloric restriction 
Park et al. 
2007 
Obese 
adolescents 
girls 
12-wk of lifestyle & 
exercise intervention 
No changes in 
adiponectin 
Nassis et al. 
2005 
Overweight & 
obese 
adolescent girls 
12-wk, 40 min, 3 days/wk, 
>150 beats/min 
No changes in 
adiponectin 
VO2max: Maximal oxygen consumption; DRCN: Diabetes Research in Children 
Network (DirecNet) Study Group; wk:Week. 
 
2.4. BROWN ADIPOSE TISSUE 
BAT displays different functions and morphological properties to WAT. BAT displays 
more mitochondria than WAT while it highly expresses the co-activator peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) [25] that is 
responsible for mitochondria biogenesis in response to external stimuli [171, 172]. 
Also, BAT is characterized by increased expression of the uncoupling protein one 
(UCP1) that is the only known contributor in NST [173], the main function of BAT. 
Table 4 displays the main differences between BAT and WAT.  
 
Table 4: Main differences between Brown Adipose Tissue and White Adipose Tissue 
 WAT BAT 
Colour Ivory or yellow Brown 
Function Storage of energy Storage of energy 
Mitochondrial number Small number High number 
UCP1 Absent High 
PCG-1α Present High 
SNS innervation Low High 
WAT: White adipose tissue, BAT: Brown adipose tissue, UCP1: Uncoupling protein 
one, PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, 
SNS: Sympathetic nervous system 
 
37	
	
BAT in humans is located in small amounts in the neck and thorax (specifically 
in the area of the lower neck and collarbone), as well as along the spine and abdomen 
[21]. Lipolysis of brown adipocytes produces heat to maintain body temperature as a 
response to cold exposure [25]. This mechanism is termed NST and occurs through 
the release of norepinephrine from SNS that activates adrenergic receptors on the 
surface of brown adipocytes [25]. Subsequently, in the mitochondria the unique protein 
UCP1 is involved in the respiratory chain process and bypasses the ATP synthase 
entry by uncoupling protons and brings them back into the mitochondrial matrix 
allowing the energy to be dissipated as heat [25]. The NST phenomenon is displayed 
in Figure 5.  
 
Figure 5: The non-shivering thermogenesis phenomenon. 
 
 
 
The neurotransmitter norepinephrine (NE) that released from the sympathetic nervous 
system (SNS), binds to β-adrenergic receptor on the surface of brown adipocytes. This 
results in the activation of lipases which hydrolyze triacylglycerols (TG) in free fatty 
acids (FFA). The FFA are then bounded to fatty acids binding proteins and transferred 
into mitochondria where they undergo β-oxidation and enter Krebs cycle. This leads 
to respiratory chain process in which protons pumped across the mitochondrial inner 
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membrane. In a normal pathway in the eukaryotic cells the latter would cause an 
electrochemical gradient formation during the entrance of protons in the mitochondrial 
matrix and subsequently would generate adenosine triphosphate (ATP) synthase. The 
presence of uncoupling protein one (UCP1) in brown adipocytes however, bypasses 
the ATP synthase entrance and return protons to the mitochondrial matrix through 
UCP1. As a result, the energy of the electrochemical gradient is dissipated as heat. 
SNS: Sympathetic nervous system; NE: Norepinephrine; TG: triacylglycerol; FFA: 
Free fatty acids; ATP: Adenosine triphosphate; UCP1: Uncoupling protein one. 
 
Under cold exposure NST occurs that may consume up to 30% of daily REE 
[174, 175] compared to diet-induced thermogenesis that consumes approximately 5-
10% of daily REE in adults [176]. Nevertheless, shivering thermogenesis cannot occur 
over prolonged periods [176]. It is well known that BAT is highly expressed in infants 
(approximately 1% of their body weight) [177]. However, it was believed that after the 
first decade of human life, BAT becomes inactive and it is only found in the area of 
kidneys, the supraclavicular area, the aorta and the mediastinum [27]. This changed 
in 2009, when two studies confirmed that BAT is activated in the area beyond the chest 
in adults after 2-hour exposure at 16-19°C, and that it is positively associated with the 
daily REE of the participants [21, 22]. It was also hypothesized that approximately 100 
gr of BAT might produce energy equal to the activity of 3-4 kg of WAT [22], due to the 
higher oxidative capacity of brown adipocytes [178].  
Following these discoveries, BAT activity has been extensively investigated for 
its potential role in mammals’ metabolism. Animal studies have shown that increased 
BAT activity reduces weight gain, up-regulates insulin sensitivity, lowers free fatty acid 
levels in serum, as well as the risk for T2D and other metabolic disorders [179-183]. 
Studies in humans revealed that BAT activity is significantly lower in overweight and 
obese individuals than in lean, healthy males [21], while BMI [28], age [29], and fat 
mass [21] are inversely associated with BAT activity. BAT was found to be more active 
in young individuals and women than in older men, respectively [28].  
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2.4.1. The link between brown adipose tissue and exercise 
There are limited scientific data on the links between exercise and classical BAT in 
humans that located beyond the chest and along the spine. To the best of our 
knowledge, only one such study is available and this was in cancer patients [29]. This 
study revealed that individuals with higher physical activity levels display more BAT 
activity, and that BAT activity was inversely associated with BMI and age [29]. 
Similalrly, animal studies suggest that chronic exercise may increase BAT activity. 
Indeed, exercise may increase PGC-1α and peroxisome proliferator activated receptor 
delta as well as nuclear respiratory factor 1 that enhance NST [184]. Similarly, 
genetically modified obese mice [B6.Cg-m Leprdb/++/J(db/db)] on a six week 
swimming programme of 2 hours/day at 35°C water temperature significantly 
improved UCP1 mRNA and protein expression in BAT [185]. However, this study was 
conducted on genetically obese mice [185], that might not represent an increase of 
energy metabolism. Indeed, obese mice generally display different eating habits and 
metabolic efficiency in relation to wild type mice [186], which may influence BAT 
activity. On the other hand, evidence also showed that chronic exercise did not 
increase the mRNA of UCP1 in BAT of wild type mice [187]. Similarly, an eight week 
running programme (90 minutes/day) showed no differences in UCP1 mRNA in BAT 
in pathogen-free rats [188], while a two week swimming programme (30 minutes/day) 
in wild type mice [189] and a twelve week's swimming for 90 minutes/day in wild type 
high-fat mice [30] reported similar results. By contrast, an eight-week treadmill running 
programme increased UCP1 mRNA in BAT in normal diet mice, compared to inactive 
mice [190]. 
A high-fat diet in combination with chronic exercise did not change BAT mass 
[191-193] in wild type rats. Another study reports that exercise in combination with 
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high-sugar diet reduced UCP1 mRNA in BAT [193], probably because the diet-induced 
thermogenesis that increased by the high-sugar diet. A seven-day running programme 
(60 minutes/day) in diet-induced mice, given ephedrine, increased levels of UCP1 
mRNA in BAT [194]. Other evidence showed that chronic exercise increased BAT 
mass in genetically modified animals (Otsuka Long Evans Tokushima fatty rats 
characterized by early-onset hyperphagia-induced obesity and Male Wistar obese 
insulin-resistant rats) [191, 195]. However, these modified animals usually display 
different metabolic efficiencies compared with wild type mice [196]. Interestingly, a 4-
week treadmill running programme augmented UCP1 mRNA in BAT in mice, but only 
when both exercise and cold stimuli were present [184].  
The mRNA measurements have been extensively used to determine BAT 
functions however, the mRNA of genes even though they usually indicate the protein 
production sometimes they do not predict it [197-199]. This is because one mRNA 
transcription may encode the protein more than one time [197-199]. Therefore, in 
several experiments measurements of protein expression may also be needed in order 
to determine the physiological mechanisms. Indeed, in vitro measurements revealed 
increased UCP1 protein expression in BAT in exercised high-fat diet mice compared 
to sedentary high-fat diet mice [190]. There is also evidence that exercise increased 
BAT mass in wild type mice with or without high-fat diet and this was further confirmed 
by increased UCP1 protein expression in BAT cells [190]. In general, the studies to 
date show contrasting results mostly in UCP1 mRNA measurements, mainly because 
of the different experimental approaches, different types of animals and/or different 
types of exercise. The effects of exercise on BAT can be found in Table 5.  
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Table 5: Effects of exercise on brown adipose tissue 
Study Participants/ 
animals 
Exercise mode Outcome 
Dinas et. al. 
2015 
Cancer patients Associations between 
habitual physical activity 
levels and BAT   
Positive association of 
physical activity levels 
with BAT  
Seebacher 
et al. 2010 
Wild rats 4-wk wheel running (30 
min/day) at 22°C or 12°C 
↑ UCP1 with combined 
exercise and cold 
Oh et al. 
2007 
Obese genotype:  
“B6.Cg-m 
Leprdb/+ +/J” 
mice; Lean 
genotype: 
“B6.Cg-m 
Leprdb/+ /J” 
mice 
6-wk swimming (2 h/day) 
at 35°C 
↑ UCP1 in obese female  
↑ UCP1 in lean male  
 
De Matteis 
et al. 2013 
Sprague Dawley 
rats 
1-wk (acute) and 6-wk 
(chronic) treadmill running, 
5 days/week, at 18 m/min 
(~ 60% VO2max) 60 
min/day at ~ 22°C 
No changes in UCP1 
Boss et al. 
1998 
Pathogen free 
rats 
8-wk treadmill running (10-
90 min/day) at 22±2°C 
No changes in UCP1 
Tsuboyama-
Kasaoka et 
al. 1998 
C57BL/6 mice 2-wk swimming (30 
min/day) at 35°C 
No changes in UCP1 
Bostrӧm et 
al. 2012 
 C57BL/6 mice 3-wk free wheel running (8 
km/night) 
No changes in UCP1 
Xu et al. 
2011 
C57BL/6 mice 8-wk treadmill running (5 
day/wk, 40 min/day) at 
25°C 
↑ UCP1 in normal diet 
↑ UCP1 in high fat diet 
de Queiroz 
et al. 2012 
Wistar rats 8-wk running (5 days a 
week, 30-60 min/day) at 
23±1°C 
No changes in BAT 
mass. 
↑ UCP1 either exercise 
or high-sugar diet alone 
¯UCP1 with combined 
exercise and high-sugar 
diet 
Slocum et al. 
2013 
Sprague Dawley 
rats 
1-wk (acute) and 6-wk 
(chronic) treadmill running, 
5 days/week, at 18 m/min 
(~ 60% VO2max) 60 
min/day at ~ 22°C 
No changes in BAT 
mass and UCP1.  
Bueno et al. 
2011 
Male Wistar rats 
& Male Wistar 
obese insulin-
resistant rats 
4-wk swimming at 32–36 
°C, 1.5 h/day 
No changes in BAT 
mass in Male Wistar 
rats. 
↑ BAT mass in Male 
Wistar obese insulin-
resistant rats 
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Sene-
Fiorese et al. 
2008 
Wistar rats 8-wk swimming, 90 
min/day, 5 days/week  
No changes in BAT 
mass 
Schroeder et 
al. 2010 
Otsuka Long 
Evans 
Tokushima fatty 
rats 
Free wheel running ↑ BAT mass 
BAT: Brown adipose tissue; UCP1: Uncoupling protein one 
 
2.4.2. The link between brown adipose tissue and nutrition  
Studies in animals revealed that low protein diet may increase REE by involving 
activation of BAT [200, 201]. Also, studies showed that high-fat diets enhanced cold 
tolerance and survival of animals [202-204] and increased animals’ mitochondria in 
BAT [205]. More recently, it was found that a ketogenic diet (high-fat, adequate-protein 
and low-carbohydrate) increased the number of mitochondria and doubled the UCP1 
protein expression in BAT, while it increased the UCP1 protein expression in 
epididymal WAT of mice independently of physical activity levels [206]. Furthermore, 
a ketogenic diet intervention in mice increased by 40% the size of mitochondria and 
1.5-3 fold the UCP1 protein expression in BAT compared to chow-fed diet [207]. The 
explanation of the latter findings is that diet-induced thermogenesis is fully dependent 
on UCP1 activity while it is also controlled by the UCP1 even though it is unclear if this 
mechanism can significantly increase NST [208]. Overall, UCP1 may boost diet-
induced thermogenesis in the BAT of mice, while its absence may increase obesity in 
mice fed with high-fat or normal diet [208]. 
 
2.5. BROWN-LIKE ADIPOSE TISSUE 
Brown-like adipocytes are cells that display properties similar to brown adipocytes and 
mainly occur within WAT depots. A number of theories explain their origin. These 
include: a) brown-like adipocytes are the result of the maturation of brown adipocytes 
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[209], b) brown-like adipocytes are split from a precursor or from a mature white 
adipocyte [178, 210-212] and c) brown-like adipocytes are the result of a precursor of 
muscle cells [213]. It should also be noted that the classical brown adipocytes come 
from the stem cell originator “myogenic factor 5”, the same as the skeletal muscle cells 
[214]. However, the brown-like adipocytes are not positive in myogenic factor 5 protein 
[214]. The main index that characterizes the brown-like adipocytes is the presence of 
the UCP1 [215]. During the 1980s it was first reported that some animal white 
adipocytes expressed UCP1 [216-219]. The UCP1 protein acts in mitochondria of 
brown adipocytes to dissipate chemical energy to produce heat [220] and is the only 
known contributor for NST that occurs in BAT [25]. Therefore, its presence in a white 
fat cell may indicate brown-like function. In this regard, the majority of the white fat 
cells that display UCP1 show brown-like fat properties and not brown fat properties 
[221]. 
It is suggested that brown-like adipocytes are metabolically active to reduce 
body weight and consequently lessen obesity [222]. Brown-like adipocytes have a role 
in metabolism regulation in humans, even though the mechanisms are not well 
established [223]. Women display more active brown-like adipocytes than men [28]. 
Their expression is low in obese individuals, but this increases after weight loss and 
bariatric surgery [224]. There are also food components that may cause a browning 
process of WAT in animals that include the reduction of amino-acids and high fat diet 
[225]. This browning process of WAT is also indicated by a study that showed that 
exercise increased the positive UCP1 white adipocytes in exercised high-fat diet mice, 
but not in sedentary high-fat diet mice [190]. It also showed that the PGC-1α mRNA 
within the white adipocytes decreased in sedentary high-fat diet mice compared to 
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sedentary normal-diet mice [190], probably indicating a role of diet in browning 
formation of WAT. 
Apart from UCP1, the presence of other genes within white adipocytes may 
also indicate a brown-like function of human WAT. These include PGC-1α [220] and 
peroxisome proliferator-activated receptor gamma (PPARγ) [215], which are involved 
in the development of brown fat cells. PGC-1α is responsible for mitochondrial 
biogenesis [171] of the external stimuli [172] and it is mainly expressed in skeletal 
muscle and BAT but, it is also present in WAT [226]. Mice with transgenic expression 
of PGC-1α in the muscle displayed more brown-like than white adipocytes in 
subcutaneous adipose tissue [30]. PPARγ is also necessary for the function of both 
brown and white adipocytes and displays similar pathways in both tissues. When 
PPARγ is mutated (P465L mutation) brown adipocytes show a reduction in 
thermogenic capacity through the reduction of UCP1, but mutated (P465L mutation) 
PPARγ can still contribute in the development of white adipocytes [227]. This may 
indicate a key role of PPARγ in WAT that may be related to increased UCP1 mRNA 
[209, 228], which may specify brown-like function. Finally, evidence suggests that 
PPARα activates UCP1 within the white adipocytes in response to exercise [30], 
leading to brown-like properties of the cells. A specific PPARα antagonist (GW6471) 
treatment in vitro decreased UCP1 in white adipocytes while PPARα was found to be 
driven by an exercise-dependent protein (FNDC5/Irisin) [30]. However, PPARα may 
not be the only activator of UCP1 even though the other mechanisms remains to be 
established [30, 229]. Overall, there is only limited evidence concerning the 
transformation of white into brown-like adipocytes, especially in response to exercise. 
Given that the formation of brown-like adipocytes via exercise may improve glucose 
homeostasis and thus may reduce metabolic diseases [30], a further exploration of 
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this formation is needed. However, the role of physical activity and exercise on the 
UCP1, PGC-1α, PPARα and PPARγ mRNAs of WAT in humans has not been 
extensively investigated to date.  
 
2.5.1. Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α)  
PGC-1α is a transcriptional co-activator that regulates genes involved in energy 
metabolism. It is responsible for several functions, including the control of the cellular 
response to oxidative stress [230]. It is also responsible for mitochondrial biogenesis 
[171] of the external stimuli [172]. It does this by activating the production of the 
Nuclear Respiratory Factor One (NRF-1) and NRF-2, stimulators of the mitochondrial 
transcription factor A, which duplicates mitochondrial DNA [231]. PGC-1α is mainly 
expressed in tissues that demand energy, such as skeletal muscle and cardiac 
muscle, but it is also present in WAT [226]. Evidence indicates that PGC-1α is 
inversely associated with age in mice [231], while mitochondrial dysfunction in mice is 
positively associated with depressed PGC-1α levels [232]. PGC-1α deficiency in mice 
leads to insulin resistance, while increased PGC-1α mRNA in skeletal muscle leads to 
increased mitochondrial density [233]. PGC-1α is also highly expressed in BAT [234] 
and it co-activates with PPARγ to stimulate genes involved in brown adipocytes 
differentiation [234, 235]. 
Evidence suggests that PGC-1α mRNA is increased in response to both acute 
[31, 33, 236, 237] and chronic exercise [32, 34, 236, 238] in human skeletal muscle. 
This may be due to increased demands of ATP and, therefore, increased demands of 
mitochondria [239]. However, studies that measured PGC-1α protein expression in 
skeletal muscle show a large range of the protein molecular weight from 70 to >110 
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Kda [240-242] that may reflect both the antibodies used to measure the protein and 
the stimuli itself (i.e. exercise). A theory suggests that the link between PGC-1α and 
exercise may be the result of free radicals that are produced in response to exercise 
stress, which may trigger a signal to increase mitochondrial biogenesis [231, 243]. 
PGC-1α increases the expression of catalase and superoxide dismutases that may 
protect against oxidative stress caused by free radicals [244] while antioxidant 
supplements may inhibit mitochondria production during exercise via the reduction of 
PGC-1α [243]. This indicates that the production of free radicals during exercise may 
increase mitochondrial biogenesis and thus, may increase PGC-1α. Indeed, PGC-1α 
may be increased in WAT in response to exercise [245]. 
 
2.5.2. Peroxisome proliferator-activated receptor alpha (PPARα) 
PPARα is a transcriptional factor that regulates genes to increase lipid metabolism 
[246] and is involved in mitochondrial fatty acid beta oxidation [247]. PPARα is a 
member of the PPAR family that also includes, PPARβ, PPARγ and PPARδ that are 
nuclear receptors for fat vitamins, steroid hormones, and sterols [247, 248]. Also, 
PPARα increases fatty acid oxidation in liver and the production of hepatic glucose to 
normalize responses to fasting [247]. While PPARα mRNA was found to be higher in 
the skeletal muscle of trained than untrained individuals [249], it was also increased in 
the skeletal muscle of mice after a chronic high-intensity interval exercise programme 
[250]. Another animal study suggested that chronic exercise can prevent weight gain, 
adiposity and hypertrophy of adipocytes, in part, via the activation of PPARα [251]. 
Recent evidence also suggests that chronic activation of PPARα via a 
pharmaceutical method increased the brown-like cells in subcutaneous WAT of mice, 
which was also accompanied by the elevation of PGC-1α and UCP1 [252]. 
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Specifically, high-fat diet animals were administered with Fenofibrate, which increased 
the mRNA of PPARα in subcutaneous WAT. This caused a decrease in body weight 
and enhanced insulin sensitivity. The increased mRNA of PGC-1α and UCP1 within 
the white adipocytes indicates a predominant role of PPARα in browning formation of 
WAT in animals [252]. Evidence also suggests that PPARα plays a role in increasing 
UCP1 in human white adipocytes in response to chronic exercise [30]. However, this 
suggestion is based on a human white adipocytes pharmacological treatment that 
inhibited PPARα and subsequently UCP1 [30]. In general, PPARα may play a role in 
browning formation of WAT, a role that should be further explored. 
 
2.5.3. Peroxisome proliferator-activated receptor gamma (PPARγ) 
Another member of the PPAR genes family is the transcriptional factor PPARγ, 
discovered to be active in BAT [253]. Its main function is to regulate fatty acid storage 
and glucose metabolism [254]. PPARγ demonstrates the highest expression of the 
PPAR family genes in adipose tissue, particularly in BAT [255]. PPARγ has also an 
adipogenic effect in BAT of animals through its effect on various genes involved in lipid 
synthesis [255, 256]. A chronic treatment of animals with PPARγ led to increased 
brown adipocytes within BAT [257]. PPARγ may also be responsible for both brown 
and white adipocytes' survival [255]. Evidence also shows that PPARγ knockout mice 
increased insulin resistance [258] while they failed to generate adipose tissue when 
fed a high-fat diet [259].  
Previous research has also investigated whether PPARγ can trigger a 
transformation of white into brown-like adipocytes via the UCP1 mRNA. PPARγ may 
increase the UCP1 mRNA in subcutaneous white fat of mice [228]. Indeed, a treatment 
of white adipocytes with PPARγ ligands for several days showed that PPARγ may 
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cause a browning effect of WAT by enhancing UCP1 mRNA [209]. Chronic exercise 
also increased PPARγ mRNA in WAT of mice [260]. A recent study showed that a nine 
week aerobic exercise programme in mice increased the PPARγ mRNA in epididymal 
WAT compared to control counterparts [261]. Interestingly, PPARγ mRNA in 
epididymal WAT was significantly increased in a group of chronic exercised rats after 
a four-week de-training period compared to a group of sedentary rats probably 
because an adipogenic effect that was triggered during the de-training period [262]. 
However, other evidence indicates that the protein levels of PPARγ of subcutaneous 
fat of mice did not alter in response to an eight-week exercise programme [263]. 
Finally, given that PPARγ may play a role in the browning process of WAT and 
probably responds to exercise stimuli in WAT, further research is needed to designate 
this. 
2.5.4. Brown-like adipose tissue and physical activity/exercise 
A study conducted in both humans and mice revealed a novel mechanism regarding 
the role of exercise in brown-like adipocytes functions. Given that exercise increases 
the PGC-1α mRNA in skeletal muscle, it was suggested that PGC-1α up-regulates the 
fibronectin type III domain-containing protein 5 (FNDC5) [30]. Subsequently, the 
FNDC5 protein is cleaved and released into the bloodstream as Irisin – a newly 
discovered protein – that is attached, via an unknown receptor, on the surface of white 
adipocytes to generate a cascade of events changing the function of white adipocytes 
into brown-like adipocytes [30]. The latter was confirmed by the presence of UCP1 
mRNA in the white adipocytes, which probably was increased in part by the PPARα 
involvement [30]. UCP1 is the only known contributor in NST in brown adipocytes and 
its presence in a white fat cell indicates brown-like fat cell function [223]. The Irisin 
mechanism is displayed in Figure 6.  
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Figure 6: The Irisin mechanism  
 
Exercise increases the peroxisome 
proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α), which 
causes the production of the fibronectin 
type III domain-containing protein 5 
(FNDC5) within the skeletal muscle. 
FNDC5 is then cleaved and released 
into the bloodstream as Irisin. Irisin is 
then attached on the surface of white 
adipocytes that may increase the 
peroxisome proliferator-activated 
receptor alpha (PPARα) and uncoupling 
protein one (UCP1). This may increase 
energy expenditure, weight loss while it 
improves glucose homeostasis as well 
as insulin sensitivity. These are 
properties of a brown adipose-like 
phenotype.   
 
 
 
 
 
Furthermore, when Irisin was administered in obese mice it improved glucose 
homeostasis and caused weight loss [30]. Given that brown-like adipocytes may have 
antidiabetic effects on mice [264] and humans display white adipocytes that contain 
UCP1 [265], it was suggested that Irisin may have a therapeutic role in humans. The 
therapeutic role of Irisin has also been investigated in humans showing that circulating 
Irisin concentrations are inversely correlated with blood glucose, insulin and 
cholesterol indicating a positive effect on metabolism [266]. 
The potential therapeutic effect of Irisin on humans has also been considered 
with caution. For instance, FNDC5 mRNA in muscle is not significantly increased by 
exercise and Irisin probably is not regularly activated by exercise in humans [267]. 
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Timmons et al. (2012) also showed that FNDC5 mRNA is 30% greater in older 
compared to younger adults, indicating that this gene is not equally expressed in 
humans [267]. Several studies have also investigated the effects of exercise on 
circulating Irisin concentrations and UCP1 in WAT with disparate results. While some 
show that acute exercise increases circulating Irisin [268, 269], others show no such 
effects [33, 270]. There is also evidence that circulating Irisin increased in response to 
chronic exercise [271] or not altered at all [33]. A recent study indicates that chronic 
exercise increases PGC-1α and FNDC5 mRNA in muscle, while the UCP1 mRNA in 
subcutaneous WAT was increased yet, not significantly [236]. Another study 
demonstrated for the first time that adults with high habitual physical activity levels 
display more BAT activity in supraclavicular and spinal areas compared to adults with 
low physical activity levels [29]. The latter may be of interest for further research, given 
that brown-like adipocytes are present within classical brown fat depots in the 
supraclavicular and spinal areas in adult humans [272, 273]. 
Given the existing evidence, the question is whether the Irisin mechanism is 
functional and causes a brown-like function in white adipocytes. Recent evidence 
indicates that the start codon of the FNDC5 gene is mutated in humans [274]. This 
suggested that lead to a short-length Irisin production into the bloodstream, which 
misses almost 50% of its sequence. The same evidence shows no effect of FNDC5 
and Irisin on human white adipocytes and thus, the function of Irisin observed in mice 
may be lost in humans [274]. However, concerns have been raised about this due to 
the type of antibody used for Irisin detection [275] and the recent revelation that the 
studies examining circulating Irisin that used commercial antibodies may not be 
accurate [35]. This is because the available antibodies may attract other proteins, 
which suggests that the circulating Irisin value measured also includes cross-reacting 
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proteins [35]. Recent evidence also shows that when Irisin is measured via mass 
spectrometry [270, 276], the Irisin concentrations appeared to be ~10-100 times lower 
than the values displayed when commercial antibodies were used. Finally, given that 
several animal studies showed that exercise may promote brown-like properties of 
subcutaneous WAT [245, 277-279], the Irisin mechanism should be further explored. 
A first step could be a systematic review of the existing literature. 
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3.	CHAPTER 3: RATIONALE, AIMS & HYPOTHESES 
3.1. RATIONALE 
Recent evidence indicates that exercise may change the mode of white adipocytes 
into brown-like mode [30]. As noted above, UCP1 is only responsible for heat 
production in the human body through its function in BAT and its presence in a white 
adipocyte may indicate brown-like function [229]. As such, research studies 
hypothesized that UCP1 may prevent the development of obesity [208] given that 
UCP1 activity triggers NST that increases REE, which may reduce weight gain through 
the development of brown-like adipocytes in mice [179, 280]. These UCP1 properties 
indicate its positive effect on the metabolism and its importance in improving health 
outcomes. UCP1 may be increased in WAT through exercise that ameliorates PGC-
1α mRNA and FNDC5 protein within the skeletal muscle [30]. Subsequently, the 
FNDC5 protein is cleaved and released into the bloodstream as Irisin that is attached, 
via an unknown receptor, on the surface of white adipocytes to increase UCP1 within 
white adipocytes [30]. However, this mechanism displays several limitations and the 
evidence to date is controversial especially in humans while the evidence regarding 
the effects of exercise on UCP1 in WAT in humans is very limited. The current PhD 
study examined for the first time the aforementioned mechanism in humans via a 
systematic review process according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines using tools from the Cochrane 
Library. The current PhD study also examined for the first time the effects of exercise 
training and de-training on the UCP1 mRNA of WAT in healthy adults in a parallel RCT 
design. 
There are also other genes that may indicate browning formation of WAT. PGC-
1α regulates the expression of several genes and indicates brown-like function via its 
interactions with PPARα and PPARγ (even though the mechanisms are not fully 
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defined) [234, 281, 282]. PGC-1α is highly expressed in BAT [283] and it co-activates 
with PPARγ to stimulate genes involved in brown adipocytes differentiation [234, 235]. 
It is also increased in WAT in response to exercise [245], which may indicate an 
increased demand of WAT energy during exercise. Recent evidence also suggests 
that chronic activation of PPARα via a pharmaceutical method increased the brown-
like adipocytes in subcutaneous WAT of mice, which was also accompanied by the 
elevation of PGC-1α and UCP1 [252]. However, these findings have not been 
confirmed by  human studies. Indeed, a study showed that PPARα may increase 
UCP1 in human white adipocytes in response to chronic exercise, but this was in vitro 
observantion [30]. PPARγ may also increase the UCP1 mRNA in subcutaneous white 
fat of mice [228, 260]. Indeed, a treatment of white adipocytes with PPARγ ligands for 
several days showed that PPARγ may enhance UCP1 mRNA that causes a browning 
effect of WAT [209]. Therefore, it could be hypothesized that physically active 
individuals display more the expression of the aforementioned genes in WAT and 
subsequently display a browning process of WAT. Nevertheless, the relationship of 
the expression of the aforementioned genes (UCP1, PGC-1α, PPARα, PPARγ) in 
WAT with physical activity levels in humans has not been investigated to date. The 
current PhD study examined for the first time this relationship in healthy adults in a 
cross-sectional design study.    
 It is well established that leptin is a key factor in the regulation of fat mass in 
humans. Increased circulating leptin concentrations are associated with increased risk 
of inflammation and increased fat mass [120]. Leptin is suppressed in response to cold 
exposure that may be accompanied by the reduction of fat mass [134]. SNS is the 
main regulator of leptin and reduces the production of this protein [137]. Evidence 
suggests that norepinephrine suppresses leptin production [122, 123], while 
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norepinephrine is necessary in BAT function [25]. This evidence indicates an inverse 
relationship between leptin and BAT activity. Data show that increased leptin 
sensitivity stimulates lipolysis in adipose tissue and hepatic fatty acid uptake and 
oxidation [126]. Recent data, however, show that increased inflammatory cytokines 
and free fatty acid levels were associated with impaired leptin sensitivity in mice [120, 
127]. Actually, circulating leptin in humans has been associated with greater levels of 
systemic inflammation and fat mass [120]. On the other hand, decreased circulating 
adiponectin concentrations are associated with increased circulating levels of free fatty 
acids [156] and increased glucose production from the liver [156, 284]. Chronic 
exercise, however, may reduce circulating leptin particularly when exercise training is 
accompanied by a reduction in fat mass [120, 141, 144, 145]. It may also reduce 
circulating leptin concentrations and increase circulating adiponectin concentrations in 
overweight and obese individuals [285]. Nevertheless, the link between different types 
of chronic exercise and de-training with leptin and adiponectin mRNA of WAT has not 
been extensively investigated in healthy individuals. Therefore, this PhD study 
examined the effects of different types of exercise and de-training on leptin and 
adiponectin mRNA of WAT in healthy adults in a parallel RCT design.  
The general aim of this PhD study was to investigate both the relationship of 
physical activity to browning formation and the effects of different exercise 
programmes on browning formation of subcutaneous WAT in humans using genes 
identified from the literature to be involved in this process. It also aimed to examine 
the effects of chronic exercise on leptin and adiponectin genes of WAT in humans.  
Given the above the specific aims and hypotheses of the current PhD study were: 
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3.2. AIMS 
Study 1: To systematically investigate the literature of the effects of physical activity 
on the link between PGC-1α and FNDC5 in muscle, circulating Irisin and UCP1 of 
WAT in humans.  
Study 2: To examine the relationship between the UCP1 mRNA and protein 
expression, as well as the mRNA of PGC-1α, PPARα and PPARγ genes of 
subcutaneous WAT in healthy men with their physical activity levels in a cross-
sectional design study. A secondary aim was to examine the associations of the UCP1 
mRNA and protein expression, as well as the mRNA of PGC-1α, PPARα and PPARγ 
genes with REE, age, fat mass, fat free mass, energy intake, WHR and BMI. 
Study 3: To examine the effects of different types of exercise and de-training on the 
UCP1 mRNA and protein expression of subcutaneous WAT in healthy untrained men, 
in a parallel RCT design. A secondary aim was to examine the effects of different types 
of exercise and de-training on the mRNA of PGC-1α, PPARα and PPARγ genes. 
Study 4: To examine the effects of different types of exercise and de-training on the 
leptin mRNA of subcutaneous WAT in healthy untrained men, in a parallel RCT design. 
A secondary aim was to examine the effects of different types of exercise and de-
training on the adiponectin and leptin to adiponectin (L/A) ratio mRNA. 
 
3.3. HYPOTHESES 
Study 1: Physical activity may increase PGC-1α that increases FNDC5 in muscle, 
circulating Irisin and UCP1 within WAT in humans. 
Study 2: mRNA and protein expression of UCP1, as well as mRNA of PGC-1α, PPARα 
and PPARγ genes of subcutaneous WAT of healthy men will be positively associated 
with increased physical activity levels and that the mRNA and protein expression of 
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UCP1, as well as mRNA of PGC-1α, PPARα and PPARγ genes will be positively 
associated with REE, fat free mass and negatively associated with energy intake, 
WHR, BMI, age and fat mass. 
Study 3: Different types of chronic exercise will increase and the following de-training 
period will decrease the UCP1 mRNA and protein expression in the subcutaneous 
WAT of healthy untrained men and that the mRNA of PGC-1α, PPARα and PPARγ 
genes will be increased in response to exercise and decreased in response to de-
training. 
Study 4: Different types of chronic exercise will decrease and the following de-training 
period will increase the leptin mRNA in subcutaneous WAT of healthy untrained men. 
Also, different types of chronic exercise will increase and the following de-training 
period will decrease the adiponectin mRNA while different types of chronic exercise 
will decrease and the following de-training period will increase L/A ratio mRNA in 
subcutaneous WAT of healthy untrained men.   
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4. CHAPTER 4: METHODS USED IN PhD STUDY 
4.1. ETHICAL APROVAL 
This PhD study conformed to the standards set by the Declaration of Helsinki and was 
approved from the Ethics Committees of the University of Wolverhampton (protocol 
number 92944/13-6-2013) and the University of Thessaly (protocol number 698/13-3-
2013) (Appendices 1 and 2, respectively). 
 
4.2. APPROACH 
The current PhD is consisted of four studies. a) A systematic review to identify 
evidence regarding the effects of physical activity on the brown-like formation of WAT 
in humans. Also, 46 healthy men were recruited to conduct b) a cross-sectional study 
to identify associations of the mRNAs and protein expression of genes that indicate 
browning formation of subcutaneous WAT with physical activity levels. From the 46 
healthy men a subset of 32 individuals were recruited to conduct an RCT. This RCT 
was split into c) a study to examine the effects of exercise and de-training on the UCP1 
mRNA and protein expression, and d) a study to examine the effects of exercise and 
de-training on the leptin mRNA of subcutaneous WAT.   
        
4.3. SYSTEMATIC REVIEW METHOD 
4.3.1. Search strategy  
Using the PRISMA guidelines [286-288] two databases [(PubMed and EMBASE 
(1980-2015)] were searched up until the 14th September 2015. Two investigators 
independently conducted two identical searches in both databases using the terms 
that appear inTable 6 (PubMed) and Table 7 (EMBASE). Finally, the reference lists of 
the included articles were reviewed in order to identify publications that were relevant 
to the topic under review.  
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Table 6: Searching algorithm for PubMed 
1. PGC1 alpha[Title/Abstract] 
2. PGC-1 alpha[Title/Abstract] 
3. PGC-1a[Title/Abstract] 
4. PGC1a[Title/Abstract] 
5. PGC-1alpha[Title/Abstract] 
6. Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha[Title/Abstract] 
7. Peroxisome proliferator-activated receptor gamma coactivator 1-
a[Title/Abstract] 
8. Peroxisome proliferator-activated receptor gamma coactivator 1 
alpha[Title/Abstract] 
9. Peroxisome proliferator-activated receptor gamma coactivator 
1a[Title/Abstract] 
10. Peroxisome proliferator-activated receptor gamma coactivator 
1alpha[Title/Abstract] 
11. PGC1alpha[Title/Abstract] 
12. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11) 
13. FNDC5[Title/Abstract] 
14. Fibronectin type III domain-containing protein 5[Title/Abstract] 
15. Irisin-encoding gene[Title/Abstract] 
16. (#13 OR #14 OR #15) 
17. Irisin[Title/Abstract] 
18. PGC1alpha-dependent myokine[Title/Abstract] 
19. (#17 OR #18) 
20. Uncoupling protein one[Title/Abstract] 
21. Uncoupling protein 1[Title/Abstract] 
22. UCP1[Title/Abstract] 
23. (#20 OR #21 OR #22) 
24. (#12 OR #16 OR #19 OR #23) 
25. exercise[MeSH Terms] 
26. exercise[Title/Abstract] 
27. motor activity[MeSH Terms] 
28. sports[MeSH Terms] 
29. sport*[Title/Abstract] 
30. resistance training[MeSH Terms] 
31. training[Title/Abstract] 
32. fitness[Title/Abstract] 
33. physical activity[Title/Abstract] 
34. physical activities[Title/Abstract] 
35. physical activity intervention*[Title/Abstract] 
36. exercise intervention*[Title/Abstract] 
37. active[Title/Abstract] 
38. aerobic[Title/Abstract] 
39. (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR 
#34 OR #35 OR #36 OR #37 OR #38) 
40. (#24 AND #39) 
41. animals[MeSH Terms] 
42. humans[MeSH Terms] 
43. (#41 NOT #42) 
59	
	
44. (#40 NOT #43) 
 
 
Table 7: Searching algorithm for EMBASE 
1. PGC1 alpha.ti,ab. 
2. PGC-1 alpha.ti,ab. 
3. PGC-1a.ti,ab. 
4. PGC1a.ti,ab. 
5. PGC-1alpha.ti,ab. 
6. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha.ti,ab. 
7. Peroxisome proliferator-activated receptor gamma coactivator 1-a.ti,ab. 
8. Peroxisome proliferator-activated receptor gamma coactivator 1 alpha.ti,ab. 
9. Peroxisome proliferator-activated receptor gamma coactivator 1a.ti,ab. 
10. Peroxisome proliferator-activated receptor gamma coactivator 1alpha.ti,ab. 
11. PGC1alpha.ti,ab. 
12. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 
13. FNDC5.ti,ab. 
14. Fibronectin type III domain-containing protein 5.ti,ab. 
15. Irisin-encoding gene.ti,ab. 
16. 13 OR 14 OR 15 
17. Irisin.ti,ab. 
18. PGC1alpha-dependent myokine.ti,ab. 
19. 17 OR 18 
20. Uncoupling protein one.ti,ab. 
21. Uncoupling protein 1.ti,ab. 
22. UCP1.ti,ab. 
23. 20 OR 21 OR 22 
24. 12 OR 16 OR 19 OR 23 
25. exercise/ 
26. exercise.ti,ab. 
27. motor activity/ 
28. sport/ 
29. sport*.ti,ab. 
30. resistance training/ 
31. training.ti,ab. 
32. fitness.ti,ab. 
33. physical activity.ti,ab. 
34. physical activities.ti,ab. 
35. physical activity intervention*.ti,ab. 
36. exercise intervention*.ti,ab. 
37. active.ti,ab. 
38. aerobic.ti,ab. 
39. 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 
OR 36 OR 37 OR 38 
40. 24 AND 39 
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4.3.2. Selection criteria  
We included studies that met at least one of the following eligibility criteria, a) 
measurements of PGC-1α in conjunction with measurements of FNDC5, b) 
measurements of FNDC5, and/or circulating Irisin concentrations and/or UCP1 in 
WAT, along with the following criteria c) measurements of physical activity levels 
and/or exercise interventions, and d) human participant study. No other eligibility 
criteria were set (e.g., language, date of publication). From the included studies, we 
retrieved outcomes regarding the effects of a) physical activity on PGC-1α in 
conjunction with FNDC5 in muscle, b) FNDC5 in muscle, c) Irisin in the bloodstream 
and d) UCP1 in WAT. We report the studies’ design, the participants’ characteristics 
and the main outcomes. Also, when the Irisin peptide was investigated in any of the 
studies included, we reported the methods of analysing Irisin (Table 9). We have also 
recorded the secondary associations in the included studies, i.e. associations between 
FNDC5 and/or circulating Irisin and several health related phenotypes (e.g. REE, 
blood pressure, WHR, BMI). 
 
4.3.3. Risk of bias assessment and quality of reporting data 
Two independent reviewers evaluated the risk of bias of the studies included in the 
systematic review via the “Cochrane Collaboration’s tool for assessing risk of bias” 
[289]. Conflicts in the risk of bias assessment were resolved by a third reviewer. Also, 
two reviewers evaluated independently the quality of the reporting data of the included 
RCTs, controlled trials (CT) and single group design studies (SGS) using the 
Consolidated Standards of Reporting Trials (CONSORT) checklist [290]. This is a 25-
item checklist and a score for each study was provided. Also, two reviewers evaluated 
independently the quality of the reporting data of the included cross sectional studies 
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(CSS) using the 22-item checklist of the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) and we also provided a score for each study 
included [291]. Disagreements on studies’ CONSORT and STROBE scores were 
resolved though the agreement refereed by a third reviewer. 
 
4.4. EXPERIMENTAL METHODS 
Written consent form (Appendix 3) was obtained from 46 healthy men who were 
recruited for a cross-sectional study in order to examine the associations of the 
mRNAs and protein expression of genes that indicate browning formation of 
subcutaneous WAT with physical activity levels. A subset of 32 out of the 46 individuals 
undertook an exercise programme followed by a de-training period in a RCT design to 
assess the effects of exercise and de-training on browning formation and on leptin 
mRNA of WAT. The measurements in these studies included anthropometry (WHR, 
BMI, blood pressure and body composition), indirect calorimetry for REE, physical 
activity levels, subcutaneous fat biopsies to assess mRNA and protein expression of 
the genes examined, VO2peak, 1-repetition maximum (1RM) and diet recalls. The 
reporting of the results of the RCT based on the CONSORT guidelines [290] and of 
the cross sectional study based on the STROBE guidelines [291].  
 
4.4.1. Study design of randomized controlled trial 
A parallel RCT of an 8-week of exercise training followed by an 8-week of de-training 
period was performed. The participants were recruited by advertisements in a local 
newspaper in the area of Trikala, Thessaly, Greece; the experimental protocol started 
in July 2013 and ended in June 2014. The participants were asked to call the 
researcher (PhD student) for an initial interview in order to identify eligibility. The 
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inclusion criteria were: healthy adult men not participated in a regular exercise 
programme, non-smoker, no chronic disease and/or being under medication 
treatment. Information of the health status was retrieved through a medical history 
questionnaire via interview (Appendix 4). Information of the physical activity levels was 
retrieved via the International Physical Activity Questionnaire (Appendix 5) [292]. 
Participants, who were healthy, not participated in a regular exercise programme and 
displayed low or moderate physical activity levels were eligible to participate in the 
study. If a candidate was eligible to participate in the study he was given a period of 
seven days to decide his participation. Upon inclusion, a participant was randomly 
assigned to a group using an online computer software [293]. The initial allocation and 
enrol of the participants to an experimental group was completed by the researcher 
(PhD student) while the supervision of the exercise interventions was completed by 
three assistants, one for each exercise group who were blinded to the aim of the study. 
The selection process along with reasons for exclusions as well as participant drop 
outs in the RCT design appear in Figure 7.  
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Figure 7: CONSORT diagram of the randomized controlled trial design 
 
4.4.2. Experimental protocol for randomized controlled trial 
The RCT involved four groups: an aerobic exercise group (AEG), a resistance exercise 
group (REG), a combined exercise group (aerobic+resistance) (CEG) and a non-
exercise control group (CG). Measurements for anthropometry, body composition, 
REE, and subcutaneous fat biopsy were obtained at baseline, after the exercise (week 
8) and the de-training (week 16) periods while physical activity and nutritional data 
were randomly collected for two weekdays and one weekend day at baseline, 8th and 
16th week. The data collection for physical activity and diet was conducted by an 
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independent investigator who was blinded to the aim of the study. VO2peak and 1RM 
were measured at baseline, 4th, 8th and 16th week. The details of the experimental 
protocol are displayed in Figure 8.  
 
Figure 8: Experimental protocol for randomized controlled trials 
 
VO2peak: Peak oxygen consumption; 1RM: One repetition maximum  
 
4.4.3. Anthropometry  
The participants visited the laboratory between 07:00 and 09:00 am and the following 
anthropometry measures took part: Height was measured using a Seca (Hamburg, 
Germany) device and weight using a scale (KERN & Sohn GmbH, Version 5.3, 
Germany) while WHR was measured using a tape measure and blood pressure 
through an acoustic method using an Aneroid sphygmomanometer. Percent body fat 
and fat-free mass were measured via bioelectrical impedance using a body 
composition monitor (Fresenius Medical Care AG & Co. KGaA D-61346 Bad 
Hamburg, Germany).  
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4.4.4. Assessment of resting energy expenditure 
REE assessments were conducted between 07:00 to 09:00 am following a 12-hour 
fast, while participants refrained from exercise, alcohol, and passive smoking in 72-
hour prior to the measurements [294, 295]. REE was measured using an automated 
gas analyser (Vmax, CareFusion, USA) that was attached to the participants to record 
respiratory variables every 20 seconds in a supine position for 30 minutes in a quiet 
room of 22-24°C. From the 30 minutes of the collected data, the first and last five 
minutes were removed [295]. Finally, the remaining 20 minutes of the collected data 
were averaged to obtain the final REE (kcal) value [295].  
 
4.4.5. Assessment of physical activity levels 
Physical activity levels were measured through a Digi-Walker SW–200, Yamax, United 
Kingdom pedometer that was given to the participants immediately after they 
confirmed their participation in the study. Previous studies have identified the Yamax 
pedometers as valid and reliable [296-298]. Physical activity levels were measured at 
baseline, at 8th and at 16th weeks on three separate days (two weekdays, one weekend 
day). The selection of the three separate days was random, and it was generated by 
an assistant that was blinded to the aim of the studies of this PhD. The participants 
were contacted by the assistant to report the outcome of the measurements via 
telephone. The values of the three days were then averaged to obtain the final value 
(steps/day). This was also done by an assistant that was blinded to the aim of the 
studies of this PhD. 
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4.4.6. Assessment of peak oxygen uptake and 1-repetition maximum 
A pre-screening was performed for each participant to identify their eligibility to 
undertake a VO2peak test using the Physical Activity Readiness Questionnaire (PAR-
Q) (Appendix 6) [299]. To ensure the familiarization of the participants with the 
VO2peak test a detailed verbal description of the protocol was given in advance. The 
protocol involved a 5-minute warm-up and a familiarization period of a cycling in a 
Monark Ergomedic 839E, Vansbro, Sweden. Consequently, the test involved a 3-
minute of pedalling at 60 rpm at 60 Watts followed by an increment of 30 Watts/minute 
until volitional exhaustion [300]. An automated gas analyser (Vmax, CareFusion, USA) 
was attached to the participants to record respiratory variables every 20 seconds. The 
highest oxygen uptake (L/min) for any 20-second interval was recorded as the final 
VO2peak value [300].  
The 1RM of leg extension and chest press were tested following an indirect 
method as previously described [301]. A suitable weight was adjusted for each 
participant in order to not be able to lift it for no more than 10 repetitions. The number 
of the repetitions were then calculated and a norm was used to predict the 1RM using 
the weight in kg that each participant lifted and the number of the repetitions that were 
performed [301].   
 
4.4.7. Subcutaneous fat biopsies  
All biopsies were executed by an experienced surgeon following a previous 
methodology [302] via a non-diathermy method. The participants underwent a 
subcutaneous fat biopsy after at least an 8-hour fast [303] and they were instructed to 
refrain from exercise, alcohol, and passive smoking in 72-hour prior the biopsy 
procedure in order to minimize the risk for misleading results [294, 295]. Each 
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participant was positioned on a surgical bed in a supine position. The site of the 
incision was disinfected and a 10 ml of xylocaine 2%-no adrenaline was injected in the 
region of the incision for local anaesthesia. An incision on the skin and subcutaneous 
tissue until adipose tissue was revealed, was executed approximately 3-5 cm nearby 
the navel while the incision length was approximately 2-2.5 cm. Subsequently, the 
subcutaneous tissue was removed with an operating scissors and when the adipose 
tissue became visible nearly 500 mg of adipose tissue was captured and removed. 
The collected adipose tissue was immediately immersed in liquid nitrogen of -190°C. 
For the final deposition the samples were placed in Eppendorfs and they were 
deposited in a freezer at -80°C until analyses.  
 
4.4.8. Gene and protein expression analyses 
The investigators that performed the gene and protein expression analyses were 
blinded to the aim of the studies of this PhD research.  
Gene expression analysis 
Total RNA was extracted from adipose tissue biopsies using RNeasy Lipid Tissue mini 
kit (QIAGEN) following the manufacturer’s protocol. First-strand cDNAs were 
synthesized from equal amounts of total RNA using random primers and M-MLV 
reverse transcriptase (Promega). Quantitative real time polymerase chain reaction for 
the UCP1, PGC-1α, PPARα, PPARγ, leptin and adiponectin genes was performed 
using Sybr Green fluorophore. The change in fluorescence at every cycle was 
monitored and a threshold cycle above background for each reaction was calculated. 
A melt curve analysis was performed following every run to ensure a single amplified 
product for every reaction. All reactions were carried out in at least duplicated for every 
sample. 18S rRNA gene was constantly expressed under all experimental conditions 
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and was then used as a reference gene for normalization given that this gene was 
suggested as the most appropriate one for normalization of UCP1 mRNA [304].  
UCP1 protein expression analysis 
Subcutaneous adipose tissue was homogenized in RIPA Lysis Buffer with protease 
inhibitors (Sigma-Aldrich, Milan, Italy), centrifuged at 800g for 10 minutes at 4°C and 
then the middle layer was collected. Equal amounts (50µg) of proteins were separated 
on 10% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane. UCP1 
from subcutaneous adipose tissue samples were detected by primary antibodies, 
respectively rabbit polyclonal anti-human UCP1 (1:1000, Sigma-Aldrich, Milan, Italy) 
and mouse monoclonal anti-human β-actin (1:5000, Sigma-Aldrich, Milan, Italy). 
Secondary antibodies were peroxidase-conjugated anti-rabbit IgG for UCP1 and anti-
mouse IgG for β-actin. Human adipocytes that treated with 100uM menthol were used 
as positive controls for UCP1 protein expression according to previous methodology 
[305]. Western blotting analysis was performed using Immobilion Western 
Chemiluminescent HRP Substrate (Millipore) and detection was made using 
photographic films. The images have been analysed by densitometry, which evaluates 
the relative amount of protein staining and quantifies the results in terms of optical 
density. Representative images of the photographic films are shown in Appendix 7. 
 
4.4.9. Exercise interventions for randomized controlled trial 
The exercise programmes (Table 8) for each group based on a previous study [306]. 
The supervised exercise interventions could not be blinded to the participants but to 
minimize risk of bias the exercise assistants were blinded to the aim and the design of 
the study. Also, the three different exercise programmes were performed in three 
different local Gyms to avoid participant cross contamination. To ensure the 
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attendance of the participants in the exercise sessions, a diary was created in each 
Gym where notes were kept for the presence of each participant. 
  
Table 8: Exercise protocols for randomized controlled trials 
Aerobic exercise group 
1st week 30 minutes of bicycle at 65% of VO2peak, 3 days/week 
2nd week 45 minutes of bicycle at 65% of VO2peak, 3 days/week 
3rd week 45 minutes of bicycle at 65% of VO2peak, 5 days/week 
4th – 8th week 60 minutes of bicycle at 65% of VO2peak, 5 days/week 
Resistance exercise group 
Resistance exercises: leg press, chest press, leg extension, leg curls, crunches, 
biceps curls, triceps extension, and lat pulldowns 
1st week A familiarization with resistance exercises and practice the 
movements with light weight for 4 training sessions 
2nd week 65% of 1RM, 2 sets, 8-10 repetitions/set to failure, 4 days/week 
3rd week 65% of 1RM, 3 sets of 8-10 repetitions/set to failure 4 days/week 
4th – 8th week 65% of 1RM, 4 sets, 8-10 repetitions to failure, 4 days/week 
Combined exercise group (aerobic + resistance) 
Resistance exercises: leg press, chest press, leg extension, leg curls, crunches, 
biceps curls, triceps extension, and lat pulldowns 
1st week 15 minutes of bicycle at 65% of VO2peak. Familiarization with 
resistance exercises and practices the movements with light 
weight. 3 days/week 
2nd week 23 minutes of cycling at 65% of VO2peak. 65% of 1 RM, 1 set, 8-
10 repetitions to failure. 3 days/week 
3rd week 23 minutes of cycling at 65% of VO2peak. 65% of 1 RM, 2 sets, 
8-10 repetitions to failure. 4 days/week 
4th – 8th week 30 minutes of cycling at 65% of VO2peak. 65% of 1 RM, 2 sets, 
8-10 repetitions to failure. 5 days/week 
VO2peak: Peak oxygen uptake; 1RM: One repetition maximum 
 
4.4.10. Diet Assessment 
The participants were randomly contacted by telephone – by an independent assistant 
who was blinded to the aim of this PhD study – on three separate days (two weekdays, 
one weekend day) during a one-week period for the completion of a three-day diet 
record. All food and beverages consumed on the day of contact were recorded. Three-
day diet records were collected at baseline, 8th and 16th week of the intervention. All 
diet records were analysed by another trained assistant that was blinded to the aim of 
this PhD study using Nutritionist Pro, Version 5.4.0, Axxya Systems (Redmond, WA, 
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USA). This software (i.e. Nutritionist Pro) has been previously used for research 
purposes [307, 308]. For the analysis, a search was conducted in Nutritionist Pro for 
each food and beverage consumed. Details regarding the amount and preparation of 
each food and/or beverage were also included. Once all the relevant information 
regarding the food or beverage was entered into the software, a corresponding list of 
macro and micronutrient content was provided and subsequently saved. This process 
was repeated for all food and beverages listed on the diet record. If a particular food 
or beverage was not found within the Nutritionist Pro database, the investigator 
manually entered the macro and micronutrient content of that particular food and 
saved it to the database for future use. The feedback provided by the software for 
each food or beverage included the following dietary variables: total energy intake 
(kcal), weight of food (g), protein (g), carbohydrate (g), total fat (g), total sugar (g) and 
caffeine (mg). 
 
4.4.11. General statistical approach 
All variables were tested for normal distribution using Kolmogorov-Smirnov. The 
associations between the variables were tested using Spearman correlations 
coefficient and linear regression analyses. Given the non-normal distribution of the 
variables examined in the RCTs, delta scores were calculated and they were tested 
for normal distribution using Kolmogorov-Smirnov. The delta scores displayed normal 
distribution. The effects of exercise and de-training on the delta scores of the variables 
were tested using analyses of variance (ANOVA) with Bonfferoni post-hoc t-tests. 
Following previous methodology, the 50th percentile of each variable was used to 
define the low and high responders in order to test the effects of exercise and de-
training on the high responders [309]. Chi square tests were used to assess 
71	
	
differences between the experimental groups and the variables examined based on 
low and high responders status. Kruskal–Wallis analysis of variance with post-hoc 
Mann-Witney U tests were used to assess the effects of exercise and de-training of 
high responders on the variables examined. Effect sizes of the variables between and 
within groups were calculated using pooled Cohen’s d effect size analyses [310, 311]. 
Finally, Wilcoxon Signed Rank tests were used to calculate differences within groups 
between time points given the abnormal distribution of some variables. All analyses 
were conducted with SPSS Inc., Chicago, IL, USA, version 22 and a P≤0.05 level of 
significance.  
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5. CHAPTER 5: EFFECTS OF PHYSICAL ACTIVITY ON THE LINK BETWEEN 
PGC-1α AND FNDC5 IN MUSCLE, CIRCULATING IRISIN, AND UCP1 OF WHITE 
ADIPOCYTES IN HUMANS: A SYSTEMATIC REVIEW (1st study) 
This systematic review was submitted for publication to the peer-reviewed journal 
F1000Research where the author of this Thesis also appears as the leading author.  
 
5.1. INTRODUCTION 
Recently it has been presented that acute and chronic exercise activates a brown 
adipose-like phenotype in WAT [30] through a number of sequential steps. Indeed, it 
has long been established that exercise increases the activation of the PGC-1α gene 
in human skeletal muscle [312]. Further, PGC-1α has been implicated in both the 
control of tissue mitochondrial content and the programme that results in BAT 
formation [313]. PGC-1α is a co-transcriptional regulator facilitating multiple 
transcription factors to regulate a complex network of genes [314]. While skeletal 
muscle properly adapts to exercise in the absence of PGC-1α [315], activation of PGC-
1α was proposed to increase the FNDC5.  
FNDC5, is a membrane protein expressed mainly in brain and skeletal muscle 
[316]. It was proposed that FNDC5 was cleaved during exercise, released into the 
bloodstream as Irisin – a peptide fragment of FNDC5 measured by western blotting 
[30]. In vitro, exposure of white adipocytes to Irisin subsequently – through an 
unknown receptor – led to increased expression of the PPARα which in turn increased 
UCP1 mRNA [30, 229]. The increase in white adipocyte UCP1 mRNA observed with 
Irisin treatment, presented as fold-change over control, was extremely modest as 
white adipocytes in culture do not usually express UCP1 mRNA and thus use of “fold 
increase” could be deceptive [209].  
Since, UCP1 is the only contributor to NST that occurs in BAT [208] and it 
appears that the presence of UCP1 in a white adipocyte is accompanied by brown-
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like adipose tissue properties [209, 317, 318] it was proposed that increased 
circulating Irisin in humans after a chronic exercise programme [30] may promote 
increased weight loss and improved metabolic control through induction of UCP1. This 
hypothesis seemed reasonable, as Irisin over-expression stimulated oxygen 
consumption and has been described to have an inverse association with blood 
glucose, insulin, total cholesterol, and a positive association with adiponectin 
concentrations [266]. Nevertheless, many other studies have failed to observe similar 
positive associations [319-321], while the ability for exercise to cause “browning” of 
white adipose phenotype remains unclear [33, 236, 238]. 
Further, a role for exercise regulating circulating Irisin concentration remains to 
be definitively established. Indeed, data indicate that while older adults appear to have 
a 30% increase in FNDC5 mRNA in muscle compared to younger adults, FNDC5 
mRNA was unresponsive to six weeks of endurance training [267] despite robust 
increase in mitochondria [322]. Indeed, results have overall, been rather ambiguous 
in terms of the effects of exercise on circulating Irisin [33, 268-271] and various 
methodological concerns have been highlighted that may explain the various highly 
conflicting results [35, 323]. Given that circulating Irisin continues to be measured 
using diverse methods, and additional correlative studies progressed, an evaluation 
of the available evidence for its relationship with humans’ health is heavily warranted. 
Therefore, the aim of the current review was to systematically identify the effects of 
physical activity on the link between PGC-1α and FNDC5 in muscle, circulating Irisin 
as well as evidence for regulation of UCP1 in WAT in humans. 
 
5.2. METHODS 
Methods of this systematic review are described in detail in Chapter 4, pages 57-61. 
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5.3. RESULTS 
5.3.1. Searching procedure results 
The searching procedure revealed 45 studies that met the inclusion criteria and 
therefore, were included in this systematic review. The reference lists of these studies 
did not result in the identification of additional relevant articles. The searching outcome 
is presented in a PRISMA flow diagram in Figure 9. 
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Figure 9: Flow diagram of study selection and identification (PRISMA guidelines) 
 
 
 5.3.2. Characteristics of the included studies  
The characteristics and the results of the included studies can be found in Table 9.
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Table 9: Characteristics of the studies included in the systematic review 
First author Design Participants Main outcome Secondary outcome measures 
Method of  
Irisin 
identification 
Randomised Controlled Trials 
Bang 2014 RCT Seven healthy Korean M 
An 8-week of CE (resistance) did not alter circulating 
Irisin  
Exercise did not alter blood glucose 
and insulin levels. 
PP, Burlingame. 
CNS 
Greulich, 
2014 RCT 
COPD patients: 26 
M, 14 F An 8-day vibration exercise increased circulating Irisin - 
AB, INC. CNS 
Hecksteden, 
2013 RCT 
Healthy sedentary: 
38 M, 64 F 
No changes in circulating Irisin after 26-week aerobic 
exercise 
No relationship between changes in 
circulating Irisin with age, sex and 
BMI 
AB, Santa Clara, 
CA. CNS 
Kim 2015 RCT 40 elderly healthy F A 12-week resistance CE increased circulating Irisin 
Increased circulating Irisin was 
positively correlated with muscle 
strength 
PP, USA 
Scharhag-
Rosenberge
r  2014 
RCT 
37 exercised and 34 
controls healthy M 
and F 
A 6-month resistance training increased circulating Irisin 
in control but not in exercise group 
Resting metabolic rate was 
increased in exercise group but was 
not associated with circulating Irisin 
PP, Burlingame. 
CNS and Sunrise 
microplate reader 
(Tecan, 
Mannerdorf, 
Switzerland) 
Huh, 2015 C-RCT 
Eight healthy 
sedentary M, 4 M 
with MetS 
AE (high density aerobic and resistance) increased 
circulating Irisin in healthy and metabolic syndrome 
patients 
Resistance exercise was more 
effective in increasing circulating 
Irisin than endurance exercise 
PP, EK-067-52, 
and EK-067-29 
Nygaard, 
2015 C-RCT 
Two F and seven M 
moderately trained 
healthy 
AE increased PGC-1α splice variant 1 mRNA in muscle. 
No changes on FNDC5 mRNA in muscle. Intense 
endurance AE and heavy strength training increased 
circulating Irisin. 
No correlations between PGC-1α 
splice variant 1 and circulating Irisin 
PP, EK-067-29 
Tsuchiya, 
2014 C-RCT 
Six healthy 
sedentary young M 
AE (running) increased circulating Irisin greater in high 
intensity than in low intensity 
Low intensity AE reduced circulating 
Irisin immediately after exercise 
compared with pre-exercise values 
PP, EK-067-52 
Tsuchiya, 
2015 C-RCT 10 healthy M 
Resistance AE increased circulating Irisin. Endurance 
and combined (endurance + resistance) AE did not alter 
circulating Irisin 
Circulating Irisin was positively 
correlated with blood glucose, lactate 
and plasma glycerol 
PP, EK-067-52 
Controlled trials 
Aydin, 2013 CT 14 obese M, and 14 normal weight M AE increased saliva Irisin. No changes in serum Irisin 
Circulating Irisin was negatively 
correlated with BMI  
PP, H-067-17 
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First author 
 
Design 
 
Participants 
 
Main outcome 
 
Secondary outcome measures 
 
Method of  
Irisin 
identification 
Ijiri 2015a CT 8 M COPD patients An 8-week of CE increased circulating Irisin. AE did not alter circulating Irisin 
Circulating Irisin was not correlated 
with pulmonary function parameters 
and 6-min walk distance 
PP, Burlingame. 
CNS 
Kraemer, 
2014 CT 
Healthy: Seven M, 
Five F 
AE increased circulating Irisin at 54th minute of the 
exercise session but decreased after the exercise 
session in men. In women AE increased circulating Irisin 
at 54th minute 
- 
AB, Burlingame, 
CA. CNS 
Miyamoto-
Mikami  
2015 
CT 
16 M and nine F 
young/ 12 m and 16 
F middle-aged older 
healthy 
An 8-week CE programme increased circulating Irisin in 
middle-aged/older healthy. Exercise did not alter 
circulating Irisin in young healthy 
Circulating Irisin was negatively 
correlated with visceral adipose 
tissue after CE. No correlation of 
circulating Irisin with abdominal 
subcutaneous adipose tissue area 
and whole-body fat. 
PP, EK-067-16 
Norheim, 
2014 CT 
13 M healthy 
controls, and 11 M 
pre-diabetic 
AE and CE increased PGC-1α mRNA in muscle in both 
controls and pre-diabetic. CE increased FNDC5 mRNA in 
muscle of both groups. AE increased circulating Irisin 
levels in both groups. CE decreased Irisin levels. No 
effect of CE on UCP1 in subcutaneous WAT 
PGC-1α mRNA in muscle was not 
correlated with circulating Irisin. 
Neither FNDC5 mRNA in muscle nor 
circulating Irisin nor UCP1 mRNA in 
subcutaneous WAT were correlated 
PP, EK-067-52, 
and EK-067-29 
Pekkala, 
2013 CT 
Healthy M: 17 
middle-age, 10 
young, 29 older 
A 21-week CE did not alter PGC-1α and FNDC5 mRNA 
in muscle, and circulating Irisin. Resistance AE increased 
FNDC5 mRNA in muscle in young 
Circulating Irisin and FNDC5 mRNA 
in muscle were not associated with 
HOMA, plasma glucose and serum 
insulin 
PP, Inc., 
Burlingame, CA 
(16–127) 
Prestes, 
2015 CT 72 elderly F 
A 16-week CE (resistance) did not increase circulating 
Irisin - 
MyBioSource 
Inc., San Diego, 
CA. CNS 
Timmons, 
2012 CT 
24 young sedentary 
and 43 healthy M 
A 6-week of CE (intense cycling and resistance) did not 
alter FNDC5 mRNA in muscle 
FNDC5 mRNA was not linked to 
diabetes status 
Not measured 
Single group interventional design studies 
Alvehus, 
2014 SGS 17 healthy young M 
An 8-week of CE did not alter PGC-1α mRNA in both 
muscle and WAT and FNDC5 mRNA in muscle - 
Not measured 
Anastasilaki
s, 2014 SGS 
20 young healthy 10 
F and 10 M 
AE increased circulating Irisin. No association of PA 
levels with circulating Irisin 
Circulating Irisin was positively 
correlated with LBM and glucose but 
it was not correlated with BMI, WHR, 
HOMA, insulin and leptin 
PP, EK-067-52 
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First author Design Participants Main outcome Secondary outcome measures 
Method of  
Irisin 
identification 
Besse-Patin,  
2014 SGS 
11 sedentary obese 
M An 8-week of CE did not alter FNDC5 mRNA in muscle - 
Not measured 
Blüher, 
2014 SGS 
65 obese children 7-
18 years old M and 
F 
A 12-month of PA intervention increased circulating Irisin 
Circulating Irisin was not correlated 
with inflammatory markers at 
baseline 
PP, EK-067-52 
Boström, 
2012 SGS Eight non-diabetic M 
A 10-week of CE increased FNDC5 mRNA in muscle, 
and circulating Irisin 
Circulating Irisin did not alter oxygen 
consumption and weight loss in vivo 
Western blot 
BCA-kit (Thermo 
Scientific) 
Camera 
2015 SGS 
Eight healthy trained 
M 
AE (resistance) increased PGC-1α mRNA in muscle four 
hours post exercise, but it did not alter FNDC5 mRNA in 
muscle 
- 
Not measured 
Comassi, 
2015 SGS 
14 M ironman 
racers, 13 M half-
ironman races 
The half-ironman race increased circulating Irisin 
The half-ironman race decreased 
body weight, BMI, LBM but not fat 
mass 
Not mentioned 
Daskalopoul
ou, 2014 SGS Healthy: 22 M, 17 F 
AE (treadmill) increased circulating Irisin, with greater 
increase in maximal workload 
Circulating Irisin was positively 
correlated with lactate after maximal 
workload and it was greater in 
individuals with higher than 
individuals with lower VO2max. No 
relationship of circulating Irisin with 
REE post exercise 
PP, EK-067-52 
Ellefsen, 
2014 SGS 
18 untrained young 
F 
A 12-week of CE decreased PGC-1α Slice4 mRNA in 
muscle, but it did not alter FNDC5 mRNA in muscle and 
circulating Irisin 
Circulating Irisin was positively 
correlated with FNDC5 mRNA in 
muscle while no relationship was 
found with fat mass after exercise 
PP, EK-067-29 
Hew-Butler,  
2015 SGS Nine F non-runners 
A 10-week of walk/running programme did not alter 
circulating Irisin 
No relationship of circulating Irisin 
with LBM, VO2peak and fat mass 
after the exercise programme 
PP, Burlingame, 
CA, EK-067-52 
and EK-067-29 
Huh, 2012 SGS 15 healthy M AE increased circulating Irisin. An 8-week of CE did not alter circulating Irisin 
Circulating Irisin was not correlated 
with ATP levels after exercise 
AB, Santa Clara, 
CA. CNS 
Huh, 2014 SGS 
Healthy: 78 m, 15 M 
and 15 F 
adolescents 
An 8-week of CE increased PGC-1α mRNA in muscle 
and FNDC5 mRNA in muscle. AE (treadmill & swimming) 
increased circulating Irisin 
Incubated Irisin in human skeletal 
muscle cells (in vitro) increased 
glucose and fatty acid uptake 
PP, EK-067-52 
Huh, 2014a SGS 14 healthy F AE (vibration) increased circulating Irisin. A 6-week of CE (vibration) did not change circulating Irisin 
Circulating Irisin was positively 
correlated with cortisol after exercise 
PP, EK-067-52 
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First author Design Participants Main outcome Secondary outcome measures 
Method of  
Irisin 
identification 
Khodadadi, 
2014 SGS 21 overweight F 
High intense interval AE increased circulating Irisin. One 
session of Pilates exercise did not alter circulating Irisin - 
ELISA, Sweden 
Kurdiova, 
2014 SGS 
Sedentary 
overweight/obese: 
10 M, Six F 
AE increased PGC-1α mRNA in muscle but it did not 
alter FNDC5 mRNA in muscle. A 12-week CE did not 
alter FNDC5 mRNA in muscle and circulating Irisin 
Circulating Irisin was negatively 
associated with fasting glycaemia 
but it was not associated with 
VO2max before and post exercise 
PP, RK-067-16 
Lee, 2014 SGS Healthy: Six m, Four F 
Submaximal AE increased circulating Irisin whereas 
maximal AE did not alter circulating Irisin following 
graded stepwise cold exposure 
Circulating Irisin increased after cold 
exposure. REE was greater after 
maximal exercise compare to cold 
exposure 
Mass 
spectrometry/  
Western blot 
BCA-kit / 
PP, Burlingame, 
CA, CNS 
Löffler 2015 SGS 
28 healthy adults. 
Children 12 years 
and older, 48 M, 40 
F 
AE increased circulating Irisin in both adults and children. 
A 6-week in house CE did not alter circulating Irisin in 
children (n=62). Three years of low grade PA intervention 
in children did not alter circulating Irisin 
Circulating Irisin was positively 
associated with BMI, LBM and 
triglycerides as well as negatively 
with HDL in adults 
PP, EK-067-52 
Moraes, 
2013 SGS 
13 M, and 13 F 
haemodialysis 
patients 
A 6-month of CE did not alter circulating Irisin 
Circulating Irisin was greater in 
haemodialysis patients than in 
healthy (baseline). No correlation 
with physical capacity, 
anthropometry and creatinine levels 
PP, Burlingame. 
CNS 
Palacios-
González,  
2015 
SGS 
85 healthy children 
8-11 years old. 45 F 
and 40 M 
An 8-month PA programme did not alter circulating Irisin 
levels 
Circulating Irisin was positively 
associated with BMI before and after 
the PA programme as well as leptin 
after the PA programme 
Cusabio 
Biotech.CNS 
Raschke, 
2013 SGS 13 healthy M A 10-week of CE did not alter FNDC5 mRNA in muscle 
The FNDC5 gene is mutated due to 
the non-ATG start codon and it is not 
activated by electrical stimulation 
Not measured 
Scalzo, 
2014 SGS 
Healthy: Seven m, 
12 F 
A 3-week of CE did not alter FNDC5 mRNA in muscle 
and it decreased circulating Irisin in M while it increased 
circulating Irisin in F 
Circulating Irisin was not correlated 
with FNDC5 mRNA, fasting glucose, 
insulin and HOMA 
PP, Burlingame, 
CA, CNS 
Cross sectional studies 
Al-Daghri, 
2015 CSS 
35 M/48 F diabetes 
type 2 patients and 
42 M/39 F healthy 
Habitual PA was positively associated with circulating 
Irisin in healthy 
Irisin was positively correlated with waist 
circumference in healthy and negatively 
with LBM and blood pressure in diabetes 
type 2 patients 
PP, CNS 
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First author Design Participants Main outcome Secondary outcome measures 
Method of  
Irisin 
identification 
Hofmann, 
2014 CSS 39 anorexic F 
Circulating Irisin was not correlated with numbers of 
steps per day 
No relationship between circulating 
Irisin and METs, as well as energy 
expenditure 
PP, RK-067-16 
Ijiri 2015b CSS 
65 M and seven F 
COPD patients. 24 
M and three F 
healthy controls 
Physical activity levels was positively associated with 
circulating Irisin in both COPD patients and controls - 
PP, Burlingame. 
CNS 
Jedrychows
ki 2015 CSS 
Four sedentary 
controls M and Six 
young healthy M 
Circulating Irisin was detected after a 12-week high-
intensity aerobic CE - 
Mass 
spectrometer 
(Thermo Fisher 
Scientific) 
Lecker, 
2012 CSS 
24 M systolic heart 
failure patients 
PGC-1α mRNA was positively correlated with FNDC5 
mRNA in muscle. - 
Not measured 
Moreno, 
2015 CSS 
191 M and 230 F 
non-diabetic 
Circulating Irisin was higher in physically active than in 
sedentary individuals 
Circulating Irisin was positively 
associated with weight, BMI, 
triglycerides, insulin and HOMA 
SK00170-01, AB 
INC, Santa Clara, 
California 
Palermo 
2015 CSS 
65 postmenopausal 
F affected by 
osteoporosis 
No correlation between circulating Irisin and daily PA 
No relationship between circulating 
Irisin and LBM, fat mass, body mass 
density and METs 
AG-45A-0046EK-
KI01; Adipogen 
AG, Liestal, 
Switzerland 
Pardo, 2014 CSS 30 anorexic, 66 obese, 49 healthy F Circulating Irisin was negatively correlated with daily PA 
Circulating Irisin was positively 
correlated with resting energy 
expenditure, LBM and fat mass 
PP, EK-067-52 
 
RCT: Randomized control trial; COPD: Chronic obstructive pulmonary disease; M: males; F: females; PGC-1α: peroxisome proliferator-activated receptor-γ coactivator 
1α; AB: Aviscera Bioscience; CNS: Code not specified; BMI: Body mass index; PP: Phoenix Pharmaceuticals; C-RCT: cross-over randomized controlled trail; MetS: 
Metabolic Syndrome; AE: Acute exercise; FNDC5: Fibronectin type III domain-containing protein 5; CT: Controlled trial; CE: chronic exercise; PA: Physical activity; UCP1: 
Uncoupling protein 1; WAT: White adipose tissue; HOMA: homeostatic model assessment; SGS: Single group design studies; LBM: Lean body mass; WHR: Waist to hip 
ratio; VO2max: Maximal oxygen uptake; REE: Resting energy expenditure; VO2peak: Maximal peak uptake; ATP: Adenosine triphosphate; HDL: High density lipoprotein; 
CSS: Cross-sectional study; METs: Metabolic equivalent; VO2peak: peak oxygen consumption; SNPs: Single nucleotide polymorphisms.
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From the 45 eligible studies, nine (20%) were RCTs, of which four were cross-over 
RCTs (C-RCT), eight (17.8%) were CTs, 21 (46.6%) were SGS, and seven (15.6%) 
were CSS. One of the included RCTs [324] report the effect of resistance exercise 
training versus the effects of resistance exercise training combined with Ursolic 
supplementation, because for the latter group the effects of resistance exercise cannot 
be isolated, we will report only the results from the resistance exercise training group. 
Furthermore, one of the CTs [325] will be included in the results of both CTs and CSS 
because this study consisted of a controlled trial nested within a cross-sectional study. 
The 84% of the included studies (n=38) examined healthy populations, while seven 
included overweight/obese adults and children [33, 309, 326-330]. Ten of the 45 
studies also included a clinical population: including patients with chronic obstructive 
pulmonary disease (COPD) [271, 325], heart failure [331], metabolic syndrome [332], 
haemodialysis [333], osteoporotic [334], anorexia nervosa [327, 335], pre-diabetes 
[236] and diabetes type 2 [336].  
 
5.3.3. Risk of bias and quality of reporting data 
The risk of bias assessment results can be found in Figure 10, while a summary is 
displayed in Figure 11.  
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Figure 10: Risk of bias assessment of the included studies using the Cochrane 
Collaboration’s tool 
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Figure 11: Summary of risk of bias 
 
 
Five RCTs/C-RCTs [31, 332, 337-339] and all the included CTs, SGS as well as CSS 
displayed high risk of bias due to inadequate generation of a randomised sequence, 
while three RCTs/C-RCTs [271, 324, 340] showed low risk of bias and one RCT/C-
RCT [341] showed unclear risk of bias because there was no description of the method 
used for allocation (even though the participants were said to be “randomly” assigned). 
Five RCTs/C-RCTs [31, 271, 337, 339, 340], displayed low risk of bias for “allocation 
concealment”, while two [332, 341] showed unclear risk of bias because of the lack of 
description of the randomization allocation. Also, two RCTs/C-RCTs [324, 338] and all 
the included CTs, SGS as well as CSS showed high risk of bias due to the lack of 
concealment of allocations before assignment. In “blinding of participants and 
personnel” all RCTs/C-RCTs, CTs, SGS and CSS displayed high risk of bias because 
the exercise interventions could not be blinded to the participants.  
In “blinding of outcome assessment”, three RCTs/C-RCTs displayed low risk of 
bias, [271, 340, 341] while four RCTs/C-RCTs [31, 332, 337, 339] and one CT [236] 
showed unclear risk of bias because of the lack of information regarding the blinding 
84	
	
of assessments. Also, two RCTs/C-RCTs [324, 338], the remaining seven CTs, all the 
included SGS and CSS showed high risk of bias due to the knowledge of the allocated 
interventions by the assessors. Five RCTs/C-RCTs [271, 324, 338, 340, 341], one CT 
[309] and three SGS [329, 342, 343] displayed low risk of bias while four RCTs/C-
RCTs [31, 332, 337, 339], the remaining seven CTs and the remaining 18 SGS as well 
as all the included CSS showed unclear risk of bias for “incomplete outcome data” 
because of the lack of information on the participants who dropped out or exclusions 
in the analysis. All the included studies showed low risk of bias of “selective reporting” 
because they reported all the outcomes measured while all the included studies 
displayed low risk of bias in “other bias”. 
The results of our evaluation in the quality of the reporting data showed a mean 
score of 14 out of 25 (55%) for the included RCTs, 11 out of 25 (42%) for the included 
CTs, 12 out of 25 (42%) for the included SGS and 13 out of 22 (60%) for the included 
CSS. Score represents the number of items (with percentage of items) on the checklist 
that were reported satisfactorily in each study. Therefore, a high score represents a 
high adherence to reporting guidelines, while a low score represents low adherence 
to reporting guidelines. The results of the reporting data can be found in Table 10 for 
the included RCTs, CTs and SGS and in Table 11 for the included CSS.   
 
Table 10: Results of the quality of the reporting of the results using the Consolidated 
Standards of Reporting Trials checklist 
 FIRST AUTHOR SCORE 
Randomized Controlled Trials 
1 Bang, 2014 (14.5/25) 58% 
2 Greulich, 2014 (18/25) 72% 
3 Hecksteden, 2013 (16.5/25) 66% 
4 Kim, 2015 (14/25) 56% 
5 Huh, 2015 (12.5/25) 50% 
6 Nygaard, 2015 (11.5/25) 46% 
7 Scharhag-Rosenberger, 2014 (15/25) 60% 
8 Tsuchiya, 2014 (10.5/25) 42% 
85	
	
9 Tsuchiya, 2015 (12/25) 48% 
Controlled Trials 
10 Aydin, 2013 (10.5/25) 42% 
11 Ijiri, 2015a (11.5/25) 46% 
12 Kraemer, 2014 (10.5/25) 42% 
13 Miyamoto-Mikami,  2015 (11.5/25) 46% 
14 Norheim, 2014 (11/25) 44% 
15 Pekkala, 2013 (9/25) 36% 
16 Prestes, 2015 (14.5/25) 58% 
17 Timmons, 2012 (6/25) 24% 
Single group design studies 
18 Alvehus, 2014 (10/25) 40% 
19 Anastasilakis, 2014 (11.5/25) 46% 
20 Besse-Patin, 2014 (13/25) 52% 
21 Blüher, 2014 (14/25) 56% 
22 Boström, 2012 (7/25) 28% 
23 Camera, 2015 (7/25) 28% 
24 Comassi, 2015 (13/25) 52% 
25 Daskalopoulou, 2014 (12.5/25) 50% 
26 Ellefsen, 2014 (10/25) 40% 
27 Hew-Butler,  2015 (12.5/25) 50% 
28 Huh, 2012 (10.5/25) 42% 
29 Huh, 2014 (11/25) 44% 
30 Huh, 2014a (6/25) 24% 
31 Khodadadi, 2014 (10.5/25) 42% 
32 Kurdiova, 2014 (11.5/25) 46% 
33 Lee, 2014 (8.5/25) 34% 
34 Löffler, 2015 (11/25) 44% 
35 Moraes, 2013 (12/25) 48% 
36 Palacios-González, 2015 (12/25) 48% 
37 Raschke, 2013 (9/25) 36% 
38 Scalzo, 2014 (11/25) 44% 
Score represents the number of items (with percentage of items) on the checklist that 
were reported satisfactorily in each study. Therefore, a high score represents a high 
adherence to reporting guidelines, while a low score represents low adherence to 
reporting guidelines. 
 
Table 11: Results of the quality of the reporting of the results using the Strengthening 
the Reporting of Observational Studies in Epidemiology checklist 
 FIRST AUTHOR SCORE 
1 Al-Daghri, 2015 (12.8/22) 58.18 % 
2 Hofmann, 2014 (15.6/22) 70.9 % 
3 Ijiri, 2015b (13.5/22) 61.36% 
4 Jedrychowski 2015 (12/22) 54.45 % 
5 Lecker, 2012 (13.3/22) 60.45 % 
6 Moreno, 2015 (12.5/22) 56.81 % 
7 Palermo, 2015 (13.5/22) 61.36 
8 Pardo, 2014 (12.2/22) 55.45 % 
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Score represents the number of items (with percentage of items) on the checklist that 
were reported satisfactorily in each study. Therefore, a high score represents a high 
adherence to reporting guidelines, while a low score represents low adherence to 
reporting guidelines. 
 
5.4. REPORTING OF OUTCOMES  
5.4.1. Main results of randomized controlled trials 
Acute effects of exercise 
A resistance training session increased PGC-1α splice variant 1 but it did not change 
FNDC5 mRNA in the muscle of healthy adults 4-hour after exercise [31] while 
circulating Irisin increased over the following 24-hour [31] so indicating that there is no 
short-term association between FNDC5 and Irisin. Similarly, a running exercise 
session in healthy individuals [337] and an aerobic exercise session as well as a 
resistance exercise session in healthy individuals and in metabolic syndrome patients 
[332] increased circulating Irisin. Also, an acute resistance exercise session increased 
circulating Irisin as oppose to aerobic and combined (aerobic+resistance) sessions 
that did not alter circulating Irisin in healthy males [339].  
Chronic effects of exercise  
Overall, the results of the RCTs/C-RCTs show large inconsistency on the effects of 
chronic exercise on circulating Irisin while the populations examined showed large 
heterogeneity. An 8-week of resistance training in healthy adults did not alter 
circulating Irisin [324]. Also, an 8-day vibration exercise increased circulating Irisin in 
COPD patients [271] while a 26-week aerobic exercise program revealed no changes 
in circulating Irisin of healthy adults [340]. A 6-month resistance training increased 
circulating Irisin in healthy controls but not in the exercisers [341]. Furthermore, a 12-
week resistance exercise increased circulating Irisin in elderly healthy females [338]. 
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5.4.2. Main results of controlled trials 
Acute effects of exercise 
A 45-minute endurance exercise session increased PGC-1α mRNA in muscle and 
circulating Irisin, but it did not change FNDC5 mRNA in muscle in both healthy and 
pre-diabetic adults [236]. Also, a resistance exercise session increased PGC-1α 
mRNA in muscle of both young and older healthy adults, while it increased FNDC5 
mRNA in muscle only in young healthy adults and it did not alter circulating Irisin of 
both young and older healthy adults [32]. These results cannot confirm the link 
between PGC-1α, FNDC5 and Irisin. Furthermore a 90-minute aerobic exercise 
session increased circulating Irisin in healthy adults [344] whereas 45 minutes of 
running did not alter circulating Irisin in obese healthy adults [326].  Similarly, an acute 
cycling session did not alter circulating Irisin in COPD patients [325]. These results 
indicate an inconsistency of the effects of acute exercise on circulating Irisin.  
Chronic effects of exercise 
A 21-week endurance and resistance combined exercise programme in healthy adults 
did not alter PGC-1α and FNDC5 mRNA in muscle, as well as circulating Irisin  [32]. 
However, a 12-week of endurance and resistance combined exercise training in both 
healthy and pre-diabetic adults increased Exon 11 of PGC-1α and FNDC5 mRNA in 
muscle when normalised to 60S acidic ribosomal protein P0 while it decreased 
circulating Irisin and had no effect on UCP1 mRNA in subcutaneous WAT [236]. One 
of the included CTs [267] found no effect on PGC1α or FNDC5 mRNA in younger 
adults (despite detecting significant changes in ~1,000 other mRNAs and finding 
mitochondrial enzyme activity was increased ~25%) [345]. Overall, the 
aforementioned findings demonstrate an inconsistency of the effects of chronic 
exercise on the link between PGC-1α and FNDC5. Furthermore, an 8-week of 
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endurance training increased circulating Irisin only in middle-aged and not in young 
healthy adults [346] while an 8-week chronic exercise program in COPD patients 
increased circulating Irisin [325]. Finally, a 16-week of resistance exercise program in 
elderly women did not increase circulating Irisin [309]. 
 
5.4.3. Main results of single-group design studies 
Acute effects of exercise 
An acute resistance exercise session increased PGC-1α mRNA in muscle four hours 
post exercise while it did not alter FNDC5 mRNA in muscle of healthy adults [237]. 
Nevertheless, an acute exercise session did not alter PGC-1α mRNA in muscle [347]. 
Also, PGC-1α mRNA in muscle increased in response to acute exercise however, 
neither FNDC5 mRNA in muscle nor circulating Irisin was altered in sedentary 
overweight and obese adults [33]. Nine out of the 21 included SGS showed that acute 
exercise increased circulating Irisin in healthy populations [34, 266, 268-270, 328, 343, 
348, 349]. These results appear to show some consistency of the effects of acute 
exercise on circulating Irisin in healthy participants.  
Chronic effects of exercise 
An 8-week sprints exercise programme increased PGC-1α and FNDC5 mRNA in 
muscle but it did not alter circulating Irisin in healthy adults [34] while an 8-week of 
resistance exercise did not alter PGC-1α or FNDC5 mRNA in muscle of young healthy 
adults [347]. However, Bostrom et al. (2012) showed that in eight older participants 
[350] chronic exercise increased both FNDC5 mRNA in muscle and circulating Irisin. 
Interestingly, 12 weeks of resistance training did not alter PGC-1α splice variant 1 
mRNA [238] while chronic resistance training changed neither the FNDC5 mRNA in 
muscle nor the circulating Irisin [238].  
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Also, a 12-week of aerobic and resistance exercise combined programme [33] 
and an 8-week aerobic exercise programme [330] did not alter FNDC5 mRNA in 
muscle of sedentary obese adults while chronic exercise had no effect on FNDC5 
mRNA in muscle of healthy adults [274]. Finally, a 3-week of sprint interval training did 
not alter FNDC5 mRNA in muscle and showed a gender difference in circulating Irisin, 
which were decreased in healthy males and increased in healthy females [351]. These 
results do not allow drawing conclusive inferences regarding the effects of chronic 
exercise on PGC-1α, FNDC5, and/or circulating Irisin.  
 Five SGS showed that chronic exercise did not alter circulating Irisin in healthy 
individuals [238, 266, 269, 342, 348] and haemodialysis patients [333]. However, a 
12-month physical activity intervention increased circulating Irisin by ~13% in obese 
children [329]. Notably, Irisin levels were 111.0 ng/ml i.e. 20 times greater than recent 
mass-spectrometry based detection concentrations strongly indicating that the ELISA 
was detecting multiple proteins. Overall, given both the inconsistency of the findings 
and the absence of a control group, the results from these SGS should be considered 
with caution.   
 
5.4.4. Main results of cross-sectional studies  
We have included seven CSS and a cross-sectional analysis within an included CT 
[325]. Particularly, PGC-1α mRNA in muscle was positively associated with FNDC5 
mRNA in muscle in a sub-set of 24 patients with heart failure [331] while stratification 
was ad hoc. Nevertheless, increased physical activity levels were positively associated 
with circulating Irisin in healthy adults but not in patients with T2D [336]. Also, one 
study contrasted plasma Irisin concentrations in six younger individuals following 12-
week high intensity aerobic exercise with those found in a separate group of four 
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individuals (no pre-training samples were presented) [276]. This study used mass 
spectrometer (Thermo Fisher Scientific) and detected 3-4ng/ml of circulating Irisin. No 
details regarding training or control of hydration in the training group were reported 
[276].  
Physical activity levels were not associated with circulating Irisin in osteoporotic 
women [334] and in anorexic women [335]. Also, physical activity levels were 
positively associated with circulating Irisin in non-diabetic active individuals, but not in 
non-diabetic sedentary individuals [352]. However, physical activity levels were 
negatively associated with circulating Irisin in groups of anorexic, obese and healthy 
women [327]. Finally, physical activity levels were positively associated with circulating 
Irisin in both COPD patients and healthy [325]. These results are disparate and cannot 
indicate the association of physical activity with circulating Irisin in humans.  
 
5.4.5. Results for associations of Irisin with secondary outcome 
measures 
The secondary results of the included studies can be found in Table 9. An important 
secondary finding was that the start-codon for the FNDC5 gene in human and mouse 
are different, raising doubts that the human gene would be efficiently translated and 
hence limit the potential for Irisin production [274]. Also, in 118 muscle profiles FNDC5 
mRNA was modestly and positively correlated with BMI (r2=0.1), rather than 
negatively, while FDNC5 mRNA was not related to fasting glucose or glycaemic 
control [267]. Furthermore, circulating Irisin was not associated with inflammatory 
indices [329], blood glucose [32, 351], homeostatic model assessment (HOMA) [32, 
349, 351], insulin [32, 349, 351], leptin [349], lean body mass [334, 342], fat mass 
[238, 334, 342], WHR [349], REE [268, 341], BMI [349], and pulmonary function [325].  
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Additional secondary results show that circulating Irisin was positively 
associated with BMI [348, 352, 353], triglycerides [348, 352], fat mass [327], HOMA 
[352], insulin [352], blood glucose [349] and leptin [353] and negatively with high 
density lipoprotein cholesterol [348], all of which indicate unfavourable effects of Irisin 
on human health. Nevertheless, some secondary evidence suggests that circulating 
Irisin was positively associated with fat-free mass [327, 348] and REE [327], while 
Irisin that was incubated within white adipocytes in vitro increased glucose and fatty 
acids uptake [34]. Furthermore, circulating Irisin after a maximal workload was 
significantly greater in individuals with higher VO2max than individuals with lower 
VO2max [268]. However, circulating Irisin was not associated with VO2peak before 
and post exercise in healthy female [342] and sedentary overweight and obese 
individuals [33].   
 
5.5. DISCUSSION 
5.5.1. Applicability of evidence 
We were unable to find strong evidence that links PGC-1α and FNDC5 mRNA in 
muscle or that circulating Irisin increases in response to exercise training or increased 
physical activity levels. Notably, we located only one study that examined the effects 
of exercise on UCP1 in WAT, and this found no effect [236]. Despite PGC-1α being 
firmly placed as a central regulator of adaptation to exercise in mice [354] and humans 
[31, 237], numerous aspects of the literature are contradictory or incomplete. For 
example, there is no evidence that PGC-1α mRNA accumulates with endurance 
training, while studies of PGC-1α protein reflect various antibodies that measure 
distinct molecular entities ranging from 70 to >110 Kda [240-242]. Furthermore, mice 
lacking PGC-1α adapt normally to endurance exercise training, and in humans the 
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PGC-1α regulated gene network does not correlate with aerobic adaptation [345]. 
Thus, any argument that places Irisin as part of the core PGC-1α regulated exercise 
adaptation programme needs to reflect, on both technical and theoretical grounds 
[355].  
When PGC-1α protein content is measured (albeit with uncertainty over protein 
identities) exercise training increases PGC-1α protein in skeletal muscle or causes 
nuclear translocation of protein [356-359]. However, the studies included in the current 
review only relied on measuring PGC-1α mRNA to determine the effects of exercise 
on PGC-1α and the time-course of mRNA and protein responses to exercise are 
distinct. Thus, the link between PGC-1α and FNDC5 in skeletal muscle may reflect 
measurement of mRNA dynamics and this may explain inconsistent findings for PGC-
1α. Also, the original hypothesis and data specifically indicated that induction of PGC-
1α mRNA and then protein would activate the transcription of FNDC5 and hence it 
would be expected if this theory was correct a strong correlation between PGC-1α 
mRNA and FNDC5 mRNA would exist. However, previous evidence showed that the 
FNDC5 mRNA in muscle is not regularly increased by exercise or differently regulated 
between those with and without insulin resistance [267], while FNDC5 mRNA was only 
modestly increased in a subset of older people following chronic exercise training 
[267]. Critically, this time it is known that the antibodies used in the detection of Irisin 
by Bostrom et al. (2012) was made to correspond against the C-terminal of human 
FNDC5, which is not the part of the protein that yields the Irisin peptide [360]. Thus, 
the original data could not possibly be Irisin. We now know that the various 
commercially available antibodies used in the ELISA kits yield a protein concentration 
that appears to be ~10-100 times greater than a more recent mass spectrometry data 
(data that requires independent validation) and still far above what others have found 
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[360]. These technical considerations may explain part or all of the equivocal results 
of the included studies in this current review regarding both the effects of exercise on 
FNDC5 mRNA in muscle and circulating Irisin, while the evidence in terms of the 
effects of exercise on UCP1 of WAT is very limited.  
 Also, evidence from the included studies showed that Irisin increased one hour 
after the exercise session, and returned to baseline levels after 24 hours [34] while 
other study showed that Irisin remained elevated up to 12 hours after the exercise 
session [337]. Furthermore, Irisin increased three minutes after the exercise session, 
and returned to baseline levels within 10 minutes [268], while it showed no elevation 
of Irisin at one, 15 and 30 minutes after the exercise session [32]. This inconsistency 
may again reflect critical defects in Irisin detection technology including the polyclonal 
nature of the Irisin antibody [35]. However, if we focus on more reliable mRNA 
measures of PGC-1α and FDNC5, then the variable findings may be explained by the 
different characteristics of the populations examined and the different exercise 
protocols used. There is a trend for old muscle tissue to show a higher FDNC5 
expression following exercise, which is unclear if it leads to Irisin.  
An interesting aspect brought forward in the included studies showed that the 
start codon of the FNDC5 gene is mutated in humans due to the non-ATG start codon 
[274]. In humans ATG is usually the first codon to lead to efficient protein production 
and therefore, the latter suggests that Irisin, if produced would be done so in an 
inefficient manner [274]. However, this notion has been questioned by a subsequent 
study, which supports that human Irisin is mainly translated from its non-ATG start 
codon while the molecular weight of the protein is similar to that of important proteins 
in human body such as insulin, leptin and resistin [276] indicating a biological role of 
Irisin. To the best of our knowledge, two studies have measured circulating Irisin via 
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mass spectrometry in response to exercise in humans. In the study by Jedrychowski 
et al. (2015) the blood samples for Irisin identification collected only after the exercise 
program from a small number of participants sedentary (n=4), aerobic exercisers (n=6) 
[276]. In the study by Lee et al. (2014) the blood samples collected only pre and post-
acute exercise without a control situation [361]. Also, Lee et al. (2014) reported an ~3-
fold increase of Irisin only after submaximal and not maximal exercise. These studies 
may display methodological limitations and a small number of participants that 
indicates that future longitudinal studies of changes in Irisin will clarify if the mass 
spectrometry measures reflect exercise. Finally, while the three studies that utilised 
mass spectrometry do not agree [35, 276, 361], reflecting issues of sensitivity and 
methodology, the latest identification and analysis of Irisin [276, 361] indicates that 
Irisin may circulate in blood and probably has similar or identical to the mouse structure 
however, whether it has genuine biological activity remains to be elucidated.    
  
5.5.2. Quality of evidence and limitations 
Based on the included RCTs/C-RCTs we cannot obtain precise conclusions regarding 
the effects of acute exercise on PGC-1α in conjunction with FNDC5 mRNA in muscle 
given the inconsistency of the findings, the different characteristics of the populations 
examined and the small number of the studies retrieved. The CTs display inconsistent 
results of the effects of both acute and chronic exercise on FNDC5 mRNA in muscle. 
Also, the CTs display high risk of bias due to the absence of generation of a 
randomised sequence, inadequate concealment of allocations before assignment and 
due to knowledge of the allocated interventions by the outcome assessors as well as 
they display unclear risk of bias due to knowledge of the allocated interventions by the 
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investigators during the study. The SGS also display inconsistent results in relation to 
the effects of acute and chronic exercise on FNDC5 mRNA in muscle.  
To the best of our knowledge this is the first systematic review that examined 
the effects of physical activity on the link between PGC-1α and FNDC5 in muscle, 
circulating Irisin and on UCP1 of WAT in humans. We compared our results with a 
recent meta-analysis that aimed to identify the effects of exercise on circulating Irisin 
[362]. This meta-analysis concluded that chronic exercise may decrease circulating 
Irisin concentrations in the RCTs while the non-RCTs cannot form any conclusion. 
However, the latter meta-analysis did not take into consideration the issues raised 
regarding the validity of the methods used for Irisin identification [35]. In contrast, while 
we considered the methods used for Irisin identification in the studies included in the 
current review our review had a different aim, to identify the proposed mechanism by 
Bostrom et al. (2012) starting from the muscle and leading to the white adipocytes. 
Regarding circulating Irisin we also report that we cannot form any firm conclusion of 
the effects of exercise on circulating Irisin. Furthermore, our results are in accordance 
with a previous review that showed equivocal results among studies examining 
circulating Irisin due to the methodological variations for Irisin detection [363]. In this 
review, the authors examined the commercial antibodies and ELISA used to measure 
circulating Irisin and concluded that the currently available antibodies should be tested 
for cross-reacting antigens detection [363]. Also, they did not confirm a link between 
Irisin and BMI, fat mass and fat-free mass which is also in accordance with our results 
[363]. 
The secondary outcomes also showed that chronic exercise may increase 
strength and REE in healthy, indicating the efficacy of the exercise program [341]. 
However, REE was not associated with circulating Irisin, while circulating Irisin was 
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not altered by exercise [341]. This is in accordance with previous data showed that 
REE is not associated with circulating Irisin in women 50-70 years old [364]. Also, an 
included CT in the current review revealed that a chronic exercise program reduced 
whole body fat and the subcutaneous WAT. However, the increased circulating Irisin 
after the exercise program was not associated with the whole body fat and the 
subcutaneous WAT [346]. These findings suggest that even though metabolic 
adaptations occur due to exercise, this is not related to Irisin. Furthermore, our 
secondary outcomes showed no association of circulating Irisin with fat mass, fat-free 
mass and REE. Thus, we cannot confirm any favourable effect of Irisin on human body 
metabolism especially due to inaccurate methods used for circulating Irisin 
identification.    
The current review has a number of strengths. For instance, we used the 
PubMed and the EMBASE databases using appropriate algorithms with standardized 
indexing terms. Standardized indexing terms can retrieve records that may use 
different words to describe the same concept and information beyond that may be 
contained in the words of the title and abstract [365]. Furthermore, the current review 
used a systematic manner to identify articles according to previous methodology [286-
288] while we used well-established tools [289-291] to evaluate the included studies. 
Also, to reduce bias two investigators worked independently on the screening of the 
included studies for eligibility, risk of bias assessment, as well as to provide 
CONSORT and STROBE scores. Also, we have not excluded studies based on 
language. However, we used only included published literature; we did not include 
grey literature searching. In this light, there is a potential of publication bias in the 
current review nevertheless, the inclusion of grey literature may itself introduce bias 
and one reason to include grey literature would be the absence of peer-review sources 
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[365]. Furthermore, the current review found no positive relationship between Irisin 
and several health indices based on the included studies, which aimed on the effects 
of physical activity on Irisin. However, Irisin may have a physiological role in human 
body independently of physical activity and therefore, the current review may not be 
representative to determine the relationship between Irisin and health indices. 
 
5.6. CONCLUSIONS 
We found little evidence to determine the link between PGC-1α mRNA and FNDC5 
mRNA in human muscle while there was limited evidence on the effects of physical 
activity on UCP1 in subcutaneous WAT. Our systematic review discovered a 
heterogeneity in populations examined in the included studies, and a relatively small 
number of RCTs (n=9) with inconsistent findings that also prevent us from making a 
firm conclusion for the link between physical activity, PGC-1α, FNDC5, and UCP1. We 
cannot form any conclusion regarding circulating Irisin in response to physical activity 
given that the methods used for Irisin identification were inaccurate in most cases. 
Mass spectrometry detection of Irisin of exercise effects were compromised by the 
methodological limitations of the existing studies. There is evidence in this systematic 
review indicating via mass spectrometry that Irisin is present in human blood at levels 
that are ~10-100 folds lower that commercial ELISA kits, therefore, future studies could 
re-examine the biological role for Irisin using accurate and valid methods for its 
analysis. 
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6. CHAPTER 6: ASSOCIATIONS OF UCP1, PGC-1α, PPARα and PPARγ IN 
WHITE ADIPOSE TISSUE WITH PHYSICAL ACTIVITY LEVELS IN HUMANS: A 
CROSS-SECTIONAL STUDY (2nd study) 
6.1. INTRODUCTION 
BAT in humans is characterized by increased mitochondrial content and its ability to 
uncouple cellular respiration via the action of UCP1 [25]. It is hypothesized that this 
phenomenon may consume up to 30% of daily REE in adult humans [176]. This 
hypothesis is mainly based on previous evidence in humans that showed that NST 
was responsible for the elevation of daily REE for 25% [366] and up to 28% [174] after 
chronic cold exposure. This may suggest a significant involvement of BAT in the 
human metabolism and a pathway to weight loss.  
Physical activity results in increased energy expenditure [78]. Exercise may 
trigger the action of PGC-1α that is thought to cause the production of the FNDC5 
protein, which is then cleaved and it is released into the bloodstream as Irisin – a newly 
discovered protein that is a product of the FNDC5 protein [30]. Irisin may generate a 
cascade of events that change the properties of white adipocytes into brown-like 
adipocytes and this was attributed to the presence of UCP1 within the white adipocytes 
[30]. This presence may occur, at least in part, by the action of PPARα [30] while 
PPARα may have a predominant role in browning formation of WAT in animals [252]. 
Also, a previous report revealed that humans display white adipocytes that contain 
UCP1 [367]. UCP1 is the only known contributor in NST that occurs in BAT and, 
therefore, its presence in WAT cells indicates brown-like adipocytes properties [223]. 
This suggests a transformation of white into brown-like adipocytes that could increase 
– similar to BAT contribution – REE in adult humans. However, the evidence to date 
either in vitro or in vivo is limited to support this mechanism.   
Following the aforementioned findings, a more recent study that examined the 
UCP1 in WAT as a possible candidate for the transformation of WAT into brown-like 
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adipose tissue in response to exercise in humans found increased, but not significant, 
UCP1 mRNA [236]. Recent evidence shows that individuals with increased habitual 
physical activity displayed increased BAT activity in supraclavicular and spinal areas 
compared with individuals with low habitual physical activity levels [29].  
PGC-1α is responsible for mitochondrial biogenesis and is expressed in several 
tissues, including WAT [226]. It co-activates with PPARγ to stimulate genes that are 
involved in the differentiation of brown adipocytes [234, 235] and its presence in WAT 
may indicate brown-like adipocytes properties [245]. PPARγ may also enhance the 
UCP1 mRNA in BAT [173]. Evidence in vitro showed that PPARγ may cause a 
browning effect in WAT by enhancing UCP1 mRNA [209]. In addition, chronic exercise 
increases PPARγ mRNA in the WAT of mice [260, 261]. However, relevant data from 
human studies are limited. Therefore, the aim of the current study was to examine the 
relationship between the UCP1 mRNA and protein expression as well as PGC-1α, 
PPARα and PPARγ mRNAs of subcutaneous WAT with the physical activity levels of 
healthy men. A secondary aim was to examine the associations of the UCP1 mRNA 
and protein expression as well as PGC-1α, PPARα and PPARγ mRNAs with REE, 
age, fat mass, fat-free mass, energy intake, WHR and BMI. To the best of our 
knowledge this is the first time that the above associations are tested.  
  
6.2. METHODS  
Height and weight were measured to calculate BMI, waist and hip circumferences to 
calculate WHR. Also, blood pressure and body composition via a bio-electrical 
impedance device were assessed. We also evaluated REE, energy intake (retrieved 
from diet recall), physical activity levels and we obtained subcutaneous fat biopsies to 
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perform mRNA and protein expression analyses. For details please see general 
methods in Chapter 4, pages 61-71.  
 
6.2.1. Participants and procedure 
The participants were recruited through an advertisement in a local newspaper in 
Trikala, Thessaly, Greece, between June 2013 and June 2014. The inclusion criteria 
included: adult men not involved in regular exercise programmes, non-smokers, with 
no chronic disease and/or being under medication treatment for any disease. The 
eligibility of the participants was screened through an interview and health status 
information was retrieved through a medical history questionnaire via interview 
(Appendix 4). Written consent forms were obtained from 46 healthy non-smokers men 
(age: 35.22±6.86, BMI: 27.26±4.17). 
Once the participants had been chosen, they were given a pedometer to 
measure physical activity levels for one week. A diet recall was also retrieved during 
the same week period. The following week the participants were given appointments 
to visit the laboratory for measurements between 07:00 to 09:00 am. They were 
instructed to refrain from exercise, alcohol, and passive smoking for 72 hours and fast 
for 12 hours prior to their visit. This was to minimize the risk of misleading results 
regarding the fat biopsies and REE [294, 295] as well as to standardise the process. 
During the appointment, the participants underwent measurements in the following 
order to avoid interaction effects between measurements: 1) anthropometry (height, 
weight, waist and hip circumferences), 2) body composition (fat mass, fat-free mass), 
3) indirect calorimetry for REE and 4) subcutaneous fat biopsy. Participants’ 
characteristics are displayed in Table 12. 
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Table 12: Characteristics of the participants (n=46) 
 Mean ± Standard deviation 
Age 35.22±6.86 
Weight (kg) 87.07±13.89 
BMI 27.26±4.17 
Waist to hip ratio 0.92±0.77 
Resting energy expenditure (kcal) 1626±226 
Energy intake (kcal) 1454±435 
Fat mass % 26.9±9.08 
Fat-free mass (kg) 54.2±6.07 
Steps/day 7209±3335 
UCP1 mRNA 0.19±0.18 
UCP1 protein expression 1.05±0.68 
PGC1α mRNA 1.38±1.11 
PPARα mRNA 1.99±0.81 
PPARγ mRNA 0.50±0.36 
Kg: Kilograms; BMI: Body mass index; Kcal: kilocalories; mm/Hg: Millimetre of 
mercury; UCP1: Uncoupling protein one; PGC-1α: Peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha; PPARα: Peroxisome proliferator-activated 
receptor alpha; PPARγ: Peroxisome Proliferator-Activated Receptor Gamma. 
 
6.2.2. Statistical analyses 
The normal distribution of the studied variables tested via the Kolmogorov-Smirnov. 
Due to the non-normal distribution of some variables, non-parametric tests were used. 
The Spearman correlation coefficient was used to assess the associations between 
UCP1 mRNA, UCP1 protein expression, PGC-1α mRNA, PPARα mRNA and PPARγ 
mRNA with physical activity levels (pedometer steps/day) as well as with BMI, WHR, 
REE, age, fat mass percentage, fat-free mass (kg) and energy intake (kcal). Linear 
regression analyses (enter mode) were used to test whether the significant 
associations detected by the Spearman’s correlations coefficient persisted, using as 
dependent variables the UCP1 protein expression, PGC-1α and PPARα mRNAs. All 
analyses were conducted with SPSS Inc., Chicago, IL, USA, version 22 and a P≤0.05 
level of significance. 
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6.3. RESULTS 
There were no missing values during the data collection of this study. No significant 
associations were detected between mRNA of UCP1, PGC-1α, PPARα and PPARγ 
genes with physical activity levels (pedometer steps/day) (P>0.05). Nevertheless, a 
negative association of UCP1 protein expression and physical activity levels 
(pedometer steps/day) (rho=-0.31, P=0.04) was found (Figure 12). Finally, there was 
no association between UCP1 mRNA and UCP1 protein expression.   
 
Figure 12: Associations of UCP1 protein expression and physical activity levels 
(pedometer steps/day) 
 
 
UCP1: Uncoupling protein one 
 
No significant associations were detected between the UCP1 mRNA and 
protein expression as well as PGC-1α, PPARα and PPARγ mRNAs with REE, energy 
intake (kcal) and age (P>0.05). However, an inverse association between PGC-1α 
mRNA and BMI (rho=-0.36, P=0.01) (Figure 13A), as well as between PPARα mRNA 
and BMI (rho=-0.33, P=0.03) (Figure 13B) were found.  
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Figure 13: Associations of PGC-1α and PPARα mRNA with BMI  
 
PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; 
PPARα: Peroxisome proliferator-activated receptor alpha; BMI: Body mass index. 
 
 
The results also revealed an inverse association between PGC-1α mRNA and 
WHR (rho=-0.48, P=0.006) (Figure 14A), as well as between PPARα mRNA and WHR 
(rho=-0.39, P=0.03) (Figure 14B).  
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Figure 14: Associations of PGC-1α and PPARα mRNA with WHR  
 
PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; 
PPARα: Peroxisome proliferator-activated receptor alpha; WHR: Waist to hip ratio. 
 
Furthermore, inverse associations between PGC-1α mRNA (rho=-0.43, 
P=0.003) (Figure 15A) and PPARα mRNA (rho=-0.37, P=0.01) (Figure 15B) with %fat 
mass were detected. A positive association between PGC-1α mRNA with fat-free 
mass (rho=0.41, P=0.01) (Figure 16) was also found. 
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Figure 15: Associations of PGC-1α and PPARα mRNA with fat mass percentage 
 
PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; 
PPARα: Peroxisome proliferator-activated receptor alpha 
 
 
Figure 16: Association of PGC-1α mRNA with fat-free mass 
 
PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
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The association of UCP1 protein expression with physical activity levels 
(pedometer steps/day) as well as the associations of PGC-1α and PPARα mRNAs 
with BMI, WHR, fat mass and fat-free mass were tested via three multiple Linear 
regression analysis models using as dependent variables UCP1 protein expression, 
PGC-1α and PPARα mRNAs and as independent variables BMI, WHR, fat mass, fat-
free mass, age, REE, energy intake and physical activity levels (steps/day). The Linear 
regression analysis model did not confirm the association between UCP1 protein 
expression and physical activity levels (pedometer steps/day) (P>0.05) as well as 
between PGC-1α mRNA and BMI, fat mass and fat-free mass (P>0.05). However, the 
inverse association between PGC-1α mRNA and WHR was confirmed [Beta=-.56, 
t(2.8)= -1.9, P=0.05] when age, BMI, REE, fat mass and fat-free mass were included 
in the model. Furthermore, the Linear regression analysis model did not confirm the 
associations between PPARα mRNA and BMI as well as fat mass (P>0.05). 
Nevertheless, the inverse association between PPARα mRNA and WHR was 
confirmed [Beta=-.41, t(1.8)= -2.23, P=0.03] when age was included in the model. 
   
6.4. DISCUSSION 
In recent years the formation of WAT into brown-like adipose tissue in response to 
exercise has attracted scientific attention [30, 32, 236]. The primary aim of the current 
study was to examine the associations of the UCP1 mRNA and protein expression as 
well as the mRNAs of PGC-1α, PPARα and PPARγ genes of subcutaneous WAT with 
physical activity levels in healthy men. A secondary aim was to inspect the 
associations of the UCP1 mRNA and protein expression as well as the mRNAs of 
PGC-1α, PPARα and PPARγ genes with REE, WHR, BMI, age, fat mass, fat-free 
107	
	
mass and energy intake. A thorough review of the available literature indicates that 
the current study is the first to examine the aforementioned associations in humans.  
The study’s hypothesis was based on the recent suggestion that exercise may 
change the mode of WAT into brown-like function [30, 229] through the presence of 
UCP1 in WAT and therefore, it was hypothesized that individuals with increased 
physical activity levels may display increased UCP1. Furthermore, PGC-1α is 
increased in WAT in response to exercise [245], PPARα was suggested to increase 
UCP1 in WAT in response to exercise [30] and PPARγ may increase the UCP1 mRNA 
in subcutaneous WAT of mice [228] while it is also increased in response to chronic 
exercise in mice [260]. As such it was hypothesized that PGC-1α, PPARα and PPARγ 
mRNAs of subcutaneous WAT in humans may be associated with physical activity 
levels indicating a browning effect of WAT. However, no associations were found 
herein between the mRNAs of UCP1, PGC-1α, PPARα and PPARγ genes that 
indicate browning formation of WAT with physical activity levels. In addition, UCP1 
protein expression was negatively associated with physical activity levels rather than 
positively in the current study. This finding does not support the hypothesis that UCP1 
is increased in response to exercise within a white adipocyte that may trigger a 
browning formation of WAT [30]. Also, this finding may explain a recent discovery that 
UCP1 mRNA in subcutaneous WAT was negatively correlated with weight loss – 
indicating no effect of UCP1 on browning formation of WAT – while it was not altered 
in response to exercise in healthy women [368]. In the current study however, the 
UCP1 mRNA tended to display a positive corellation with physical activity levels 
(p=0.27, P=0.06) while measurements were performed in healthy men. The latter is in 
line with evidence from a controlled trial that examined the effects of chronic exercise 
on the UCP1 mRNA of subcutaneous WAT in healthy adults, also confirming no 
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significant alteration of UCP1 mRNA even though UCP1 mRNA was increased [236]. 
The first study of this PhD (systematic review) also failed to detect a link between 
physical activity/exercise with UCP1 mRNA of WAT in humans. Overall, this evidence 
suggests that the initial hypothesis of the current study should be rejected.  
UCP1 mRNA and UCP1 protein expression were not associated in the current 
study. Previous evidence showed no obvious relationship between UCP1 mRNA and 
the functional protein under cold exposure in BAT of animals [304]. Also, there is a 
delay between elevated UCP1 mRNA and elevated UCP1 protein expression in BAT 
probably because of an unchanged translational effectiveness [304]. Furthermore, 
UCP1 mRNA found to be increased more in WAT than in BAT in response to cold 
exposure, in animals [304]. However, there is no evidence regarding the differences 
between WAT and BAT in UCP1 mRNA in response to physical activity/exercise. The 
current study detected positive white fat cells of the UCP1 gene which may indicate a 
browning formation process of white fat cells; this however, cannot be attributed to 
physical activity given the lack of relevant positive associations between physical 
activity levels and UCP1. The UCP1 protein expression half-life is about 3-6 days in 
response to cold exposure [369, 370] nevertheless, the mode of the current study did 
not allow us to examine potential variations in UCP1 values in response to physical 
activity, based on the half-life of the protein. It was previously suggested that the 
presence of the UCP1 in white fat cells in animals is dependent on a synergetic 
interactions between selective genes and variations in recessive and dominants genes 
that affect UCP1 gene even though the mechanisms are unknown [371]. It was also 
demonstrated that a subset of the precursor cells in white adipocytes may promote 
rise of brown-like adipocytes that express UCP1 [272].  The mode of the current study 
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could not highlight the latter issues and therefore, the presence of UCP1 in 
subcutaneous fat cells in untrained individuals remains to be elucidated. 
The inverse association of PGC-1α mRNA with BMI, WHR and %fat mass and 
its positive association with fat-free mass indicate that PGC-1α is mainly expressed in 
tissues that demand large amounts of energy such as skeletal muscle. Studies show 
that PGC-1α increases fatty acid oxidation [372, 373] and fat-free mass is positively 
associated with REE in humans [374], which indicates increased demands of energy. 
REE is highly dependent on the amount of fat-free mass in both men and women [375, 
376]. This is because the fat-free mass is the most proportional tissue in human body 
compared to fat mass [377] and it includes skeletal muscles and organs, which 
demand high amounts of energy [378]. PGC-1α is highly expressed in tissues that 
demand energy, such as the skeletal muscle [226] while increased PGC-1α activation 
is associated with increased REE in mice [379]. This is because PGC-1α is 
responsible for mitochondrial biogenesis that are responsible for energy production in 
the form of ATP [171].  
Even though a positive association between PGC-1α mRNA and fat-free mass 
was detected in the current study, no association of PGC-1α mRNA with REE was 
found. Previous evidence showed that when a browning process occurs in WAT in 
response to exercise this lead to increased REE in mice [380]. Also, physical activity 
levels are positively associated with REE in humans [68]. However, no association of 
PGC-1α mRNA with physical activity levels was detected in the current study. 
Regarding the inverse association of PGC-1α mRNA with fat mass, this is probably 
because PGC-1α is involved in the regulation of genes that control energy 
homeostasis in metabolic tissues including WAT [381]. In specific, PGC-1α is involved 
in controlling the development of obesity by regulating oxidative phosphorylation and 
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fatty acid oxidation that regulate lipid metabolism and lessen insulin resistance in mice 
[382].  
 An inverse association between PPARα mRNA with BMI, WHR and %fat mass 
was also found. PPARα appears to be more active in BAT, liver, intestine, heart, and 
kidney than in WAT [383]. It is activated under conditions of energy deprivation [246] 
and its activation promotes the catabolism of fatty acid beta oxidation [247]. Given that 
WAT is mainly responsible for energy storage [88], the inverse associations of PPARα 
mRNA with BMI, WHR and fat mass percentage indicate white adipocytes 
accumulation. PPARα increases ketogenesis and subsequently the uptake of fatty 
acids, ameliorates beta oxidation in mitochondria and increases triglyceride uptake 
[247]. Therefore, it triggers lipid catabolism in WAT and this may explain its inverse 
association with BMI, WHR and fat mass percentage we observed in the current study.  
Overall, the inverse associations of PGC-1α and PPARα mRNAs with fat mass, 
BMI and WHR indicate a possible positive association of these factors with weight 
loss. However, in order to assume a browning effect of these factors in WAT in 
response to physical activity, we would expect to observe negative associations of 
UCP1 mRNA and protein expression with fat mass, BMI and WHR, which were not 
detected in the current study. Furthermore, a recent study revealed that UCP1 mRNA 
of subcutaneous WAT in healthy women was negatively associated with weight loss 
in response to exercise [368], which indicates no relationship of UCP1 with a browning 
formation of WAT given that increased UCP1 would expect to cause weight loss via 
an elevation of REE [30]. Given also that PGC-1α and PPARα genes display multiple 
interactions with other genes other than UCP1, we cannot assume that the inverse 
associations of PGC-1α and PPARα mRNAs with fat mass, BMI and WHR that were 
observed in the current study indicate a browning formation of WAT. 
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It is reasonable to assume that the present results may have been influenced 
by methodological limitations such as the lack of prior power calculation to determine 
the sample size. However, this was not possible given the lack of similar design studies 
that could be utilised to perform sample size calculations. Therefore, a post-
measurements power calculation was conducted using an online software (DSS 
Research) to test >95% statistical power. This revealed 100% of statistical power 
based on the UCP1 mRNA value (0.19±0.18) we detected in our study and expected 
UCP1 mRNA value (0.00010±0.0003) from the only previous controlled trial that 
examined the effect of exercise on UCP1 mRNA of subcutaneous WAT in humans 
[236]. The study only measured mRNAs of the PGC-1α, PPARα and PPARγ genes. 
The mRNA of genes usually indicate the protein production sometimes however, they 
do not predict it [197-199] given that one mRNA transcription may encode the protein 
more than one time [197-199]. Therefore, protein concentrations may also have 
needed for PGC-1α, PPARα and PPARγ to determine the physiological function of 
these genes.  
  
6.5. CONCLUSIONS 
The UCP1 protein expression is negatively associated with physical activity levels 
while UCP1 mRNA and protein expression are not linked with body weight (BMI, WHR, 
fat mass) as well as REE. These findings indicate no browning effect of WAT in 
response to physical activity in healthy men. The mRNA of PGC-1α, PPARα and 
PPARγ genes that along with UCP1 could indicate browning formation of 
subcutaneous WAT are not associated with physical activity levels in healthy men. 
PGC-1α and PPARα mRNAs are negatively associated with increased fat mass 
accumulation parameters (BMI, WHR and fat mass) suggesting a potential association 
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between PGC-1α and PPARα with human WAT metabolism. The mechanisms of the 
latter associations remain to be determined.  
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7. CHAPTER 7: EFFECTS OF DIFFERENT TYPES OF EXERCISE AND DE-
TRAINING ON UCP1 mRNA AND PROTEIN EXPRESSION OF SUBCUTANEOUS 
WHITE ADIPOCYTES IN HUMANS: A RANDOMIZED CONTROLLED TRIAL (3rd 
STUDY) 
7.1. INTRODUCTION 
BAT produces heat to maintain body temperature as a response to cold exposure via 
NST, which occurs through the action of UCP1 [25]. The link between exercise and 
BAT has been investigated because animal studies have shown that increased BAT 
activity reduces weight gain, up-regulates insulin sensitivity, lowers free fatty acid 
levels in serum, as well as the risk for T2D and other metabolic disorders [179-183] 
while exercise seems to increase BAT activity [185, 190, 195, 384, 385]. Evidence 
from several animal studies shows that exercise may also transform subcutaneous 
WAT into brown-like adipose tissue through the action of UCP1 and several other 
genes (i.e. PGC-1α, PPARα and PPARγ) [245, 277-279]. A recent study that 
examined the latter in both mice and humans [30] found that exercise increases the 
activation of PGC-1α in skeletal muscle that up-regulates the FNDC5 protein, which is 
subsequently cleaved and released into the bloodstream as Irisin. Irisin is attached – 
through an unknown receptor – on the surface of white adipocytes and generates a 
cascade of events changing the function of white adipocytes into brown-like 
adipocytes [30]. This transformation was thought to occur in part because of PPARα 
involvement that enhances UCP1 mRNA within WAT [30]. Indeed, FNDC5 increased 
by 3-fold the mRNA of PPARα in vitro and a pharmacological inhibition by antagonists 
of PPARα limited the action of FNDC5 [30]. This indicates that the increased UCP1 
mRNA within the white adipocytes was caused, at least in part, by the action of PPARα 
[30]. Given that UCP1 is the only known contributor in NST that occurs in brown 
adipocytes, its presence in white adipocytes may indicate brown-like adipocytes 
properties [223]. 
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The above mechanism triggered a series of research projects in the area. In 
particular, human Irisin attracted a lot of attention given its inverse correlation with 
blood glucose, insulin and cholesterol [266] and its role in the transformation of WAT 
into brown-like adipose tissue via the action of UCP1 [30]. However,  other evidence 
shows that the FNDC5 gene – the precursor of Irisin – is not significantly increased by 
exercise in human muscle [267] and that the start codon of FNDC5 gene is mutated 
in humans [274], which raises doubts about the biological activity of Irisin. In line with 
this, some human studies show that acute exercise increases circulating Irisin [268, 
269]; others show no effects [33, 270] and others show that either circulating Irisin is 
increased in response to chronic exercise [271] or it is not altered [33]. Also, the first 
study of this PhD (systematic review) revealed that the previous studies in humans 
used inaccurate methods to identify circulating Irisin. Therefore, there is no evidence 
to support that Irisin is increased in response to exercise while the evidence regarding 
the effects of exercise on UCP1 in WAT in humans is very limited. Indeed, the first 
study of this PhD (systematic review) detected only one study that investigated the 
effects of exercise on UCP1 mRNA in WAT in humans.  
The current study aimed to examine part of the mechanism that seems to 
change the mode of WAT into brown-like mode. Apart from the exercise intervention, 
we also included a de-training period that followed the exercise intervention in order 
to compare its results with the potential effects of exercise on the indices examined. 
Specifically, the current study aimed to examine the effects of different types of 
exercise and de-training on the UCP1 mRNA and protein expression of subcutaneous 
WAT in healthy untrained men in a parallel RCT design. A secondary aim was to 
examine the effects of different types of exercise and de-training on the mRNA of PGC-
1α, PPARα and PPARγ genes. It was hypothesized that different types of chronic 
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exercise would increase and the following de-training period would decrease the 
UCP1 mRNA and protein expression in subcutaneous WAT of healthy untrained men. 
Anthropometry indices, REE (kcal), physical activity levels, energy intake (kcal) and 
diet – factors known to influence metabolism – were also recorded throughout the trial 
for their use as confounding factors.  
 
7.2. METHODS 
We measured height and weight to calculate BMI, waist and hip circumferences to 
calculate WHR, blood pressure and body composition via a bio-electrical impedance 
device. Also, we measured REE, physical activity levels, we retrieved diet recalls and 
we obtained subcutaneous fat biopsies. Upon inclusion, a participant was randomly 
assigned to a group using an online computer software (DSS Research) [293]. The 
initial allocation and enrol of the participants to an experimental group was done by 
the Researcher in charge (PhD student). The supervision of the exercise interventions 
was done by three different assistants, one for each exercise group who were blinded 
to the aim of the study and they were supervised by the Researcher in charge (PhD 
student) to ensure adherence to the exercise protocols. The methods of this parallel 
RCT regarding inclusion criteria, anthropometry, assessments of REE, VO2peak, 
energy intake, diet elements, physical activity, subcutaneous fat biopsies procedure, 
gene and protein expression analyses, exercise protocols (Table 8) and allocation of 
the participants in groups (Figure 7) are described in details in the general methods in 
Chapter 4, pages 61-71. Figure 8 depicts the methodological design of the present 
study, which can be found in Chapter 4, page 64.   
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7.2.1. Participants and procedures 
The current study was conducted in Trikala, Thessaly, Greece, and the experimental 
protocol started in July of 2013 and ended in June of 2014. A priori power calculation 
was conducted using an online software (DSS Research) to test statistical power 
based on previous data of UCP1 mRNA [(baseline=0.00010±0.0003), (post-
exercise=0.00020±0.00005)] that retrieved from a similar controlled trial that 
conducted in humans [236]. The power calculation analysis showed a required sample 
size of at least seven participants per group. This result ensured 100% of statistical 
power in the current study (alpha error 5%). The participants were recruited through 
an advertisement in a local newspaper in the area of Trikala, Thessaly, Greece. The 
inclusion criteria included: adult men who had not participated in a regular exercise 
programme, non-smokers, with no chronic disease and/or not on medication.  
Once the participants confirmed their participation, they were given a 
pedometer. This was to measure their physical activity levels during a week period 
prior to baseline measurements as well as at weeks eight and sixteen (please see 
general methods, page 65). Diet recalls were retrieved during a week period prior to 
baseline measurements as well as at weeks eight and sixteen (please see general 
methods, pages 69-70). Following the methodological design (Figure 8, page 64), the 
participants were given appointments to measure VO2peak and 1RM at baseline and 
at the end of weeks four, eight and sixteen. Three days after the first appointment 
participants were given a second appointment at baseline week and at the end of 
weeks eight and sixteen to measure the following in the specific order to avoid 
interaction effects between measurements: 1) anthropometry, 2) body composition, 3) 
REE and 4) subcutaneous fat biopsy. For the latter measurements the participants 
visited the laboratory between 07:00 to 09:00 am after been instructed to refrain from 
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exercise, alcohol, and passive smoking in 72-hour prior the measurements as well as 
to undertake a 12-hour fast prior the measurements in order to minimize the risk for 
misleading results [294, 295]. Written consent forms were obtained from 32 healthy 
non-smokers men (age: 36.06±7.36, BMI: 27.60±4.62). The baseline characteristics 
of the participants can be found in Table 13. 
 
Table 13: Baseline characteristics of the participants (n=32) 
Variables Mean ± Standard deviation 
Age 36.06±7.36 
BMI 27.60±4.62 
Waist to hip ratio 0.91±0.08 
VO2peak (L/min) 2.49±0.52  
Systolic Blood pressure (mm/Hg) 124.28±10.08  
Diastolic Blood pressure (mm/Hg) 84.28±6.91  
IPAQ (METs-min/week) 914±735 
Steps/day 7842±3321 
1RM chest press (kg) 59±17  
1RM leg extension (kg) 77±36  
Fat mass % 28.3±8.9 
Fat-free mass (kg) 52.9±5.02 
Resting energy expenditure (kcal) 1567±215 
Energy intake (kcal) 1464±456 
Weight of food intake (gr) 1039±330 
Protein (gr) 64±21 
Carbohydrates (gr) 145±43 
Total fat intake (gr) 65±28 
Total sugar intake (gr) 62±26 
Caffeine (gr) 98±175 
UCP1 mRNA 0.27±0.15 
UCP1 protein expression 1.05±0.69 
PGC-1α mRNA 1.07±0.74 
PPARα mRNA 1.74±0.71 
PPARγ mRNA 0.44±0.29 
BMI: Body mass index; VO2peak: Maximal oxygen uptake; ml/kg-1/min-1 ; Millilitre per 
kilogram, per minute; 1RM: One repetition maximum; kg: Kilograms; kcal: kilocalories; 
gr: Grammars; mm/Hg: Millimetre of mercury; UCP1: Uncoupling protein one; PGC1α: 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARα: 
Peroxisome proliferator-activated receptor alpha; PPARγ: Peroxisome Proliferator-
Activated Receptor Gamma. 
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7.2.2. Statistical analysis 
The normal distribution of the variables was tested using Kolmogorov-Smirnov. Due 
to the non-normal distribution of some variables, we calculated the delta scores of 
baseline and post-exercise values (week 8) as well as of post-exercise (week 8) and 
de-training values (week 16) for UCP1 mRNA and protein expression as well as PGC-
1α, PPARα and PPARγ mRNAs as previously described [386, 387]. The delta scores 
were again tested for normal distribution using Kolmogorov-Smirnov and displayed 
normal distribution. ANOVA with Bonfferoni post-hoc t-tests were used to assess 
between and within groups differences of delta scores for UCP1 mRNA and protein 
expression as well as PGC1-α, PPARα and PPARγ mRNAs to test the effects of 
exercise interventions and de-training on these variables. Given that the analyses did 
not display any significant effects of exercise interventions and de-training on the delta 
scores of UCP1 mRNA and protein expression as well as PGC-1α, PPARα and PPARγ 
mRNAs, we did not perform additional analyses or used any of the studied 
confounding factors.  
 Following previous methodology, the 50th percentile was used to define the low 
and high responders for UCP1 mRNA and protein expression as well as for PGC-1α, 
PPARα and PPARγ mRNAs in order to test the effects of exercise interventions and 
de-training period on the high responders [309], based on the hypothesis of the current 
study. Chi square tests were used to assess differences between the categorical 
variable of the experimental group (four groups) and the categorical variable of low 
and high responders for UCP1 mRNA and protein expression as well as for PGC-1α, 
PPARα and PPARγ mRNAs. Kruskal–Wallis analysis of variance with post-hoc Mann-
Witney U tests were used to assess the effects of exercise and de-training of high 
responders – both to exercise stimuli and de-training period – on UCP1 mRNA and 
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protein expression as well as on PGC-1α, PPARα and PPARγ mRNAs. Wilcoxon 
Signed Rank tests were used to assess the effects of exercise and de-training within 
groups of the high responders – both to exercise stimuli and de-training period – on 
UCP1 mRNA and protein expression as well as on PGC-1α, PPARα and PPARγ 
mRNAs. 
Pooled Cohen’s d effect size analyses were also used to assess differences 
between and within groups [310, 362, 388]. Effect size analysis should be included in 
a parallel RCT, according to the CONSORT guidelines for RCTs [389], because the 
relative and/or absolute measures alone may not provide a complete understanding 
of the practical and/or the mechanistic value of the findings and their implications [389]. 
Pooled Cohen’s d effect size was calculated by dividing the mean difference of the 
variables examined with the pooled standard deviation of these variables (please see 
the following formula): ("#$"%)'()( ∗(+,()-. '-)( ∗(+,-)-'(.'-)-  (N=group sample size, M=mean, 
SD=standard deviation) [310, 311]. According to Cohen an effect size 0.20-0.50 
represents a small effect, 0.50-0.80 a moderate effect, and >0.80 a large effect [310]. 
For instance, a value of 0.20 in Cohen’s d effect size means that the two values differ 
by 0.2 standard deviations and this difference is not trivial even if it is statistically 
insignificant [310]. Furthermore, according to Cohen a small effect size represents a 
real effect but it needs careful exploration while a large effect size it is an obvious 
effect that is very considerable [310]. Pooled Cohen’s d effect size analyses were used 
to identify effect sizes between baseline and week 8 and between weeks 8 and 16 
within groups and to identify effect sizes between each exercise group with the CG for 
UCP1 mRNA and protein expression as well as PGC-1α, PPARα and PPARγ mRNAs 
at all time points.  
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Wilcoxon Signed Rank tests were also used to calculate differences and to test 
mediating effects of exercise and de-training within groups for REE, WHR, BMI, 
systolic blood pressure (SBP), diastolic blood pressure (DBP), VO2peak, 1RM upper 
body, 1RM lower body, fat mass percentage, fat-free mass (kg), weight of food intake 
(gr), protein (gr), carbohydrates (gr), total fat intake (gr), total sugar intake (gr), caffeine 
(gr), total energy intake (kcal) and pedometer steps/day at all time points. All analyses 
were conducted with SPSS Inc., Chicago, IL, USA, version 22 and a P≤0.05 level of 
significance.  
The number of the participants randomly assigned in the exercise programmes, 
the drop outs with reasons and the number of the participants included in the final 
analysis are displayed in Figure 7, Chapter 4, page 63. 
 
7.3. RESULTS 
The average attendance of the participants in the supervised exercise programmes 
was 31.6 out of 34 sessions (92.9%) for the AEG, 30 out of 31 sessions (96.8%) for 
the REG and 26.8 out of 29 sessions (92.41%) for the CEG. During the aerobic and 
combined (aerobic+resistance) exercise programmes heart rate monitors (Polar 
RS800CX Electro Oy, Kempele, Finland) were used to ensure that the participants 
follow the appropriate exercise intensity in every exercise session. Also, 1RM tests 
were used for each resistance exercise at baseline and at week 4 to ensure adherence 
to the exercise intensities for each participant. No harms (e.g. injuries) were reported 
from the participants during this experiment.  
 
7.3.1. Primary outcomes 
Results from ANOVA analysis 
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No significant differences between and within groups in delta scores of UCP1 mRNA 
and protein expression were detected between baseline and post-exercise values 
(week 8) nor between post-exercise (week 8) and de-training values (week 16). The 
individual data for UCP1 mRNA are shown in Figure 17A and for UCP1 protein 
expression are shown in Figure 17B.   
 
Figure 17:  Individual data for UCP1 mRNA (A) and protein expression (B) at baseline, 
post exercise (week 8) and de-training (week 16) 
 
Each number in the x axis represents one participant; The participants 1, 5, 11, 13, 
18, 19, 20, 24 and 32 belong to the aerobic exercise group; The participants 4, 6, 8, 
14, 21, 23, 25, and 29 belong to the resistance exercise group; The participants 2, 10, 
12, 15, 26, 28, 30, and 31 belong to the combined (aerobic+resistance) exercise 
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group; The participants 3, 7, 9, 16, 17, 22, and 27 belong to the control group; UCP1: 
Uncoupling protein one.  
 
Results from low responders versus high responders analysis  
Regarding UCP1 mRNA and protein expression, the low responders to the exercise 
stimuli were considered those who displayed values less than the 50th percentile while 
the high responders to the exercise stimuli were considered those who displayed 
values equal or more than the 50th percentile. Furthermore, the low responders to the 
de-training period were considered those who displayed values equal or more than 
the 50th percentile while the high responders to the de-training period were considered 
those who displayed values less than the 50th percentile [309]. This is because 
according to the hypothesis of this study the exercise intervention was expected to 
increase UCP1 mRNA and protein expression while the de-training period was 
expected to decrease UCP1 mRNA and protein expression.  
Chi square analysis revealed no significant differences between the 
experimental groups (categorical variable consisted of four groups) and a) UCP1 
mRNA (categorical variable of low and high responders to exercise stimuli) [χ2 (3, 
n=29)=0.60, P>0.05] as well as b) UCP1 protein expression (categorical variable of 
low and high responders to exercise stimuli) [χ2 (3, n=29)=3.92, P>0.05]. Chi square 
analysis also showed no significant differences between the experimental groups 
(categorical variable consisted of four groups) and a) UCP1 mRNA (categorical 
variable of low and high responders to de-training period) [χ2 (3, n=25)=1.49, P>0.05] 
as well as b) UCP1 protein expression (categorical variable of low and high responders 
to de-training period) [χ2 (3, n=25)=3.49, P>0.05].  
Kruskal–Wallis analysis of variance revealed no differences for UCP1 mRNA 
and protein expression between the experimental groups in high responders to the 
123	
	
exercise stimuli and in high responders to the de-training period at all time points 
(P>0.05). Wilcoxon Signed Rank tests revealed no differences of UCP1mRNA and 
protein expression in high responders to the exercise stimuli between baseline and 
post-exercise as well as in high responders to the de-training period between post-
exercise and de-training within each experimental group. The number and the 
percentage of the low and high responders of UCP1mRNA and protein expression for 
each experimental group are shown in Table 14.  
 
Table 14: Number and percentage of the low and high responders for UCP1 mRNA 
and protein expression 
Group Low responders High responders 
 UCP1 mRNA UCP1  
protein 
expression 
UCP1 mRNA UCP1  
protein 
expression 
Exercise stimuli 
AEG 3 (37.5%) 4 (50%) 5 (62.5%) 4 (50%) 
REG 3 (50%) 2 (33.3%) 3 (50%) 4 (66.7%) 
CEG 4 (50%) 6 (75%) 4 (50%) 2 (25%) 
CG 3 (42.9%) 2 (28.6%) 4 (57.1%) 5 (71.4%) 
De-training period 
AEG 2 (33.3%) 2 (33.3%) 4 (66.7%) 4 (66.7%) 
REG 4 (66.7%) 5 (83.3%) 2 (33.3%) 1 (16.7%) 
CEG 4 (50%) 4 (50%) 4 (50%) 4 (50%) 
CG 3 (60%) 2 (40%) 2 (40%) 3 (60%) 
UCP1: Uncoupling protein one; AEG: Aerobic exercise group; REG: Resistance 
exercise group; CEG: Combined (aerobic+resistance) exercise group; CG: Control 
group 
 
Results from Cohen’s d effect size analysis 
The UCP1 mRNA was increased in response to aerobic exercise, yet not significantly, 
while a small effect size (d=0.39) between baseline and post-exercise (Figure 18) was 
found. The UCP1 mRNA was also increased in response to de-training, yet not 
significantly, in REC, CEG and CG, while a small effect size in REG (d=0.25) (Figure 
19A), in CEG (d=0.49) (Figure 19B) and in CG (d=0.48) (Figure 19C) between post-
exercise and de-training was detected.  
124	
	
Figure 18: Cohen’s d effect size in UCP1 mRNA between baseline and post-exercise 
(week 8) in AEG 
 
 
*Small effect size (d=0.39); Values are depicted as mean and standard deviation; 
UCP1: Uncoupling protein one 
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Figure 19: Cohen’s d effect size in UCP1 mRNA between post-exercise (week 8) and 
de-training (week 16) in REG, CEG and CG 
 
 
Figure 19A: *Small effect size (d=0.25); Figure 19B: #Small effect size (d=0.49); 
Figure 19C: £Small effect size (d=0.48); Values are depicted as mean and standard 
deviation; UCP1: Uncoupling protein one. 
 
 
Regarding the baseline values, a small effect size between CG and AEG 
(d=0.38), between CG and REG (d=0.38) and between CG and CEG (d=0.35) of 
UCP1 mRNA was identified (Figure 20A). The CG displayed the lowest values 
compared to the exercise groups. At post-exercise values, a moderate effect size 
between CG and AEG (d=0.54), a small effect size between CG and REG (d=0.40) as 
well as between CG and CEG (d=0.26) of UCP1 mRNA was found (Figure 20B). 
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Similar to the baseline values, the CG displayed the lowest values compared to the 
exercise groups. Finally, a small effect size between CG and CEG (d=0.26) was 
identified in UCP1 mRNA at de-training (Figure 20C).  
 
Figure 20: Cohen’s d effect size in UCP1 mRNA between control and exercise groups 
at baseline, post-exercise (week 8) and de-training (week 16) 
 
 
Figure 20A: *Small effect size (d=0.38),  #Small effect size (d=0.38), £Small effect size 
(d=0.35); Figure 20B: *Moderate effect size (d=0.54), #Small effect size (d=0.40), 
£Small effect size (d=0.26); Figure 20C: *Small effect size (d=0.24); Values are 
depicted as mean and standard deviation; UCP1: Uncoupling protein one. 
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The UCP1 protein expression was increased in response to exercise, yet not 
significantly, in AEG, CEG and CG. In this regard a small effect size between baseline 
and post-exercise was found in AEG (d=0.26) (Figure 21A), in CEG (d=0.30) (Figure 
21C) and in CG (d=0.31) (Figure 21D). The UCP1 protein expression was also 
increased in response to de-training, yet not significantly, in REC and CEG, while a 
large effect size in REG (d=1.28) (Figure 21B) and in CEG (d=0.88) (Figure 21C) was 
detected. Finally, the UCP1 protein expression was decreased in response to de-
training in CG while a small effect size between post-exercise and de-training was 
revealed (d=0.34) (Figure 21D). 
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Figure 21: Cohen’s d effect size in UCP1 protein expression between baseline, post-
exercise (week 8) and de-training (week 16) 
  
 
Figure 21A: *Small effect size (d=0.26); Figure 21B: #Large effect size (d=1.28); 
Figure 21C: *Small effect size (d=0.30),  #Large effect size (d=0.88); Figure 21D: 
*Small effect size (d=0.31),  #Small effect size (d=0.34); Values are depicted as mean 
and standard deviation; UCP1: Uncoupling protein one. 
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Regarding the baseline values, a small effect size between CG and AEG 
(d=0.42), and a large effect size between CG and CEG (d=0.90) of UCP1 protein 
expression was identified (Figure 22A). In this regard, the CG displayed the highest 
values compared to the exercise groups. At post-exercise values, a small effect size 
between CG and AEG (d=0.38), a small effect size between CG and REG (d=0.32) 
and a moderate effect size between CG and CEG (d=0.76) of UCP1 protein 
expression was found (Figure 22B). Similar to the baseline values, the CG displayed 
the highest values compared to the exercise groups. Finally, a large effect size 
between CG and REG (d=1.10) and a small effect size between CG and CEG (d=0.43) 
was identified in UCP1 protein expression at de-training (Figure 22C). 
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Figure 22: Cohen’s d effect size in UCP1 protein expression between control and 
exercise groups at baseline, post-exercise (week 8) and de-training (week 16) 
 
 
Figure 22A: *Small effect size (d=0.42), £Large effect size (d=0.90); Figure 22B: 
*Small effect size (d=0.38), #Small effect size (d=0.32), £Moderate effect size 
(d=0.76); Figure 22C: #Large effect size (d=1.10), £Small effect size (d=0.43); Values 
are depicted as mean and standard deviation; UCP1: Uncoupling protein one. 
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7.3.2. Secondary outcomes 
Results from ANOVA analysis 
No significant differences between and within groups in delta scores of PGC-1α, 
PPARα and PPARγ mRNAs were revealed between baseline and post-exercise 
values (week 8) nor between post-exercise (week 8) and de-training values (week 16). 
Figure 23 depicts the individual data for PGC-1α (Figure 23A), PPARα (Figure 23B) 
and PPARγ (Figure 23C) mRNAs. 
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Figure 23: Individual data for PGC-1α (Α), PPARα (Β) and PPARγ (C) mRNAs at 
baseline, post-exercise (week 8) and de-training (week 16) 
 
 
Each number in the x axis represents one participant; The participants 1, 5, 11, 13, 
18, 19, 20, 24 and 32 belong to the aerobic exercise group; The participants 4, 6, 8, 
14, 21, 23, 25, and 29 belong to the resistance exercise group; The participants 2, 10, 
12, 15, 26, 28, 30, and 31 belong to the combined (aerobic+resistance) exercise 
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group; The participants 3, 7, 9, 16, 17, 22, and 27 belong to the control group; PGC-
1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARα: 
Peroxisome proliferator-activated receptor alpha; PPARγ: Peroxisome proliferator-
activated receptor gamma.  
 
 
Results from low responders versus high responders analysis  
For PGC-1α, PPARα and PPARγ mRNAs the low responders to the exercise stimuli 
were considered those who displayed values less than the 50th percentile while the 
high responders to the exercise stimuli were considered those who displayed values 
equal or more than the 50th percentile. Furthermore, the low responders to the de-
training period were considered those who displayed values equal or more than the 
50th percentile while the high responders to the de-training period were considered 
those who displayed values less than the 50th percentile [309]. This is because 
according to the hypothesis of this study the exercise intervention was expected to 
increase PGC-1α, PPARα and PPARγ mRNAs while the de-training period was 
expected to decrease PGC-1α, PPARα and PPARγ mRNAs.  
Chi square analyses revealed a significant difference between the experimental 
groups (categorical variable consisted of four groups) and PGC-1α mRNA [χ2 (3, 
n=29)=12.64, P=0.005] as well as PPARα mRNA [χ2 (3, n=29)=9.47, P=0.02] 
(categorical variables of low and high responders to exercise stimuli). However, no 
significant difference between the experimental groups (categorical variable consisted 
of four groups) and PPARγ mRNA (categorical variable of low and high responders to 
exercise stimuli) [χ2 (3, n=29)=1.110, P>0.05] was detected. Similalrly, no significant 
differences between the experimental groups (categorical variable consisted of four 
groups) and a) PGC-1α mRNA [χ2 (3, n=25)=6.30, P>0.05], PPARα mRNA [χ2 (3, 
n=25)=0.16, P>0.05] as well as b) PPARγ mRNA [χ2 (3, n=25)=0.16, P>0.05] 
(categorical variables of low and high responders to de-training period) were found.  
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Kruskal–Wallis analysis of variance revealed no differences for PGC-1α and 
PPARγ mRNAs between the experimental groups in high responders to the exercise 
stimuli and in high responders to the de-training period at all time points (P>0.05). 
However, Kruskal–Wallis analysis of variance with post-hoc Mann-Witney U tests 
showed that PPARα mRNA was significantly higher in CG than in REG in high 
responders to the exercise stimuli at both baseline and post-exercise (P=0.02). 
Wilcoxon Signed Rank tests revealed no differences of PGC-1α, PPARα and PPARγ 
mRNAs in high responders to the exercise stimuli between baseline and post-exercise 
as well as in high responders to the de-training period between post-exercise and de-
training within each experimental group. The number and the percentage of the low 
and high responders of PGC-1α, PPARα and PPARγ mRNAs for each experimental 
group are shown in Table 15. 
 
Table 15: Number and percentage of the low and high responders for PGC-1α, 
PPARα and PPARγ mRNAs 
Group Low responders High responders 
 PGC-1α  
mRNA 
PPARα 
mRNA 
PPARγ 
mRNA 
PGC-1α   
mRNA 
PPARα 
mRNA 
PPARγ 
mRNA 
Exercise stimuli 
AEG 3 (37.5%) 5 (62.5%) 3 (37.5%) 5 (62.5%) 3 (37.5%) 5 (62.5%) 
REG  4 (66.7%) 3 (50%) 3 (50%) 2 (33.3%)  3 (50%) 3 (50%) 
CEG  7 (87.5%) 6 (75%) 5 (62.5%) 1 (12.5%) 2 (25%) 3 (37.5%) 
CG  0 (0%) 0 (0%) 3 (42.9%) 7 (100%) 7 (100%) 4 (57.1%) 
De-training period 
AEG 2 (33.3%) 3 (50%) 3 (50%) 4 (66.7%) 3 (50%)  3 (50%) 
REG  2 (33.3%) 3 (50%) 3 (50%) 4 (66.7%)  3 (50%) 3 (50%) 
CEG 4 (50%) 4 (50%) 4 (50%) 4 (50%)  4 (50%) 4 (50%) 
CG  5 (100%)  3 (60%) 3 (60%) 0 (0%) 2 (40%) 2 (40%) 
PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; 
PPARα: Peroxisome proliferator-activated receptor alpha; PPARγ: Peroxisome 
proliferator-activated receptor gamma; AEG: Aerobic exercise group; REG: 
Resistance exercise group; CEG: Combined (aerobic+resistance) exercise group; CG: 
Control group. 
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Results from Cohen’s d effect size analysis 
Results for PGC-1α 
The PGC-1α mRNA augmented in CEG and CG and reduced in AEG after the 
exercise protocols while it reduced in response to de-training in all groups. More 
specifically, in AEG a small effect size (d=0.21) between baseline and post-exercise 
and a large effect size (d=0.96) between post-exercise and de-training was found 
(Figure 24A). In REG a large effect size (d=0.89) between post-exercise and de-
training was identified (Figure 24B), while in CEG a small effect size (d=0.26) between 
baseline and post-exercise and a small effect size (d=0.43) between post-exercise 
and de-training were detected (Figure 24C). Finally, in CG a moderate effect size 
(d=0.50) between baseline and post-exercise and a small effect size (d=0.35) between 
post-exercise and de-training were found (Figure 24D).      
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Figure 24: Cohen’s d effect size in PGC-1α mRNA between baseline, post-exercise 
(week 8) and de-training (week 16) 
 
  
Figure 24A: *Small effect size (d=0.21),  #Large effect size (d=0.96); Figure 24B:  
#Large effect size (d=0.89); Figure 24C: *Small effect size (d=0.26), #Small effect size 
(d=0.43); Figure 24D: *Moderate effect size (d=0.50), #Small effect size (d=0.35); 
Values are depicted as mean and standard deviation; PGC-1α: Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha. 
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At baseline values the PGC-1α mRNA was lower in REG than in CG, while a 
large effect size (d=1.01) between REG and CG was detected (Figure 25A). In CEG 
the PGC-1α mRNA was lower than in CG, while a large effect size (d=1.36) (Figure 
25A) between CEG and CG was found. At post-exercise values the exercise groups 
displayed lower PGC-1α mRNA than the CG. A moderate effect size between CG and 
AEG (d=0.73) as well as a large effect size between CG and REG (d=1.13) and 
between CG and CEG (d=1.14) (Figure 25B) was revealed. Finally, at de-training 
values the exercise groups displayed lower PGC-1α mRNA than the CG. A large effect 
size between CG and AEG (d=1.61), between CG and REG (d=1.49) and between 
CG and CEG (d=1.39) (Figure 25C) was discovered. 
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Figure 25: Cohen’s d effect size in PGC-1α mRNA between control and exercise 
groups at baseline, post-exercise (week 8) and de-training (week 16) 
 
 
Figure 25A:  #Large effect size (d=1.01), £Large effect size (d=1.36); Figure 25B: 
*Moderate effect size (d=0.73), #Large effect size (d=1.13), £Large effect size 
(d=1.14); Figure 25C: *Large effect size (d=1.61), #Large effect size (d=1.49), £Large 
effect size (d=1.39); Values are depicted as mean and standard deviation; PGC-1α: 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha. 
 
 
Results for PPARα 
The PPARα mRNA was decreased, yet not significantly, after the de-training period in 
all groups. The effect size analyses showed in AEG a small effect size (d=0.38) (Figure 
26A), in REG a moderate effect size (d=0.61) (Figure 26B), in CEG a small effect size 
(d=0.47) (Figure 26C) and in CG also a moderate effect size (d=0.66) (Figure 26D) 
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between post- exercise and de-training. Finally, a small effect size (d=0.27) in CEG 
between baseline and post-exercise was found (Figure 26C).  
 
Figure 26: Cohen’s d effect size in PPARα mRNA between baseline, post-exercise 
(week 8) and de-training (week 16) 
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Figure 26A:  #Small effect size (d=0.38); Figure 26B:  #Moderate effect size (d=0.61); 
Figure 26C: *Small effect size (d=0.27), #Small effect size (d=0.47); Figure 26D:  
#Moderate effect size (d=0.66); Values are depicted as mean and standard deviation; 
PPARα: Peroxisome proliferator-activated receptor alpha. 
 
 
The PPARα mRNA displayed lower values in the exercise groups than the CG 
at all time points. At baseline a large effect size between CG and AEG (d=1.48), 
between CG and REG (d=1.80), as well as between CG and CEG (d=1.84) (Figure 
27A) was revealed. At post-exercise a large effect size between CG and AEG 
(d=1.47), between CG and REG (d=1.71) and between CG and CEG (d=1.68) (Figure 
27B) was found. At de-training a large effect size between CG and AEG (d=1.21), 
between CG and REG (d=1.41) and between CG and CEG (d=1.30) (Figure 27C) was 
also detected. 
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Figure 27: Cohen’s d effect size in PPARα mRNA between control and exercise 
groups at baseline, post-exercise (week 8) and de-training (week 16) 
 
 
Figure 27A: *Large effect size (d=1.48),  #Large effect size (d=1.80), £Large effect 
size (d=1.84); Figure 27B: *Large effect size (d=1.47), #Large effect size (d=1.71), 
£Large effect size (d=1.68); Figure 27C: *Large effect size (d=1.21), #Large effect size 
(d=1.41), £Large effect size (d=1.30); Values are depicted as mean and standard 
deviation; PPARα: Peroxisome proliferator-activated receptor alpha 
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Results for PPARγ 
The PPARγ mRNA was increased in response to exercise, yet not significantly in REG, 
CEG and CG and decreased in response to de-training in AEG, REG and CEG. In 
AEG a moderate effect size (d=0.57) between post-exercise and de-training was found 
(Figure 28A). In REG a moderate effect size (d=0.52) between baseline and post-
exercise and a moderate effect size (d=0.75) between post-exercise and de-training 
was detected (Figure 28B). In CEG the PPARγ mRNA was also increased, yet not 
significantly in response to exercise, while a small effect size (d=0.30) between 
baseline and post-exercise and a small effect size between post-exercise and de-
training (d=0.22) was noticed (Figure 28C). Finally, in CG the PPARγ mRNA was 
reduced, yet not significantly in response to exercise, while a small effect size (d=0.20) 
between baseline and post-exercise was identified (Figure 28D).  
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Figure 28: Cohen’s d effect size in PPARγ mRNA between baseline, post-exercise 
(week 8) and de-training (week 16)  
 
 
 
Figure 28A: #Moderate effect size (d=0.57); Figure 28B: *Moderate effect size 
(d=0.52), #Moderate effect size (d=0.75); Figure 28C: *Small effect size (d=0.30), 
#Small effect size (d=0.22); Figure 28D: *Small effect size (d=0.20); Values are 
depicted as mean and standard deviation; PPARγ: Peroxisome proliferator-activated 
receptor gamma. 
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The exercise groups displayed lower PPARγ mRNA compared to the CG at all 
time points. At baseline a small effect size between CG and AEG (d=0.49), a moderate 
effect size between CG and REG (d=0.76) and a large effect size between CG and 
CEG (d=0.98) (Figure 29A) was found. At post-exercise a small effect size between 
CG and AEG (d=0.41) and between CG and REG (d=0.26) as well as a moderate 
effect size between CG and CEG (d=0.66) (Figure 29B) was shown. At de-training a 
moderate effect size between CG and AEG (d=0.71), between CG and REG (d=0.59) 
and between CG and CEG (d=0.67) (Figure 29C) was detected. 
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Figure 29: Cohen’s d effect size in PPARγ mRNA between control and exercise 
groups at baseline, post-exercise (week 8) and de-training (week 16) 
 
	
Figure 29A: *Small effect size (d=0.49),  #Large effect size (d=0.76), £Large effect 
size (d=0.98); Figure 29B: *Small effect size (d=0.41), #Small effect size (d=0.26), 
£Moderatel effect size (d=0.66); Figure 29C: *Moderate effect size (d=0.71), 
#Moderate effect size (d=0.59), £Moderate effect size (d=0.67); Values are depicted 
as mean and standard deviation; PPARγ: Peroxisome proliferator-activated receptor 
gamma. 
 
7.3.3. Results from analysis within groups 
Aerobic exercise group 
Wilcoxon Signed Rank tests showed a reduction in 1RM lower body (z=-1.992, 
P=0.05) between baseline and post-exercise, while a reduction between baseline and 
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de-training in 1RM lower body (z=-2.032, P=0.04) and in steps per day (z=-2.201, 
P=0.03) were also detected. Finally, WHR (z=-2.041, P=0.04) and SBP (z=-2.226, 
P=0.03) were significantly decreased within the AEG between post-exercise and de-
training. The mean differences between the time points within the AEG can be found 
in Table 16.  
 
Table 16: Mean and standard deviation of outcome variables in AEG (n=9) 
 Baseline Week 4 Post-exercise 
(week 8) 
De-training  
(week 16) 
Age 37±6.24  37±6.24 37±6.24 
BMI 29.89±4.36  30.20±4.93 31.31±5.31 
Waist to hip 
ratio 
0.93±0.07  0.92±0.08* 0.93±0.07* 
VO2peak 
(L/min) 
2.53±0.62 3.06±0.74 2.98±0.75 3.39±0.33 
Systolic Blood 
pressure 
(mm/Hg) 
120±8  117±12* 122±14* 
Diastolic 
Blood 
pressure 
(mm/Hg) 
88±7  84±9 87±8 
Steps/day 7122±1829£  7808±5836 4901±2752£ 
1RM upper 
body (kg) 
57±16 59±18 56±17 60±20 
1RM lower 
body (kg) 
70±20¥£ 75±19 67±17¥ 76±13£ 
Fat mass % 32.9±6.6  33.2±6.01 32.8±7.6 
Fat-free mass 
(kg) 
52.8±4.9  52.9±3.1 54.4±5.6 
REE (kcal) 1706±262  1814±263 1872±208 
Energy intake 
(kcal) 
1688±600  2040±824 1561±372 
Weight of food 
intake (gr) 
1173±412  1214±378 1036±231 
Protein (gr) 69±27  85±34 77±23 
Carbohydrates 
(gr) 
147±67  176±72 153±37 
Total fat intake 
(gr) 
83±33  94±46 65±22 
Total sugar 
intake (gr) 
67±30  83±57 59±10 
Caffeine (gr) 120±204  53±73 60±59 
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UCP1 mRNA 0.28±0.11  0.34±0.15 0.37±0.32 
UCP1 protein 
expression 
0.93±0.80  1.15±0.79 1.19±1 
PGC-1α 
mRNA 
1.34±1.14  1.14±0.72 0.59±0.21 
PPARα mRNA 1.51±0.67  1.56±0.56 1.36±0.48 
PPARγ mRNA 0.44±0.33  0.44±0.22 0.34±0.06 
BMI: Body mass index; VO2peak: Maximal oxygen uptake; ml/kg-1/min-1 ; Millilitre per 
kilogram, per minute; 1RM: One repetition maximum; kg: Kilograms; REE: Resting 
energy expenditure; kcal: kilocalories; gr: Grammars; mm/Hg: Millimetre of mercury; 
UCP1: Uncoupling protein one; PGC1α: Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha; PPARα: Peroxisome proliferator-activated receptor alpha; 
PPARγ: Peroxisome Proliferator-Activated Receptor Gamma. 
*Significant differences between post-exercise and de-training 
¥ Significant differences between baseline and post-exercise 
£ Significant differences between baseline and de-training 
 
Resistance exercise group 
In REG an increase between baseline and week 4 in 1RM upper body (z=-2.226, 
P=0.03) was found. Additionally, an increase in VO2peak between baseline and post-
exercise (z=-1.992, P=0.05), and between baseline and de-training (z=-1.992, P=0.05) 
were revealed. Also, an increase in WHR (z=-2.060, P=0.04) between post-exercise 
and de-training was detected. An increase in 1RM upper body (z=-2.226, P=0.03) and 
in 1RM lower body (z=-2.201, P=0.03) between baseline and post-exercise was also 
identified while a reduction in 1RM upper body (z=-2.023, P=0.04) and in 1RM lower 
body (z=-2.023, P=0.04) between post-exercise and de-training was found. A 
decrease in SBP (z=-2.041, P=0.04) between baseline and post-exercise was 
detected while a decrease in SBP (z=-2.023, P=0.04) between baseline and de-
training was noticed. Finally, a reduction in DBP (z=-2.000, P=0.05) between baseline 
and post-exercise was revealed.  The mean differences between the time points within 
the REG can be found in Table 17. 
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Table 17: Mean and standard deviation of outcome variables in REG (n=8) 
 Baseline Week 4 Post-exercise 
(week 8) 
De-training 
(week 16) 
Age 34.38±6.41  34.38±6.41 34.38±6.41 
BMI 27.32±2.95  28.05±3.19 27.98±3.17 
Waist to hip 
ratio 
0.89±0.07  0.92±0.06¥ 0.94±0.07¥ 
VO2peak 
(L/min) 
2.42±0.46*£ 2.47±0.42 2.66±0.24* 2.64±0.46£ 
Systolic Blood 
pressure 
(mm/Hg) 
127±15*£  118±10* 116±12£ 
Diastolic Blood 
pressure 
(mm/Hg) 
81±6*  78±7* 82±7 
Steps/day 7086±2728  6553±3755 6779±4143 
1RM upper 
body (kg) 
70±23*# 78±21# 82±24*¥ 78±23¥ 
1RM lower 
body (kg) 
81±27* 90±32 111±77*¥ 95±60¥ 
Fat mass % 28.08±4.7  29.3±3.6 30.2±3.8 
Fat-free mass 
(kg) 
54.6±4.3  54.5±3.9 53.2±3.3 
REE (kcal) 1597±118  1623±260 1520±172 
Energy intake 
(kcal) 
1401±386  1524±140 1781±601 
Weight of food 
intake (gr) 
996±381  1133±250 1220±361 
Protein (gr) 62±23  65±20 83±25 
Carbohydrates 
(gr) 
146±41  180±34 185±61 
Total fat intake 
(gr) 
58±19  58±9 69±34 
Total sugar 
intake (gr) 
66±32  71±9 85±31 
Caffeine (gr) 20±30  35±63 23±38 
UCP1 mRNA 0.29±0.13  0.31±0.16 0.36±0.19 
UCP1 protein 
expression 
1.30±0.84  1.24±0.48 1.98±0.58 
PGC-1α mRNA 0.86±0.39  0.80±0.25 0.59±0.20 
PPARα mRNA 1.53±0.37  1.52±0.28 1.31±0.38 
PPARγ mRNA 0.39±0.17  0.48±0.18 0.34±0.18 
BMI: Body mass index; VO2peak: Maximal oxygen uptake; ml/kg-1/min-1 ; Millilitre per 
kilogram, per minute; 1RM: One repetition maximum; kg: Kilograms; REE: Resting 
energy expenditure; kcal: kilocalories; gr: Grammars; mm/Hg: Millimetre of mercury; 
UCP1: Uncoupling protein one; PGC1α: Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha; PPARα: Peroxisome proliferator-activated receptor alpha; 
PPARγ: Peroxisome Proliferator-Activated Receptor Gamma. 
 
149	
	
*Significant differences between baseline and post-exercise 
¥Significant differences between post-exercise and de-training 
£Significant differences between baseline and de-training 
#Significant differences between baseline and week 4 
 
Combined exercise group 
In CEG we detected an increase in 1RM lower body (z=-2.023, P=0.04) between 
baseline and week 4. There was an increase in BMI (z=-2.035, P=0.04), in 1RM upper 
body (z=-2.366, P=0.02) and in 1RM lower body (z=-2.366, P=0.02) between baseline 
and post-exercise. Finally, there was a reduction in 1RM upper body (z=-2.371, 
P=0.02), in 1RM lower body (z=-2.201, P=0.03), in energy intake (z=-2.521, P=0.01) 
and in carbohydrates intake (z=-2.380, P=0.02) between post-exercise and de-
training. The mean differences between the time points within the CEG can be found 
in Table 18. 
 
Table 18: Mean and standard deviation of outcome variables in CEG (n=8) 
 Baseline Week 4 Post-exercise 
(week 8) 
De-training 
(week 16) 
Age 37.75±9.22  37.75±9.22 37.75±9.22 
BMI 27.16±5.78¥  27.43±5.62¥ 27.36±5.76 
Waist to hip 
ratio 
0.93±0.07  0.93±0.06 0.93±0.05 
VO2peak 
(L/min) 
2.50±0.58 2.54±0.61 2.81±0.67 2.39±0.56 
Systolic Blood 
pressure 
(mm/Hg) 
128±7  122±14 126±8 
Diastolic 
Blood 
pressure 
(mm/Hg) 
86±8  86±10 85±11 
Steps/day 8968±5040  9490±5104 8195±3017 
1RM upper 
body (kg) 
52±11¥ 55±9 57±9*¥ 51±11* 
1RM lower 
body (kg) 
94±60¥# 122±71# 137±99*¥ 103±73* 
Fat mass % 28.4±12  28.3±12.03 29.7±10.6 
Fat-free mass 
(kg) 
50.3±6.2  51.2±6.9 49.5±5.5 
REE (kcal) 1516±171  1625±273 1525±200 
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Energy intake 
(kcal) 
1346±327  1691±683* 1488±655* 
Weight of food 
intake (gr) 
998±207  1196±424 1132±388 
Protein (gr) 63±16  90±46 81±47 
Carbohydrates 
(gr) 
140±31  168±78* 138±70* 
Total fat intake 
(gr) 
59±22  70±28 64±24 
Total sugar 
intake (gr) 
61±24  62±44 51±33 
Caffeine (gr) 134±219  197±313 218±254 
UCP1 mRNA 0.28±0.12  0.29±0.23 0.41±0.24 
UCP1 protein 
expression 
0.77±0.44  0.92±0.49 1.55±0.82 
PGC-1α 
mRNA 
0.75±0.26  0.84±0.41 0.68±0.31 
PPARα mRNA 1.44±0.44  1.55±0.36 1.37±0.42 
PPARγ mRNA 0.33±0.15  0.38±0.19 0.34±0.15 
BMI: Body mass index; VO2peak: Maximal oxygen uptake; ml/kg-1/min-1 ; Millilitre per 
kilogram, per minute; 1RM: One repetition maximum; kg: Kilograms; REE: Resting 
energy expenditure; kcal: kilocalories; gr: Grammars; mm/Hg: Millimetre of mercury; 
UCP1: Uncoupling protein one; PGC1α: Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha; PPARα: Peroxisome proliferator-activated receptor alpha; 
PPARγ: Peroxisome Proliferator-Activated Receptor Gamma. 
*Significant differences between post-exercise and de-training 
¥Significant differences between baseline and post-exercise 
#Significant differences between baseline and week 4 
 
 
Control group 
In CG we found a decrease in BMI (z=-2.201, P=0.03) and fat-free mass (z=-2.201, 
P=0.03) between post-exercise and de-training. There was also a reduction in BMI 
(z=-1.997, P=0.04) between baseline and de-training. The mean differences between 
the time points within the CG can be found in Table 19. 
 
Table 19: Mean and standard deviation of outcome variables in CG (n=7) 
 Baseline Week 4 Post-exercise 
(week 8) 
De-training 
(week 16) 
Age 34.86±8.39  34.86±8.39 34.86±8.39 
BMI 25.47±4.74¥  25.21±4.37* 23.55±3.50*¥ 
Waist to hip 
ratio 
0.86±0.08  0.85±0.05 0.83±0.02 
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VO2peak 
(L/min) 
2.52±0.50 2.53±0.52 2.69±0.38 2.56±0.32 
Systolic Blood 
pressure 
(mm/Hg) 
122±7  118±10 124±7 
Diastolic Blood 
pressure 
(mm/Hg) 
82±2  78±6 81±2 
Steps/day 8344±3266  8052±4661 6518±4013 
1RM upper 
body (kg) 
59±16 56±14 55±13 56±13 
1RM lower body 
(kg) 
61±13 65±13 61±14 63±12 
Fat mass % 22.6±9.1  21.2±8.3 19.4±7.1 
Fat-free mass 
(kg) 
54±4.1  55.4±4.4* 53.4±5.7* 
REE (kcal) 1412±189  1503±202 1454±140 
Energy intake 
(kcal) 
1384±436  1342±417 1611±240 
Weight of food 
intake (gr) 
965±280  1053±170 1200±362 
Protein (gr) 62±20  56±23 63±12 
Carbohydrates 
(gr) 
145±18  148±41 163±48 
Total fat intake 
(gr) 
58±31  49±23 66±12 
Total sugar 
intake (gr) 
51±16  57±20 66±23 
Caffeine (gr) 116±187  154±282 157±253 
UCP1 mRNA 0.21±0.24  0.23±0.22 0.35±0.26 
UCP1 protein 
expression 
1.24±0.55  1.49±0.89 1.18±0.76 
PGC-1α mRNA 1.37±0.61  1.88±1.28 1.49±0.87 
PPARα mRNA 2.55±0.72  2.51±0.74 2.05±0.65 
PPARγ mRNA 0.62±0.41  0.55±0.30 0.49±0.31 
BMI: Body mass index; VO2peak: Maximal oxygen uptake; ml/kg-1/min-1 ; Millilitre per 
kilogram, per minute; 1RM: One repetition maximum; kg: Kilograms; REE: Resting 
energy expenditure; kcal: kilocalories; gr: Grammars; mm/Hg: Millimetre of mercury; 
UCP1: Uncoupling protein one; PGC1α: Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha; PPARα: Peroxisome proliferator-activated receptor alpha; 
PPARγ: Peroxisome Proliferator-Activated Receptor Gamma 
*Significant differences between post-exercise and de-training 
¥ Significant differences between baseline and de-training 
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7.4. DISCUSSION 
The primary aim of this study was to examine the effects of different types of exercise 
and de-training on the UCP1 mRNA and protein expression within the subcutaneous 
WAT in healthy untrained men. The statistical analysis revealed no effects of exercise 
and de-training on the UCP1 mRNA and protein expression, neither in the entire 
sample size nor in the high responders not only to the exercise stimuli, but also to the 
de-training period. This follows the findings of the first study (systematic review) of this 
thesis, even though the available evidence was limited. The current study’s results are 
in accordance with a previous controlled trial in humans that examined the effects of 
exercise on UCP1 mRNA of subcutaneous WAT that showed no effects – even though 
the UCP1 mRNA was increased in response to a 12-week combined 
(aerobic+resistance) exercise programme – in both healthy and pre-diabetic 
individuals [236]. In this regard, UCP1 mRNA and protein expression were also 
increased, yet not significantly, in response to aerobic exercise and showed a small 
effect size in the current study. This small effect size in AEG indicates a trend of UCP1 
mRNA and protein expression to be increased in response to aerobic exercise that 
needs further exploration. The results of the current study are also in accordance with 
a recent single group design study that examined the effects of a 16-week exercise 
intervention on browning formation markers of WAT including UCP1 mRNA in healthy 
women. This study showed no differences between baseline and post-exercise in 
UCP1 mRNA [368]. The later study also showed an inverse association of UCP1 
mRNA in subcutaneous WAT with weight loss of the participants in response to 
exercise [368]. This evidence cannot indicate that the presence of UCP1 in WAT could 
lead to weight loss and subsequently to lessen obesity, as previously described [30].    
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In the current study the PPARα mRNA did not alter in response to exercise and 
de-training neither in the entire sample size nor in the high responders not only to the 
exercise stimuli, but also to the de-training period. The proposed mechanism that 
circulating Irisin increases the UCP1 within the white adipocytes may be partly 
dependent on the action of PPARα. This is because FNDC5 – the precursor of Irisin – 
has been shown to increase PPARα mRNA in vitro while pharmacological inhibition 
by antagonists of PPARα limits the action of FNDC5 [30]. Given that PPARα mRNA 
did not alter in the current study it could therefore, explain, at least in part, why UCP1 
mRNA and protein expression did not also alter. Previous evidence from animal 
studies showed that exercise increased the positive UCP1 white fat cells in exercised 
high-fat diet mice, but not in sedentary high-fat diet mice [190]. The fat diet (along with 
the most of the dietary elements) of our participants did not significantly alter 
throughout the experimental protocol. This may also explain the non-significant 
alterations of the UCP1 mRNA and protein expression given that previous evidence 
showed that high-fat diet increased UCP1 in mice [206, 207].  
Surprisingly, a moderate effect size was detected – values increased – of UCP1 
mRNA after the de-training period in the CG. However, regarding UCP1 protein 
expression a small effect size was found – values decreased – between post-exercise 
and de-training, which is completely different trend than the one of the UCP1 mRNA. 
The CG displayed significantly decreased BMI after the de-training period which may 
not explain the finding of the UCP1 protein expression, given that BMI is inversely 
correlated with BAT activity and subsequently a thermogenic effect that the UCP1 
represents [29, 183]. Despite the aforementioned alteration of BMI in CG we found no 
significant changes in nutrition and physical activity levels – that could explain the BMI 
reduction – of the participants in the CG throughout the experimental protocol (Table 
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19). Even though the participants of the CG were instructed not to participate in 
exercise and to keep their physical activity and behaviour constant, this could not be 
fully controlled. Furthermore, at post-exercise there was a moderate effect size in 
UCP1 mRNA between values of the AEG and the REG with the CG. The UCP1 mRNA 
in the exercise groups was higher than the CG. This may be explained by the fact that 
the differences between the AEG and the REG with the CG occur at baseline values 
as well. Indeed, a moderate effect size was found in UCP1 mRNA at baseline values 
between the exercised groups and the CG. The effect sizes of the UCP1 mRNA are 
not in accordance with the effect sizes of the UCP1 protein expression. Indeed, the 
UCP1 protein expression values of the CG were higher than the values of the AEG, 
REG and CEG at post-exercise. This may be explained by the fact that the differences 
between the AEG, REG and the CEG with the CG occur at baseline values as well. 
Actually, at baseline a small and a large effect size were found between AEG and CG 
and between CEG and CG, respectively. At de-training however, the values of the CG 
were lower than the values of the REG and the CEG which is in accordance with the 
UCP1 mRNA values.  
The proposed mechanism that exercise may increase UCP1 within the WAT is 
that exercise produces Irisin in the bloodstream – via the action of the FNDC5 gene 
within the skeletal muscle – that then attaches to the surface of white adipocytes [30]. 
However, this biological activity of the Irisin protein has not been well-established. 
Indeed, the first study (systematic review) of this thesis failed to confirm that Irisin is 
produced in response to exercise in humans due to earlier studies' use of inaccurate 
methods to quantify circulating Irisin (the available commercial antibodies attract 
cross-reacting proteins) [35], that led to misleading and disparate results. The current 
study did not measure circulating Irisin – even though this was planned – due to the 
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latter issues. Human Irisin displays a non-canonical start codon (non-ATG), because 
the FNDC5 gene – the precursor of Irisin – is mutated in humans [274]. This may lead 
to a short-length Irisin production into the bloodstream, which misses almost 50% of 
its sequence [274], and therefore, the biological activity of human Irisin is questioned. 
Nevertheless, more recent mass spectrometry analysis of Irisin in humans showed 
that Irisin is translated from its non-canonical start codon (non-ATG) but, it circulates 
and showed to be increased in response to exercise, which implies a biological activity 
of the protein [276]. A recent animal study showed that FNDC5 produced in 
subcutaneous white adipocytes may be more responsible than the action of circulating 
Irisin [380] for the browning process of WAT in response to exercise. However, the 
current study did not investigate FNDC5.  
Similar to the second study of this PhD (cross-sectional study) the current study 
also detected positive white adipocytes of the UCP1 gene and protein expression at 
baseline, post-exercise and de-training. The presence of UCP1 in subcutaneous WAT 
could be dependent on a synergetic interactions between selective genes and 
variations in recessive and dominants genes [371] as well as in precursor cells in WAT 
that may promote rise of brown-like adipocytes that express UCP1 [272]. In this light, 
the presence of UCP1 in subcutaneous adipocytes after an exercise programme and 
a de-training period that was detected by the current study remains to be elucidated. 
A secondary aim of the current study was to examine the effects of different 
types of exercise and de-training on the mRNA of the PGC-1α, PPARα and PPARγ 
genes that indicate browning formation of subcutaneous WAT in healthy untrained 
men. The ANOVA analysis revealed no effects of exercise and de-training on the 
mRNA of the PGC-1α, PPARα and PPARγ genes neither in the entire sample size nor 
in the high responders not only to the exercise stimuli, but also to the de-training 
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period. Also, the effect size analysis did not detect effect sizes in the exercised groups 
between baseline and post-exercise values. Moderate and large effect sizes, however, 
were observed in exercise groups – values decreased – between post-exercise and 
de-training. Recent evidence has shown that PGC-1α increased in subcutaneous 
WAT of mice in response to chronic exercise [380]. In this study, the thermogenic 
capacity of the animals was tested and showed increased body heat temperature 
during the day/night cycle along with increased energy expenditure [380]. Therefore, 
PGC-1α was proposed to cause a browning formation of WAT that increases energy 
expenditure [380]. In the current study PGC-1α mRNA did not alter and REE did not 
significantly change throughout the experimental protocol. We found moderate and 
large effect sizes – values decreased – between post-exercise and de-training in 
exercise groups in PGC-1α mRNA. It could be hypothesized therefore, that PGC-1α 
was increased in response to exercise and subsequently decreased in response to 
de-training but, we only detected a small effect size between baseline and post-
exercise in the CEG while the AEG displayed decreased PGC-1α mRNA in response 
to exercice. As such, this PGC-1α trend remains to be elucidated.  
PPARγ mRNA displayed a trend of increasing in response to resistance and 
combined (aerobic+resistance) exercise given the small and moderate effect sizes – 
values increased – that were detected. However, PPARα mRNA of the REG showed 
significantly lower values than the CG at post-exercise and de-training in the high 
responders to the exercise stimuli, which cannot indicate an effect of exercise on the 
high responders. PPARα may control lipid metabolism [246] and fatty acid oxidation 
in response to fasting [247] while PPARγ is responsible for the regulation of fatty acid 
storage and glucose metabolism [254]. Neither the fat mass nor the diet of the 
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participants in the current study were changed in response to exercise and de-training, 
that may explain the non-alteration of PPARα and PPARγ.  
VO2peak was significantly increased only in the REG after the exercise 
programme, while it was increased, yet not significantly, in both AEG by 15% and CEG 
by 10%. Previous evidence showed that an 8-week of resistance training significantly 
increased VO2peak in healthy men [347] while chronic resistance exercise increased 
VO2peak in healthy older women that was equal to chronic aerobic exercise [390]. 
This increase occurs due to the significant improvement of the total muscle aerobic 
capacity and fat oxidation in response to resistance exercise that led to muscle 
hypertrophy [347]. Indeed, in the current study the 1RM of upper and lower body was 
significantly increased in response to resistance exercise that may indicate muscle 
hypertrophy especially in the early stages of resistance training [391]. Notably, the 
participants of the current study were untrained and therefore, these adaptations seem 
reasonable. In line with the VO2peak adaptations the 1RM of upper and lower body 
were significantly increased in CEG after the exercise programme. 
It would be expected that aerobic training would significantly increase VO2peak 
of the participants in the current study. Even though VO2peak was increased by 15% 
this was not significant. However, previous evidence showed that high intensities of 
aerobic training are more effective for improving VO2max than lower intensities [392]. 
The exercise programmes in the current study were set at 65% of VO2peak and 1RM 
throughout and along with the small number of participants (eight per group) may not 
have allowed a significant alteration. This was because we followed previous exercise 
programmes that led to increase of PGC-1α – the precursor of the Irisin mechanism – 
in skeletal muscle [306].  
158	
	
A number of limitations have been identified in the current study. The mRNA 
measurements were widely used in the past to determine BAT [22] and/or brown-like 
adipose tissue functions [31, 32, 236, 266, 267]. However, even though the mRNA of 
genes usually indicate the protein production sometimes they do not predict it [197-
199] given that one mRNA transcription may encode the protein more than one time 
[197-199]. Only mRNAs for PGC-1α, PPARα and PPARγ were measured in the 
current study and this is a limitation. Furthermore, the acute effects of exercise were 
not examined given that in humans the acute effects of exercise on PGC-1α, FNDC5 
in muscle and Irisin were examined in the past and showed a significant alteration 
[236]. As such it could be hypothesized that acute alterations could be identified in the 
genes and protein expressions examined in the current study. However, this would 
require more than three surgical biopsies for each participant and therefore, due to 
ethical considerations it was not included in the measurements. Circulating Irisin was 
not measured to see if it is altered in response to exercise and its associations with 
the mRNAs and protein expression of the genes that were examined. Blood samples 
were retrieved from the participants, because the plan was to measure circulating 
Irisin, but during the study new evidence showed that the ELISA kits used for Irisin 
identification were neither valid nor accurate [35]. Because alternative methods to 
measure this protein (e.g. mass spectrometry) were unavailable within the study 
laboratory, the Irisin identification in blood samples was omitted; however the samples 
are stored and will be analysed in the future. 
Another limitation is that even though the participants of the control group were 
instructed not to change their physical activity behaviour during the experimental 
period, this could not be fully controlled. The participants were also instructed to refrain 
from passive smoking, and alcohol for 72 hours prior to the REE, anthropometry, body 
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composition measurements and fat biopsies. This could not be fully controlled and 
may have caused some disturbances in the measurements and therefore, misleading 
results. The physical activity data and diet elements data were collected by telephone. 
This may have allowed a greater risk of bias in the reporting data from the participants.  
The exercise programmes were based on a specific intensity (65% VO2peak, 
1RM). The effects of various exercise intensities on the genes and protein expressions 
examined could not be tested. Finally, even though a priori power calculation was used 
to determine sample size, the effect size analyses showed that more participants may 
have been needed per group. However, we located only one relevant controlled trial 
on humans to be used for the power calculation analysis. 
 
7.5. CONCLUSIONS 
In conclusion, different types of chronic exercise and de-training do not affect the 
UCP1 mRNA and protein expression of subcutaneous WAT in healthy untrained men, 
which may indicate no effect of chronic exercise on browning formation of WAT in 
humans. In addition, no alterations of body weight and REE in response to exercise 
were found, which indicate no link between UCP1 and body weight/REE that could 
designate a browning effect on WAT. Also, no effects of exercise and de-training on 
the mRNAs of PGC-1α, PPARα and PPARγ genes of subcutaneous WAT in healthy 
untrained men were found, suggesting no synergetic effect of these genes with UCP1 
in order to designate a browning formation of WAT in humans. There is a trend of 
UCP1 mRNA and protein expression to be increased in response to aerobic exercise, 
which may indicate a thermogenic function and a browning process of WAT in healthy 
men. The study found positive UCP1 subcutaneous adipocytes, which cannot be fully 
attributed to exercise stimuli. There is also a trend of PPARγ mRNA to be increased 
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in response to both resistance and combined (aerobic+resistance) exercise. This 
indicates increased lipid metabolism and fatty acid beta oxidation. Finally, there is a 
trend of PPARγ mRNA to be decreased in response to de-training. This indicates a 
decline in lipid metabolism and fatty acid beta oxidation. More studies are required to 
study and understand these phenomena.  
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8. CHAPTER 8: EFFECTS OF DIFFERENT TYPES OF EXERCISE AND DE-
TRAINING ON LEPTIN mRNA EXPRESSION OF SUBCUTANEOUS WHITE 
ADIPOCYTES IN HUMANS: A RANDOMIZED CONTROL TRIAL (4th study) 
8.1. INTRODUCTION 
Leptin is an adipokine secreted by the adipose tissue and regulates the appetite levels 
through its action on the hypothalamus [120, 393]. Increased leptin sensitivity with its 
receptor stimulates lipolysis in adipose tissue and hepatic fatty acid uptake and 
oxidation [126]. The leptin resistance condition is an inadequate communication of 
leptin with its receptor in the hypothalamus and leads to increased circulating leptin 
concentrations [394]. Increased circulating leptin concentrations may up-regulate the 
production of TNFα and IL-6 indicating an inflammation state [394], which usually 
occurs in obese individuals [120]. Leptin production is reduced by the SNS activation 
[137] and is suppressed in response to cold exposure [25]. When leptin is suppressed 
in response to cold exposure it may be accompanied by the reduction of fat mass 
[134]. Also, the reduction in fat mass in response to chronic exercise is usually 
accompanied by a reduction in circulating leptin concentrations [120, 141, 144, 145].  
Adiponectin, an adipokine also secreted by the adipose tissue, controls energy 
homeostasis and appetite [120]. Low circulating adiponectin concentrations are 
associated with increased appetite [120] and high circulating adiponectin 
concentrations may decrease glucose production from the liver, indicating enhanced 
insulin sensitivity [156, 284]. Chronic exercise has been shown to increase circulating 
adiponectin concentrations in healthy obese men [13, 395] and postmenopausal 
women [396]. L/A ratio can be used as an index to identify risk of disease. Increased 
L/A ratio may indicate increased atherosclerosis and glycated haemoglobin, which is 
an index of increased insulin resistance [397, 398].  
The aim of the present study was to examine the effects of different types of 
exercise and de-training on the leptin mRNA of subcutaneous WAT in healthy 
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untrained men in a parallel RCT design. A secondary aim was to examine the effects 
of different types of exercise and de-training on the adiponectin and L/A ratio mRNAs. 
It was hypothesized that different types of chronic exercise will decrease (and the 
following de-training period will increase) the leptin mRNA in subcutaneous WAT of 
healthy untrained men. Finally, anthropometry indices, REE (kcal), physical activity 
levels, energy intake (kcal) and diet data were recorded throughout the trial in order to 
be used as confounding factors.  
 
8.2. METHODS 
The methods of this parallel RCT regarding the procedure, the random 
allocation/blinding procedures and inclusion criteria of the participants, anthropometry 
measurements, assessments of REE, VO2peak, energy intake, diet elements, physical 
activity, subcutaneous fat biopsy procedure, gene expression analysis and exercise 
protocols (Table 8) are described in detail in the general methods in Chapter 4, pages 
61-71. The methodological design can be found in Figure 8 in Chapter 4, page 64. 
 
8.2.1. Participants and procedures 
The baseline characteristics of the participants of this study are presented in details in 
Table 13, page 117. The baseline characteristics of the participants regarding leptin, 
adiponectin and L/A ratio mRNAs can be found in Table 20. 
 
Table 20: Baseline characteristics of the participants (n=32) 
 Mean ± Standard deviation 
Leptin mRNA 2.85±2.24 
Adiponectin mRNA 1.02±0.44 
Leptin to adiponectin ratio mRNA 2.82±1.77 
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8.2.2. Statistical analysis 
The statistical approach of this study is identical to the statistical approach of the 3rd 
study and it is described in details on pages 118-120. The number of the participants 
who were randomly assigned in the exercise programmes (and the drop outs with 
reasons) as well as the number of the participants included in the final analysis can be 
found in Figure 7, Chapter 4, page 63. 
 
8.3. RESULTS 
Details regarding the exercise attendance and intensity supervision as well as harms 
of this study are identical to the 3rd study and they are presented on page 120. 
 
8.3.1. Primary outcomes 
Results from ANOVA analysis 
No significant differences between and within groups in delta scores of mRNA for 
leptin were detected neither between baseline and post-exercise (week 8) nor 
between post-exercise (week 8) and de-training (week 16). The individual data for 
leptin mRNA are shown in Figure 30. 
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Figure 30: Individual data for leptin mRNA at baseline, post exercise (week 8) and de-
training (week 16) 
 
 
Each number in the x axis represents one participant; The participants 1, 5, 11, 13, 
18, 19, 20, 24 and 32 belong to the aerobic exercise group; The participants 4, 6, 8, 
14, 21, 23, 25, and 29 belong to the resistance exercise group; The participants 2, 10, 
12, 15, 26, 28, 30, and 31 belong to the combined (aerobic+resistance) exercise 
group; The participants 3, 7, 9, 16, 17, 22, and 27 belong to the control group. 
 
Results from low responders versus high responders analysis  
For leptin mRNA the low responders to the exercise stimuli were considered those 
who displayed values equal or more than the 50th percentile while the high responders 
to the exercise stimuli were considered those who displayed values less than the 50th 
percentile. Furthermore, the low responders to the de-training period were considered 
those who displayed values less than the 50th percentile while the high responders to 
the de-training period were considered those who displayed values equal or more than 
the 50th percentile [309]. This is because according to the hypothesis of this study the 
exercise intervention was expected to decrease leptin mRNA while the de-training 
period was expected to increase leptin mRNA.  
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Chi square analysis revealed no significant differences between the 
experimental groups (categorical variable consisted of four groups) and a) leptin 
mRNA (categorical variable of low and high responders to exercise stimuli) [χ2 (3, 
n=29)=1.75, P>0.05] as well as b) leptin mRNA (categorical variable of low and high 
responders to de-training period) [χ2 (3, n=25)=1.32, P>0.05].  
Kruskal–Wallis analysis of variance revealed no differences for leptin mRNA 
between the experimental groups in high responders to the exercise stimuli and in high 
responders to the de-training period at all time points (P>0.05). Wilcoxon Signed Rank 
tests revealed no differences of leptin mRNA in high responders to the exercise stimuli 
between baseline and post-exercise as well as in high responders to the de-training 
period between post-exercise and de-training within each experimental group. The 
number and the percentage of the low and high responders of leptin mRNA for each 
experimental group are shown in Table 21. 
 
Table 21: Number and percentage of the low and high responders for leptin mRNA  
Group Low responders High responders 
 Leptin mRNA Leptin mRNA 
Exercise stimuli 
AEG 4 (50%) 4 (50%) 
REG  3 (50%) 3 (50%) 
CEG  3 (37.5%) 5 (62.5%) 
CG  5 (71.4%) 2 (28.6%) 
De-training period 
AEG 4 (66.7%)  2 (33.3%) 
REG 3 (50%)  3 (50%) 
CEG 3 (37.5%) 5 (62.5%) 
CG 2 (40%) 3 (60%) 
AEG: Aerobic exercise group; REG: Resistance exercise group; CEG: Combined 
(aerobic+resistance) exercise group; CG: Control group. 
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Results from Cohen’s d effect size analysis  
The leptin mRNA was increased in response to aerobic exercise and was decreased 
in response to de-training. A small effect size (d=0.33) between baseline and post-
exercise and a large effect size (d=0.98) between post-exercise and de-training in 
AEG (Figure 31A) were found. A small effect size (d=0.41) in REG (Figure 31B), in 
CEG [(d=0.39) (Figure 31C)] and in CG [(d=0.43) (Figure 31D)] between post-exercise 
and de-training were also detected. 
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Figure 31: Cohen’s d effect size in leptin mRNA between baseline, post-exercise 
(week 8) and de-training (week 16)  
 
 
Figure 31A:  *Small effect size (d=0.33), #Large effect size (d=0.98); Figure 31B:  
#Small effect size (d=0.41); Figure 31C:  #Small effect size (d=0.39); Figure 31D: 
#Small effect size (d=0.43); Values are depicted as mean and standard deviation. 
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The leptin mRNA of the CG showed higher values compared to the exercise 
groups at all time points. At baseline, a moderate effect size between CG and AEG 
(d=0.64), a small effect size between CG and REG (d=0.35), and a small effect size 
between CG and CEG (d=0.40) were identified (Figure 32A). At post-exercise, a small 
effect size between CG and AEG (d=0.45), a small effect size between CG and REG 
(d=0.35) and a moderate effect size between CG and CEG (d=0.50) were revealed 
(Figure 32B). At de-training, a large effect size between CG and AEG (d=0.90) and a 
small effect size between CG and CEG (d=0.37) were found (Figure 32C). 
 
Figure 32: Cohen’s d effect size in leptin mRNA between control and exercise groups 
at baseline, post-exercise (week 8) and de-training (week 16) 
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Figure 32A: *Moderate effect size (d=0.64), #Small effect size (d=0.35), £Small effect 
size (d=0.40); Figure 32B: *Small effect size (d=0.45), #Small effect size (d=0.35), 
£Moderate effect size (d=0.50); Figure 32C: *Large effect size (d=0.90), £Small effect 
size (d=0.37); Values are depicted as mean and standard deviation. 
 
 
8.3.2. Secondary outcomes 
Results from ANOVA analysis 
No significant differences between and within groups in delta scores of adiponectin, 
and L/A ratio mRNAs were detected between baseline and post-exercise values (week 
8) nor between post-exercise (week 8) and de-training values (week 16). The 
individual data for adiponectin and L/A ratio mRNAs are depicted in Figure 33. 
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Figure 33: Individual data for adiponectin (A) and leptin to adiponectin ratio (B) 
mRNAs at baseline, post exercise (week 8) and de-training (week 16) 
 
 
Each number in the x axis represents one participant; The participants 1, 5, 11, 13, 
18, 19, 20, 24 and 32 belong to the aerobic exercise group; The participants 4, 6, 8, 
14, 21, 23, 25, and 29 belong to the resistance exercise group; The participants 2, 10, 
12, 15, 26, 28, 30, and 31 belong to the combined (aerobic+resistance) exercise 
group; The participants 3, 7, 9, 16, 17, 22, and 27 belong to the control group; L/A: 
Leptin to adiponectin.  
 
Results from low responders versus high responders analysis  
For adiponectin mRNA the low responders to the exercise stimuli were considered 
those who displayed values less than the 50th percentile while the high responders to 
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the exercise stimuli were considered those who displayed values equal or more than 
the 50th percentile. Furthermore, the low responders to the de-training period were 
considered those who displayed values equal or more than the 50th percentile while 
the high responders to the de-training period were considered those who displayed 
values less than the 50th percentile  [309]. This is because according to the hypothesis 
of this study the exercise intervention was expected to increase adiponectin mRNA 
while the de-training period was expected to decrease adiponectin mRNA. For L/A 
ratio mRNA the low responders to the exercise stimuli were considered those who 
displayed equal or more than the 50th percentile while the high responders to the 
exercise stimuli were considered those who displayed values less than the 50th 
percentile. Furthermore, the low responders to the de-training period were considered 
those who displayed values less than the 50th percentile while the high responders to 
the de-training period were considered those who displayed values equal or more than 
the 50th percentile [309]. This is because according to the hypothesis of this study the 
exercise intervention was expected to decrease L/A ratio mRNA while the de-training 
period was expected to increase L/A ratio mRNA.  
Chi square analyses revealed no significant differences between the 
experimental groups (categorical variable consisted of four groups) and a) adiponectin 
mRNA (categorical variable of low and high responders to exercise stimuli) [χ2 (3, 
n=29)=4.54, P>0.05] as well as b) L/A ratio mRNA  (categorical variable of low and 
high responders to exercise stimuli) [χ2 (3, n=29)=1.77, P>0.05]. Chi square analyses 
also showed no significant differences between the experimental groups (categorical 
variable consisted of four groups) and a) adiponectin mRNA (categorical variable of 
low and high responders to de-training period) [χ2 (3, n=25)=6.13, P>0.05]  as well as 
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b) L/A ratio mRNA  (categorical variable of low and high responders to de-training 
period) [χ2 (3, n=25)=1.32, P>0.05].  
Kruskal–Wallis analysis of variance with post-hoc Mann-Witney U tests showed 
that the REG displayed significantly higher adiponectin mRNA in high responders to 
the de-training period than the AEG (P=0.03) and the CEG (P=0.03) at post-exercise. 
Furthermore, Kruskal–Wallis analysis of variance revealed no differences for L/A ratio  
mRNA between the experimental groups in high responders to the exercise stimuli 
and in high responders to the de-training period at all time points (P>0.05). Finally, 
Wilcoxon Signed Rank tests revealed that adiponectin mRNA was significantly higher 
at post-exercise than after the de-training in high responders to the de-training period 
in the CEG (z=-2.023, P=0.04). The number and the percentage of the low and high 
responders of adiponectin and L/A ratio mRNAs for each experimental group are 
shown in Table 22.  
 
Table 22: Number and percentage of the low and high responders for adiponectin and 
leptin to adiponectin ratio mRNAs  
Group Low responders High responders 
 Adiponectin 
mRNA 
L/A mRNA Adiponectin 
mRNA 
L/A mRNA 
Exercise stimuli 
AEG  5 (62.5%)  3 (37.5%)  3 (37.5%)  5 (62.5%) 
REG  3 (50%)  4 (66.7%)  3 (50%) 2 (33.3%) 
CEG  5 (62.5%)  5 (62.5%)   3 (37.5%)  3 (37.5%) 
CG 1 (14.3%)  3 (42.9%)  6 (85.7%)  4 (57.1%) 
De-training period 
AEG  3 (50%)  4 (66.7%)  3 (50%) 2 (33.3%) 
REG  2 (33.3%) 3 (50%)  4 (66.7%)  3 (50%) 
CEG 3 (37.5%)  3 (37.5%) 5 (62.5%)  5 (62.5%) 
CG  (100%) 2 (40%) 0 (0%) 3 (60%) 
L/A: Leptin to adiponectin ratio; AEG: Aerobic exercise group; REG: Resistance 
exercise group; CEG: Combined (aerobic+resistance) exercise group; CG: Control 
group.  
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Results from Cohen’s d effect size analysis 
Results for adiponectin 
The adiponectin mRNA was increased in response to exercise in the AEG, REG and 
CEG and was decreased in response to de-training in all groups. The effect size 
analyses showed a small effect size (d=0.20) in AEG between baseline and post-
exercise and a moderate effect size (d=0.52) between post-exercise and de-training 
(Figure 34A). In REG a large effect size (d=0.81) between baseline and post-exercise 
and a large effect size (d=1.04) between post-exercise and de-training was detected 
(Figure 34B). In CEG a small effect size (d=0.31) between baseline and post-exercise 
and a moderate effect size (d=0.78) between post-exercise and de-training  was 
identified (Figure 34C). Finally, in CG a large effect size (d=0.81) (Figure 34D) 
between post-exercise and de-training was also noticed.  
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Figure 34: Cohen’s d effect size in adiponectin mRNA between baseline, post-
exercise (week 8) and de-training (week 16) 
 
 
Figure 34A: *Small effect size (d=0.20), #Moderate effect size (d=0.52); Figure 34B: 
*Large effect size (d=0.81),  #Large effect size (d=1.04); Figure 34C: *Small effect 
size (d=0.31), #Moderate effect size (d=0.78); Figure 34D:  #Large effect size (d=0.81); 
Values are depicted as mean and standard deviation. 
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The CG showed higher values in adiponectin mRNA than the exercise groups 
at all time points. The effect size analysis showed at baseline a large effect size 
between CG and AEG (d=0.81), between CG and REG (d=1.26), and between CG 
and CEG (d=1.33) (Figure 35A). At post-exercise, a moderate effect size between CG 
and AEG (d=0.73), a moderate effect size between CG and REG (d=0.68) and a large 
effect size between CG and CEG (d=1.08) were identified (Figure 35B). At de-training, 
a large effect size between CG and AEG (d=1.03), between CG and REG (d=0.91) 
and between CG and CEG (d=1.21) was revealed (Figure 35C). 
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Figure 35: Cohen’s d effect size in adiponectin mRNA between control and exercise 
groups at baseline, post-exercise (week 8) and de-training (week 16) 
 
 
Figure 35A: *Large effect size (d=0.81), #Large effect size (d=1.26), £Large effect size 
(d=1.33); Figure 35B: *Moderate effect size (d=0.73), #Moderate effect size (d=0.68), 
£Large effect size (d=1.08); Figure 35C: *Large effect size (d=1.03), #Large effect size 
(d=0.91) £Large effect size (d=1.21); Values are depicted as mean and standard 
deviation. 
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Results for leptin to adiponectin ratio 
According to the effect size analysis, the L/A ratio mRNA was decreased after the 
resistance exercise programme while it was decreased in response to de-training in 
AEG, REG and CG. Specifically, the L/A ratio mRNA displayed a moderate effect size 
in AEG (d=0.77) between post-exercise and de-training (Figure 36A). In REG the L/A 
ratio mRNA was decreased and showed a moderate effect size (d=0.50) between 
baseline and post-exercise while it displayed a small effect size (d=0.20) between 
post-exercise and de-training (Figure 36B). In CEG the L/A ratio mRNA showed a 
small effect size (d=0.21) between post-exercise and de-training (Figure 36C) while in 
CG it also showed a small effect size (d=0.26) between post-exercise and de-training 
(Figure 36D). At baseline and post-exercise, there was any effect size between the 
CG and the exercise groups. However, at de-training, the AEG displayed lower values 
than the CG and a moderate effect size was found (d=0.52), while the CEG displayed 
higher values than the CG and a small effect size was detected (d=0.35) (Figure 37). 
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Figure 36: Cohen’s d effect size in leptin to adiponectin ratio mRNA between baseline, 
post-exercise (week 8) and de-training (week 16) 
 
 
Figure 36A:  #Moderate effect size (d=0.77); Figure 36B: *Moderate effect size 
(d=0.50),  #Small effect size (d=0.20); Figure 36C: #Small effect size (d=0.21); Figure 
36D: #Small effect size (d=0.26); Values are depicted as mean and standard deviation. 
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Figure 37: Cohen’s d effect size in leptin to adiponectin ratio mRNA between control 
and exercise groups at de-training (week 16) 
 
 
*Moderate effect size (d=0.52), £Small effect size (d=0.35); Values are depicted as 
mean and standard deviation. 
 
8.3.3. Results from analysis within groups 
The mean differences of the assessed variables between the time points are identical 
to the 3rd study of this PhD and can be found in detail in Table 16 for the AEG, Table 
17 for the REG, Table 18 for the CEG and Table 19 for the CG on pages 146-151. The 
mean differences between the time points of all experimental groups regarding leptin, 
adiponectin and L/A ratio mRNAs can be found in Table 23.  
 
Table 23: Mean and standard deviation of leptin, adiponectin and L/A mRNAs  
 
 Baseline Post-exercise 
(week 8) 
De-training (week 16) 
Aerobic exercise group 
Leptin mRNA 2.18±1.27 2.67±1.63 1.36±0.75 
Adiponectin 
mRNA 
0.94±0.58 1.06±0.51 0.83±0.31 
L/A ratio mRNA 2.54±1.35 2.53±1.20 1.71±0.76 
Resistance exercise group 
Leptin mRNA 2.92±1.12 2.94±0.97 2.23±2.23 
Adiponectin 
mRNA 
0.94±0.29 1.17±0.26 0.82±0.38 
L/A ratio mRNA 3.16±1.34 2.57±0.89 2.34±1.22 
Combined exercise group 
Leptin mRNA 2.64±2.34 2.59±1.58 1.95±1.67 
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Adiponectin 
mRNA 
0.88±0.35 0.99±0.37 0.68±0.42 
L/A ratio mRNA 2.79±1.92 2.54±0.89 2.81±1.61 
Control group 
Leptin mRNA 3.86±3.73 3.68±2.75 2.62±1.92 
Adiponectin 
mRNA 
1.35±0.35 1.39±0.36 1.12±0.24 
L/A ratio mRNA 2.81±2.67 2.90±2.83 2.28±1.33 
L/A: Leptin to adiponectin. 
 
 
8.4. DISCUSSION
The primary aim of the present study was to examine the effects of different types of 
exercise and de-training on leptin mRNA of subcutaneous adipocytes in healthy 
untrained men. No effects of exercise and de-training on the mRNA of leptin were 
found neither in the entire sample size nor in the high responders not only to the 
exercise stimuli, but also to the de-training period. Previous evidence showed that the 
reduction of circulating leptin concentrations in response to exercise is usually 
accompanied by a reduction in fat mass [120, 141, 144]. The fat mass of the 
participants did not alter in response to exercise and de-training in the current study 
and thus, this may explain, at least in part, the non-alteration of leptin mRNA. Also, 
previous data from a human study showed that caloric intake restriction in conjuction 
with a 2-month exercise programme decreased circulating leptin as opposed to either 
caloric intake restriction or exercise alone [147]. The participants of the current study 
did not follow a caloric restriction neither during the exercise programme nor during 
the de-training period, and this may also explain the non-alteration of leptin mRNA.  
 Even though statistically insignificant, the leptin mRNA tended to increase in 
response to exercise in AEG and to decrease in response to de-training in the exercise 
groups in the current study. This was also depicted by the effect size analyses that 
showed a small effect size in AEG between baseline and post-exercise (the leptin 
mRNA was increased) and effects sizes in the exercised groups between post-
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exercise and de-training (the leptin mRNA was decreased). The odd finding of 
increased leptin mRNA in WAT after a physical activity intervention was previously 
reported by a RCT. In this study, even though the circulating leptin concentrations 
were decreased in response to the six month physical activity intervention, the leptin 
mRNA in WAT was increased in sedentary healthy overweight adults [399]. The latter 
was also observed in an animal study [400]. A possible explanation is that post 
transcriptional regulations of the leptin mRNA may not have allowed a natural 
prediction of circulating leptin [399]. Therefore, both mRNA and circulating protein 
concentrations measurements would probably have formed a firm conclusion in the 
current study.  
A secondary aim of the current study was to examine the effects of different 
types of exercise and de-training on the adiponectin and L/A ratio mRNAs of 
subcutaneous WAT in healthy untrained men. No effects of exercise and de-training 
on the adiponectin and L/A ratio mRNAs of subcutaneous WAT were found in the 
entire sample however, the adiponectin mRNA was significantly decreased in 
response to de-training in the high responders to the de-training in the CEG. Also, 
even though statistically insignificant, the adiponectin mRNA was increased in 
response to resistance exercise and decreased in response to de-training in all the 
exercise groups in the current study. Evidence from a study in rats also showed that 
a 10-week aerobic exercise increased adiponectin mRNA in adipose tissue [401]. 
Therefore, the trend of increased adiponectin mRNA in response to exercise and 
decreased in response to de-training may represent a normal trend in the current 
study, given that chronic exercise may increase circulating adiponectin concentrations 
[13, 395, 396]. Low circulating adiponectin concentrations are associated with 
increased appetite [120] and high circulating adiponectin concentrations may enhance 
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insulin sensitivity [156, 284].  Furthermore, previous evidence showed that long-term 
exercise increased circulating adiponectin concentrations in healthy obese men [13, 
395] and postmenopausal women [396].  
The effect size analyses in the current study showed a decrease of the L/A ratio 
mRNA in response to resistance exercise and an increase in response to de-training 
in the AEG. The L/A ratio can be used to identify insulin resistance in T2D patients 
[397]. Increased L/A ratio may indicate increased atherosclerosis and glycated 
haemoglobin, which is an index of increased insulin resistance [397, 398]. There is no 
enough evidence however, to determine a role of L/A ratio in the current study, and 
instead the trend of the values is reported.  
The results regarding the VO2peak alterations as well as the limitations of the 
current study are identical to the 3rd study of this PhD and they are discussed in details 
on pages 157-159. The current study did not use a priory power calculation to 
determine the sample size, given that this RCT is a part of the third RCT study of this 
PhD. A post measurements power calculation was conducted using an online software 
(DSS Research) to test statistical power based on the baseline leptin mRNA 
expression values (2.85±2.24) of the overall sample of the current study that 
demonstrated at least a sample size of 10 participants per group. Therefore, given the 
sample size of this study the statistical power was 72%. 
  
8.5. CONCLUSIONS 
Based on the statistical analysis, different types of chronic exercise and de-training do 
not affect mRNA of leptin, adiponectin genes and L/A ratio of subcutaneous WAT in 
healthy untrained men. There is a trend of adiponectin mRNA to be increased, in 
response to resistance exercise and to be decreased in response to de-training. There 
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is also a trend of L/A ratio mRNA to be decreased, in response to resistance exercise 
and to be increased in response to de-training. Future studies should increase sample 
sizes and investigate these phenomena. 
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9. CHAPTER 9: GENERAL DISCUSSION 
This PhD study aimed to investigate both the relationship of physical activity to 
browning formation of WAT as well as the effects of different exercise programmes on 
browning formation of subcutaneous WAT in humans using mRNA and protein 
expression mesurements of genes involved in this process. It also aimed to examine 
the effects of exercise on leptin and adiponectin mRNAs of WAT in humans. The 
approach was to analyse the mRNA and protein expression of several genes through 
subcutaneous adipose tissue samples obtained via biopsies.  
This PhD thesis consists of four studies. The first study is a systematic review 
conducted to identify evidence regarding the effects of physical activity on the brown-
like formation of WAT in humans. In the second study, 46 healthy men were recruited 
to identify associations of the mRNA and protein expression of genes that indicate 
brown-like formation of subcutaneous WAT with physical activity levels. From the 46 
healthy men, a subset of 32 individuals participated in a RCT. This RCT was split into 
two studies. The third study, an examination of the effects of different types of exercise 
and de-training on the UCP1 mRNA and protein expression, and the fourth, an 
examination of the effects of different types of exercise and de-training on the leptin 
mRNA of subcutaneous WAT. 
 
The effects of physical activity on browning formation of white adipocytes: A 
systematic review (1st study) 
The systematic review examined the effects of physical activity on the link between 
PGC-1α and FNDC5 in skeletal muscle, circulating Irisin, and UCP1 of WAT in 
humans. The systematic review found little evidence for the link between PGC-1α and 
FNDC5 in muscle in response to exercise training or increased physical activity levels. 
Also, the methods used for Irisin identification were inaccurate in most cases. Only 
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one study that examined the effects of exercise on UCP1 in WAT was retrieved, which 
found no effect [236]. Previous evidence showed that the FNDC5 mRNA in muscle is 
not regularly increased by exercise or differently regulated between those with and 
without insulin resistance [267]. Also, the antibody used in the initial detection of Irisin 
was made to correspond against the C-terminal of human FNDC5, which is not the 
part of the protein that yields the Irisin peptide [360]. The FNDC5 gene – the precursor 
of Irisin – is mutated in humans due to the non-ATG start codon [274] that questions 
the biological activity of Irisin [274]. Also, the various generations of antibodies used 
for Irisin detection in the ELISA kits yield a protein concentration that appears to be 
~10-100 times greater than newer mass-spectrometry data [276].This evidence may 
explain part or all of the equivocal results of the studies in the systematic review 
regarding both the effects of exercise on the link between PGC-1α and FNDC5 in 
muscle and circulating Irisin. 
Overall, there is little evidence to determine the link between PGC-1α and 
FNDC5 in human muscle in response to physical activity. We cannot form any 
conclusion regarding circulating Irisin in response to physical activity given that the 
methods used for Irisin identification were inaccurate in most cases. Mass 
spectrometry detection of Irisin of exercise effects were compromised by the 
methodological limitations of the existing studies. There was limited evidence on the 
effects of physical activity on UCP1 in WAT.  
  
Association of UCP1 with physical activity levels (2nd study) 
The primary aim of the second study was to examine the associations of the UCP1 
mRNA and protein expression as well as of the mRNAs of PGC-1α, PPARα and 
PPARγ genes that indicate browning formation of subcutaneous WAT with physical 
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activity levels in healthy men. The current study found no associations between the 
mRNA of UCP1, PGC-1α, PPARα and PPARγ genes of subcutaneous WAT with 
physical activity levels. There is only one controlled trial that examined the effects of 
chronic exercise on the UCP1 mRNA of subcutaneous WAT in healthy adults, also 
confirming no effect of exercise on UCP1 mRNA [236]. The first study of this PhD 
(systematic review) also failed to confirm a link between physical activity/exercise with 
a browning formation of WAT in humans. However, the current study revealed an 
inverse association of UCP1 protein expression with physical activity levels rather than 
positive. This finding does not support the hypothesis that UCP1 is increased in 
response to exercise within a white adipocyte that may trigger a browning formation 
of WAT [30]. Also, this finding may explain a recent discovery that UCP1 mRNA in 
subcutaneous WAT was negatively correlated with weight loss – indicating no effect 
of UCP1 on browning formation of WAT – while it was not altered in response to 
exercise in healthy women [368]. Overall, this evidence suggests that the initial 
hypothesis of the current study should be rejected. 
The current study detected positive white adipocytes of the UCP1 gene which 
may indicate a browning formation process of white adipocytes; this however, cannot 
be attributed to physical activity given the lack of relevant associations between 
physical activity levels and UCP1. It was previously suggested that the presence of 
the UCP1 in white adipocytes in animals is dependent on a synergetic interactions 
between selective genes and variations in recessive and dominants genes that affect 
UCP1 gene even though the mechanisms are unknown [371]. It was also 
demonstrated that a subset of the precursor cells in white adipocytes may promote 
rise of brown-like adipocytes that express UCP1 [272].  The mode of the current study 
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could not highlight the latter issues and therefore, the presence of UCP1 in 
subcutaneous fat cells in healthy individuals remains to be elucidated. 
A secondary aim was to examine the associations of UCP1 mRNA and protein 
expression as well as of the mRNAs of PGC-1α, PPARα and PPARγ genes with REE, 
WHR, BMI, age, fat mass, fat-free mass and energy intake. The study found an inverse 
association of PGC-1α mRNA with BMI, WHR and fat mass percentage and a positive 
association with fat-free mass. Fat-free mass is positively associated with REE in 
humans [374], which indicates increased demands of energy, while PGC-1α is highly 
expressed in tissues that demand energy [226]. Indeed, REE is highly dependent on 
the amount of fat-free mass in both men and women [375, 376]. This is because the 
fat-free mass is the most proportional tissue in human body compared to fat mass 
[377] and it includes skeletal muscles, which demand high amounts of energy [378]. 
PGC-1α is responsible for mitochondrial biogenesis [171] and it is positively 
associated with increased REE in mice [379] while it increases fatty acids oxidation 
[372, 373]. Previous evidence showed that when a browning process occurs in WAT 
in response to exercise this lead to increased REE in mice [380]. Also, physical activity 
levels are positively associated with REE in humans [68]. However, we found no 
association of PGC-1α mRNA with physical activity levels that may explain why PGC-
1α and REE have no relationship in the current study. Finally, regarding the inverse 
association of PGC-1α mRNA with fat mass, this is probably because PGC-1α is 
involved in oxidative phosphorylation and fatty acid oxidation that regulate lipid 
metabolism and lessen insulin resistance in mice [382]. 
An inverse association between PPARα mRNA with BMI, WHR and fat mass 
percentage was also found. PPARα is responsible for the activation of several genes 
to regulate lipid metabolism [247]. In specific, it increases ketogenesis and 
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subsequently the uptake of fatty acids, ameliorates beta oxidation in mitochondria and 
increases triglyceride uptake [247]. Therefore, it triggers lipid catabolism in WAT and 
this may explain its inverse association with BMI, WHR and fat mass percentage we 
found in the current study.  
It is concluded that UCP1 protein expression is negatively associated with 
physical activity levels while UCP1 mRNA and protein expression are not linked with 
body weight (i.e. BMI, WHR, fat mass) and REE, which indicate no browning effect of 
WAT in response to physical activity in healthy men. The mRNA of PGC-1α, PPARα 
and PPARγ genes, that along with UCP1 alterations could indicate a browning 
formation of subcutaneous WAT, are not associated with physical activity levels in 
healthy men. PGC-1α and PPARα mRNAs are negatively associated with increased 
fat mass accumulation parameters (BMI, WHR and fat mass) suggesting a potential 
association between PGC-1α and PPARα with human WAT metabolism. The 
mechanisms of the latter associations remain to be determined.  
 
Effects of exercise and de-training on browning formation in white adipose tissue (3rd 
study) 
The primary aim of this study was to examine the effects of different types of exercise 
and de-training on UCP1 mRNA and protein expression within the subcutaneous WAT 
in healthy untrained men. The statistical analysis revealed no effects of exercise and 
de-training on the UCP1 mRNA and protein expression neither in the entire sample 
size nor in the high responders not only to the exercise stimuli, but also to the de-
training period. This is in accordance with the findings of the first study of this PhD 
thesis (systematic review), even though the available evidence was limited. The 
results in the current study are in accordance with a previous human study that 
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examined the effects of exercise on UCP1 mRNA of subcutaneous WAT that showed 
no effects – even though UCP1 mRNA was increased in response to exercise – in 
both healthy and pre-diabetic individuals [236]. The results are also in accordance with 
a single group design study that showed no effect of exercise on UCP1 mRNA of 
subcutaneous WAT in healthy women [368]. The proposed mechanism that circulating 
Irisin increases the UCP1 within the white adipocytes may be partly dependent on the 
action of PPARα. This is because FNDC5 – the precursor of Irisin – increased PPARα 
mRNA in vitro and pharmacological inhibition by antagonists of PPARα limited the 
action of FNDC5 [30]. In the current study the PPARα mRNA did not alter in response 
to exercise and de-training. This may explain, in part, why UCP1 mRNA and protein 
expression did not also alter. However, UCP1 mRNA and protein expression were 
increased, yet not significantly, in response to aerobic exercise and showed a small 
effect size in the current study. This small effect size in AEG indicates a trend of UCP1 
mRNA and protein expression to be increased in response to aerobic exercise that 
needs further exploration. 
Similar to the second study of this PhD (cross-sectional study) the current study 
also detected positive white fat cells of the UCP1 gene at baseline, post-exercise and 
de-training. The presence of UCP1 in subcutaneous WAT could be dependent on a 
synergetic interaction between selective genes and variations in recessive and 
dominants genes [371] as well as in precursor cells in WAT that may promote rise of 
brown-like adipocytes that express UCP1 [272]. In this light, the presence of UCP1 in 
subcutaneous fat cells after an exercise programme and a de-training period that was 
detected by the current study remains to be elucidated. 
A secondary aim of the current study was to examine the effects of different 
types of exercise and de-training on the mRNA of the PGC-1α, PPARα and PPARγ 
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genes that along with UCP1 alterations could indicate browning formation of 
subcutaneous WAT in healthy untrained men. The statistical analysis revealed no 
effects of exercise and de-training on the mRNA of the PGC-1α, PPARα and PPARγ 
genes neither in the entire sample size nor in the high responders not only to the 
exercise stimuli, but also to the de-training period. Recent evidence has shown that 
PGC-1α increased in subcutaneous WAT of mice in response to chronic exercise 
[380]. In this study the thermogenic capacity of the animals was also tested and 
showed increased body heat temperature during the day/night cycle, along with 
increased energy expenditure [380]. Therefore, PGC-1α was proposed to cause a 
browning formation of WAT that increases energy expenditure [380]. In the current 
study, PGC-1α mRNA did not alter while REE has not been significantly changed 
throughout the experimental protocol.  
The mRNA of PPARα and PPARγ genes did not change significantly 
throughout the experimental protocol. Regarding PPARγ mRNA a moderate and a 
small effect sizes – values increased – were detected between baseline and post-
exercise in REG and in CEG, respectively. This indicates a trend of increasing PPARγ 
mRNA in response to chronic exercise. PPARγ is responsible for the regulation of fatty 
acid storage and glucose metabolism [254] and it is increased in adipose tissue in 
response to high fat diet [259]. PPARα increases lipid metabolism [246], is involved in 
mitochondrial fatty acid beta oxidation [247] and regulates the liver to increase fatty 
acid oxidation in response to fasting [247]. Neither the fat mass nor the diet of the 
participants in the current study were changed in response to exercise and de-training, 
indicating that the action of PPARα and PPARγ was not necessary. 
It is concluded that different types of chronic exercise and de-training do not 
affect the UCP1 mRNA and protein expression of subcutaneous WAT in healthy 
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untrained men. In addition, no alterations of body weight and REE in response to 
exercise were found, which potentially means that there is no link between UCP1 and 
body weight/REE that could designate a browning effect on WAT. There is a trend of 
UCP1 mRNA and protein expression to be increased in response to aerobic exercise, 
which may indicate a thermogenic function and a browning process of WAT in healthy 
men. The study found positive UCP1 subcutaneous fat cells, which cannot be fully 
attributed to exercise stimuli. There is also a trend of PPARγ mRNA to be increased 
in response to both resistance and combined (aerobic+resistance) exercise. This 
indicates increased lipid metabolism and fatty acid beta oxidation. Finally, there is a 
trend of PPARγ mRNA to be decreased in response to de-training. This indicates a 
decline lipid metabolism and fatty acid beta oxidation. 
 
Effects of exercise and de-training on leptin mRNA in white adipose tissue (4th study) 
The primary aim of the fourth study was to examine the effects of different types of 
exercise and de-training on leptin mRNA of subcutaneous adipocytes in healthy 
untrained men. No effects of chronic exercise and de-training on the mRNA of leptin 
were found neither in the entire sample size nor in the high responders not only to the 
exercise stimuli, but also to the de-training period. Previous evidence showed that the 
reduction of circulating leptin concentrations in response to exercise is usually 
accompanied by a reduction in fat mass [120, 141, 144]. The fat mass of the 
participants did not alter in response to exercise in the current study and thus, this may 
explain, at least in part, the non-alteration of leptin mRNA. Also, previous data from a 
human study showed that caloric restriction in conjuction with a 2-month exercise 
programme decreased circulating leptin as opposed to either caloric restriction or 
exercise alone [147]. The participants of the current study did not follow a caloric 
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restriction neither during the exercise programme nor during the de-training period, 
and this may also explain the non-alteration of leptin mRNA. 
A secondary aim of the current study was to examine the effects of different 
types of exercise and de-training on the adiponectin and L/A ratio mRNAs of 
subcutaneous WAT in healthy untrained men. No effects of exercise and de-training 
on the adiponectin and L/A ratio mRNAs of subcutaneous WAT were found in the 
entire sample size however, the adiponectin mRNA was significantly decreased in 
response to de-training in the high responders to de-training in the CEG. Also, the 
adiponectin mRNA was increased in response to resistance exercise, yet not 
significanlty. The effect size analysis showed a large effect size in the REG and a small 
effect size in the CEG between baseline and post-exercise. This is in accordance with 
previous evidence showed that chronic exercise increased circulating adiponectin 
concentrations in healthy obese men [13, 395] and postmenopausal women [396]. The 
adiponectin mRNA was decreased in response to de-training in the AEG and CEG in 
the current study, yet not significantly. The effect size analysis showed a large effect 
size in REG and a moderate effect size in AEG and CEG between post-exercise and 
de-training. These findings may represent a normal trend, given that chronic exercise 
may increase circulating adiponectin concentrations [13, 395, 396]. Low circulating 
adiponectin concentrations are associated with increased appetite [120] and high 
circulating adiponectin concentrations may enhance insulin sensitivity [156, 284].  
The L/A ratio can be used to identify insulin resistance in T2D patients [397]. 
Increased L/A ratio may indicate increased atherosclerosis and glycated haemoglobin, 
which is an index of increased insulin resistance [397, 398]. The effect size analyses 
in this study showed a decrease of the L/A ratio mRNA in response to resistance 
exercise and an increase in response to de-training in the AEG. However, there is no 
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enough evidence to determine a role of L/A ratio in the current study, and instead the 
trend of the values is reported. 
It is concluded that different types of chronic exercise and de-training do not 
affect mRNAs of leptin, adiponectin genes and L/A ratio of subcutaneous WAT in 
healthy untrained men. There is a trend of adiponectin mRNA to be increased, in 
response to resistance exercise and to be decreased in response to de-training. There 
is also a trend of L/A ratio mRNA to be decreased, in response to resistance exercise 
and to be increased in response to de-training. Future studies should increase sample 
sizes and investigate these phenomena. 
 
Overall perspective 
The recent discovery of active BAT in adult humans suggested a potential contribution 
of this tissue on human REE [22]. It was suggested that 100 gr of a single BAT depot 
has a rate of 12.2 μmol of glucose uptake per minute, which during a year period could 
spend energy equal to the energy capacity of 4 kg of WAT [22]. Given also that NST 
in humans could elevate the daily REE for 25-28% after chronic cold exposure [174, 
366], we could hypothesize that in a total of 1500 kcal of daily REE, BAT activity could 
contribute an additional of 375-420 kcal/day. However, this would be a contribution of 
BAT to REE under cold exposure, while there is no evidence in humans to support 
BAT’s contribution to REE under thermoneutral conditions. In this light, the 
thermogenic capacity of BAT in response to exercise also remains unknown. On the 
other hand, brown-like adipose tissue seems to not have the same thermogenic 
capacity and can display only 10% of BAT’s thermogenic capacity based on the 
hypothesis that the amount of the UCP1 protein expression that is displayed in brown-
like adipocytes is significantly lower than the one of brown adipocytes [304]. This 
194	
	
represents a brown-like adipose tissue contribution to daily REE of 37.5-42 kcal/day 
in the aforementioned example. However, this would also be a contribution of brown-
like adipose tissue to REE under cold exposure, while at the moment there is no 
evidence to show differences in the thermogenic capacity between brown and brown-
like adipocytes in humans. Based on the results of the current PhD study it seems that 
exercise cannot increase the thermogenic capacity of WAT in humans while there is 
no link between the thermogenic capacity of white adipocytes and REE. Finally, the 
current PhD, showed positive UCP1 white adipocytes and a trend of both UCP1 mRNA 
and protein expression to be increased in response to aerobic exercise. Whether this 
UCP1 trend could contribute to daily REE in humans should be explored by future 
studies.  
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10. CHAPTER 10: LIMITATIONS 
The limitations of the current PhD study are: 
v In the systematic review only included published literature; grey literature was 
excluded. There is a potential of publication bias towards peer-reviewed work, 
but the inclusion of grey literature may itself introduce bias. One reason to 
include grey literature would be the absence of peer-reviewed sources [365]. 
v In the systematic review, the secondary outcomes that indicate no positive 
relationship between Irisin and several health indices were derived from the 
included studies. These examined the effects of physical activity on Irisin. 
However, Irisin may have a physiological role in the human body independently 
of physical activity, therefore, the current systematic review may not be 
representative enough to determine the relationship between Irisin and health 
indices. 
v Only men participated in all the experimental studies, so gender differences 
could not be determined. 
v There was no priory power calculation for the second (cross-sectional) and the 
forth (RCT) studies. 
v Apart from UCP1, in all the experimental studies, only mRNAs were measured. 
Protein expressions should have also been required to determine the 
physiological function of the genes examined.  
v In the third study (RCT), Irisin was not assessed in relation to exercise and its 
association with the genes was not examined. The initial plan was to measure 
circulating Irisin. That is why, blood samples were retrieved from the 
participants. However, while this study was conducted, new evidence revealed 
that the ELISA kits used for Irisin identification gave neither valid nor accurate 
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data. Given that there was no alternative method within our laboratory, the Irisin 
identification in blood samples was omitted. 
v In the RCT (third, fourth studies), the chronic exercise programmes followed 
previous research and were set at a specific intensity (65% VO2peak, 1RM). 
The effects of various intensities on the genes examined could not be tested. 
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11. CHAPTER 11: SUGGESTIONS FOR FUTURE RESEARCH 
The results of the first study, the systematic review, suggest that future RCTs should 
examine the link between PGC-1α and FNDC5 within the skeletal muscle in humans 
in response to physical activity. In this regard, the differences between young and 
older individuals as well as between healthy and patients should be explored given 
that previous evidence showed that the FNDC5 mRNA in muscle is expressed more 
in older than in younger individuals and it is differently regulated between those with 
and without insulin resistance [267]. In addition to that, future studies must re-examine 
the biological role of Irisin using accurate and valid methods for its analysis. Indeed, 
the recent evidence via mass spectrometry – the gold standard method for circulating 
Irisin measurements nowadays – indicates that Irisin is increased in response to 
exercise [270, 276]. However, these existing studies display several methodological 
limitations (i.e. post hoc measurements, no control) that do not allow for clear 
concusion to be drawn. Therefore, future studies should explore this further in humans, 
and also need to take into consideration the type and intensities of exercise that may 
play a role in exercise-induced Irisin changes [266, 337, 339]. In line with this, the role 
of human Irisin on insulin sensitivity and glucose uptake should also be explored given 
that the potential of Irisin function is to improve health mainly via an improvement in 
insulin sensitivity [30]. Futhermore, the link between circulating Irisin and white 
adipocytes should be investigated, given that the receptor that Irisin was proposed to 
attach to the surface of white adipocytes is unknown and thus, the biological activity 
of the protein cannot be fully determined.  
The third study of this PhD indicates that UCP1 mRNA and protein expression 
are not positively linked with physical activity/exercise. Even though one previous 
single group design study [368], one previous controlled trial [236] and the current 
PhD/RCT study showed no effect of exercise on UCP1 of WAT in healthy individuals, 
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two out of the three studies showed a trend of increased UCP1 in response to aerobic 
exercise. To the best of our knowledge these are the only studies that examined this 
mechanism in humans and only one of them is a RCT. Therefore, future studies should 
use the methodological limitations provided within these studies to develop robust 
methodologies to investigate these phenomena. Also, according to the available 
evidence the link between Irisin and UCP1 is not well-established and therefore, the 
possibility of UCP1 to be altered within the human WAT in response to exercise but, 
not in response to Irisin should be also investigated. This however, implies that 
important confounding factors (e.g. cold exposure, warm environment) should be 
taken into consideration given that UCP1 is altered in WAT in response to different 
ernvironmental conditions [304]. In addition, in the current PhD/RCT the UCP1 mRNA 
and protein expression were examined only in response to exercise at 65% of 
VO2peak and 1 RM. In this light, more studies are needed to explore the effects of 
different types and intensities of exercise on UCP1 of WAT given the lack of evidence 
in humans.  
Brown-like adipocytes may display a thermogenic capacity lower than the one 
of brown adipocytes however, this suggestion was based on the hypothesis that the 
amount of the UCP1 protein expression that is displayed in brown-like adipocytes is 
significantly lower than the one of brown adipocytes [304]. Therefore,  further studies 
may also be needed to explore the role of UCP1 positive cells in WAT and the 
thermogenic capacity of these cells compared to the thermogenic capacity of brown 
adipocytes in humans considering different stimuli (e.g. exercise, cold exposure). This 
would highlight any potential contribution of brown-like adipocytes on REE and 
whether this could help towards body weight loss and subsequently to lessen obesity 
in humans. Regarding the third study of this PhD, future research projects are required 
199	
	
to examine the full mechanism that exercise may cause transformation of white 
adipocytes into brown-like adipocytes. This would include muscle biopsies to 
determine any link between PGC-1α and FNDC5, accurate measurements of 
circulating Irisin to determine any link with FNDC5 and adipose tissue biopsies to 
determine any link between circulating Irisin and UCP1. 
Previous evidence showed that after four weeks of cold exposure, UCP1 was 
increased in subcutaneous WAT of mice, which subsequently increased 
hyperlipidemia that could develop atherosclerotic plaques [402]. Given that physical 
activity/exercise can reduce the risk for atherosclerosis in humans [403], the role of 
physical activity/exercise on UCP1 in subcutaneous WAT should be explored in 
combination with any potential effect of UCP1 on atherosclerosis. Furhtermore, 
specific UCP1 gene polymorphisms (i.e. A-3826G, A-1766G, A-112C, Ala64Thr) may 
promote the development of cardiovascular disease in humans including T2D [404], 
while T2D in humans is positively associated with the environmental temperature 
[405]. In this light, an examination of the associations of the UCP1 gene 
polymorphisms with cardiovascular disease and physical activity levels could add 
important information to our existing knowledge around this field.  
The second study of this PhD suggests that the role of PGC-1α, PPARα and 
PPARγ genes in human metabolism should be further explored independently of their 
potential synergetic action with UCP1 towards the browning formation of WAT. More 
specifically, the effects of the function of these genes on body weight, fat mass and 
REE should be explored given the potential of these genes to increase fatty acid 
oxidation. This however, should be investigated in combination with diet given that 
PPARα and PPARγ are nuclear receptors for fat vitamins, steroid hormones, and 
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sterols [247, 248]. Overall, this could highlight potential mechanisms that could help 
towards body weight loss in humans.    
The forth study of this PhD showed no effect of different types of exercise on 
leptin mRNA. This has been examined to identify potential links of leptin with browning 
formation of WAT given that leptin is suppressed in response to cold exposure [134], 
SNS activation and norepinephrine production [122, 123]. Also, Bostrom et al. (2012) 
showed that leptin mRNA is downregulated by UCP1 in human white adipocytes [30]. 
This evidence indicates an inverse relationship between leptin and brown/brown-like 
adipose tissue activity, which needs to be further explored, given that leptin is a key 
regulator in WAT function. In this PhD/RCT study, only leptin mRNA was examined 
and the function of circulating leptin has not been determined in response to chronic 
exercise. Therefore, more experiments are needed to define the role of leptin mRNA 
and circulating leptin during a potential browning formation of WAT.   
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13. APPENDICES 
13.1. APPENDIX 1: Ethical approval from the University of Wolverhampton 
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13.2. APPENDIX 2: Ethical approval from the University of Thessaly 
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13.3. APPENDIX 3: Written consent form 
 
(The form was supplied in Greek due to the participants were Greek citizens) 
Written informed consent form 
Title of the study: The effects of prolonged exercise on brown-like tissue formation 
in humans 
Scientific responsible-advisor: Yiannis Koutedakis PhD, Professor in Applied 
Physiology (Tel. 2431047056, email: y.koutedakis@uth.gr)  
Scientific Advisor: Andreas Flouris PhD, Researcher in Environmental Physiology 
(Tel. 2431500601, email: aflouris@cereteth.gr)  
Researcher: Petros Ntinas (Tel.6974010118, email: petros.cd@gmail.com) 
1. Aim of the study 
The aim of the study is to identify the secretion of the protein irisin in the circulation 
across different types of chronic exercise. A secondary aim is to confirm the presence 
or absence of transformed white adipocytes to brown-like adipocytes by examining the 
presence or absence of Uncoupling Protein 1 through subcutaneous white adipose 
tissue biopsies. Another aim is to assess the relationship between the sympathetic 
nervous system (SNS) activity and irisin levels by assessing heart rate variability.   
2. Procedure  
As soon as you sign the present manuscript given your consent to participate in the 
study, you will be asked to fill via interview a medical history, a short nutrition 
questionnaire and two short physical activity questionnaires. Then, you will be 
randomised to be included in one of the following groups: 1) An aerobic exercise group 
which will perform a 2-month of an aerobic exercise protocol that will start from 20 min 
at 60% of your maximum oxygen consumption and will lead to 60 min at 70% of your 
maximum oxygen consumption. The exercise sessions will be performed 3-5 times 
per week. 2) A resistance exercise group which will perform a 2-month of resistance 
exercise protocol aiming to muscle hypertrophy, 3-5 times per week at 60-70% of your 
1 repetition maximum (your maximum strength). 3) A combined exercise group 
(aerobic and resistance) which will perform a 2-month of a combined (aerobic and 
resistance) exercise protocol. Aerobic exercise will start from 20 min at 60% of your 
maximum oxygen consumption and will lead to 60 min at 70% of your maximum 
oxygen consumption. Resistance exercise will aim to muscle hypertrophy and will be 
at 60-70% of your 1 repetition maximum (your maximum strength). The exercise 
sessions will be performed 3-5 times per week. 4) A control group which will not 
perform any exercise.  
 After the exercise period all groups will not follow any exercise programme for 
2 more months as a de-training period. During both exercise and de-training period (4-
month period) you will be asked to give 20-30 ml of blood 4 times (Baseline, 1st, 2nd, 
and 4th month). Additionally, you will be asked to apply a recorder (stop watch) Polar 
RS800CX as to measure heart rate variability 4 times (Baseline, 1st, 2nd, and 4th 
month). Furthermore, you will be asked to apply a mask of a VO2 analyser to measure 
your basal metabolic rate 4 times (Baseline, 1st, 2nd, and 4th month). Additionally, you 
will undergo 4 times (Baseline, 1st, 2nd, and 4th month) a maximal oxygen consumption 
test and a 1 repetition maximum test (your maximum strength). The latter tests will be 
done to determine the exercise intensity that you will follow in the exercise programme 
and to determine your progress in your aerobic capacity and strength. Finally, you will 
be asked to provide diet recalls, your physical activity levels that you will obtain via a 
pedometer, anthropometry measurements (height, weight, blood pressure) and body 
composition measurements during the baseline week and 1st, 2nd, and 4th month. 
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3. Dangers and Annoyances 
There is a risk of skin irritation from the needle injection during the blood sample 
collection. We inform you that all blood samples will be collected by a certified 
Phlebotomist to minimize the risk of any discomfort. White adipose tissue biopsies 
might cause an irritation on the skin by the injection of the scalpel. There is also a 
small possibility to be remained in the area a small scar. Furthermore, if you do not be 
aware that you have an allergy in the local anaesthetic (xylocaine) that will be used in 
the biopsy procedure there is a risk of an allergic reaction. Please note that fat biopsy 
procedures will be performed by a certified Physician to minimize the risk of any 
discomfort. There is a risk of injury during the 1 repetition maximum (1RM) test. Before 
the 1RM test you will perform a 10-min warm up to minimize any injury risk. In this 
light, before a 1RM test you will be given full instruction by the main researcher and 
you will perform tests in terms of the correct techniques that you will use in the 1RM 
test as to minimize any injury risk. Moreover, there is a risk of injury during the exercise 
period. However, you will be giving full instructions by experts regarding safe exercise 
techniques as to minimize the risk of any injury. 
4. Potential Benefits 
By participating in the study you will receive information regarding your fitness level, 
your physical activity levels, and your nutrition habits. Moreover, you will benefit the 
positive effects of a chronic exercise programme. This study will help us to better 
understand the effects of chronic exercise on the action of the protein irisin which may 
affect brown adipose tissue. This would be a crucial information due to activity of brown 
adipose tissue may increase human body energy expenditure with a potential effect 
on weight loss.   
5. Data Publication  
By participating in the study implies that you agree with a future publication of its 
results in the precondition that your name will not be appearing anywhere. Your 
personal data will be coded as your name will not be appearing anywhere.   
6. Information 
Please do not hesitate to ask about the aim of the study and/or the procedure of the 
study. If you have any doubt or question please inform us to define them.  
7. Freedom Consensus   
Your participation is volunteered. You are free to not consent or to stop you 
participation in the study at any time.  
8. Declaration of Consent  
I have read this manuscript and I completely understand the whole procedure. I 
declare that I consent to participate in the study.  
Date:   /   /     
Participant’s full name       Researcher’s signature                      Observer’s signature 
and signature                    
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13.4. APPENDIX 4: Medical history form (by interview) 
 
Medical History Form 
 
Name: ____________________________ Date: __/ __/ ____ Date of Birth: __/ __/ ____ 
  DD MM YYYY  DD MM YYYY 
 
PRESENT STATUS: 
1. Are you in good health at the present time to the best of your knowledge?   Yes     No   
    If you answered “No”, please explain: 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
2. Are you under a doctor's care at the present time?   Yes     No  
    If you answered “Yes”, please explain: 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
3. Are you taking any medications at the present time?   Yes     No  
    If you answered “Yes”, please explain: 
Prescription Drugs (list all): 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
Dosage: 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
 
 
4. Are you taking any over the counter medications, vitamins, supplements?   Yes     No  
    If you answered “Yes”, please explain: 
Name (list all): 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
Dosage: 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
________________________________ 
 
5. Do you have a history of high blood pressure?    Yes     No  
6. Do you have a history of diabetes?      Yes     No  
7. Do you have a history of heart attack, chest pain, or other heart condition?   Yes     No  
8. Do you have a history of swelling of feet?     Yes     No   
9. Do you have a history of vascular disease?                 Yes     No   
10. Do you have a history of frequent headaches?    Yes     No  
11. Do you have a history of frequent migraines?                Yes     No  
12. Do you have a history of constipation?     Yes     No  
13. Do you have a history of glaucoma?                   Yes     No  
14. Do you have a history of sleep apnoea?     Yes     No  
15. Do you have a history of dyslipidemia?     Yes     No  
16. Do you have a history of elevated triglycerides?    Yes     No  
17. Do you have a history of elevated fasting glucose?       Yes     No  
18. Do you have a history of metabolic syndrome?    Yes     No  
19. Do you have a history of kidney disease?     Yes     No  
20. Do you have a history of joint pain/weakness?    Yes     No  
21. Do you have a history of muscle pain/weakness?    Yes     No  
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22. Do you have a history of thyroid disease?                      Yes     No  
23. Do you have a history of immunological disease?    Yes     No  
24. Do you have a history of cancer?                    Yes     No  
25. Do you have a history of alcohol abuse?     Yes     No  
26. Do you have a history of drug abuse ?                 Yes     No  
26A. Do you have a history of Blood Coagulation Disorders?  Yes     No  
26B. Do you have a history of hepatitis?                                    Yes     No  
26C. Do you have a history of immunosuppression?                 Yes     No  
26D. Do you have a history of malignant hyperthermia?           Yes     No  
27. Do you have a history of smoking?                        Yes     No  
    If you answered “Yes”, please state the average number of packs you smoke per day: _______ 
 
    If you answered “Yes”, please state the number of years that you smoke or used to smoke: _______ 
28. Are you a current smoker?               Yes     No  
29. Do you use any other form of tobacco? Yes     No  
    If you answered “Yes”, please explain: 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
30. Do you have a history of serious injuries?   Yes     No  
    If you answered “Yes”, please list all with dates: 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
31. Do you have a history of surgeries?   Yes     No  
    If you answered “Yes”, please list all with dates: 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
WEIGHT INFORMATION: 
32. What is your desired weight? __________ (kg) 
33. What is your maximum lifetime weight (non-pregnant)? __________ (kg) 
34. What was your weight one year ago? __________ (kg) 
35. What was your weight at age 20? __________ (kg) 
36. What was your birth weight? __________ (kg) 
 
EARLY LIFE INFORMATION 
37. Where were you born?      ______________________     _________________     __________________ 
              Village/Town   Closer City                 Country 
 
38. How old was your mother when you were born?    _____________ 
 
39. How old was your father when you were born?    _____________ 
 
40. How many months did you breastfeed for?    _____________ 
 
 
FAMILY 
HISTORY Age Disease  
If deceased, state 
cause of death 
   
Father    Overweight?   Yes     No   
Mother    Overweight?   Yes     No  
Brothers    Overweight?   Yes     No  
    Overweight?   Yes     No  
    Overweight?   Yes     No  
    Overweight?   Yes     No  
    Overweight?   Yes     No  
Sisters    Overweight?   Yes     No  
    Overweight?   Yes     No  
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    Overweight?   Yes     No  
    Overweight?   Yes     No  
    Overweight?   Yes     No  
 
Do you have any blood relatives had any of the following (and who): 
    Relationship 
Glaucoma  Yes     No     Don’t know   
Asthma Yes     No     Don’t know   
High blood pressure Yes     No     Don’t know   
Kidney disease Yes     No     Don’t know   
Diabetes Yes     No     Don’t know   
Heart disease Yes     No     Don’t know   
Dyslipidemia Yes     No     Don’t know   
Elevated triglycerides Yes     No     Don’t know   
Elevated fasting glucose Yes     No     Don’t know   
Metabolic syndrome Yes     No     Don’t know   
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13.5. APPENDIX 5: International Physical Activity Questionnaire 
 
(The questionnarie was supplied in a valid Greek version due to the participants 
were Greek citizens) 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives.  The questions will ask you about the time you spent being 
physically active in a usual week.  Please answer each question even if you do not 
consider yourself to be an active person.  Please think about the activities you do at 
work, as part of your house and yard work, to get from place to place, and in your 
spare time for recreation, exercise or sport. 
Think about all the vigorous activities that you did in a usual week.  Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe 
much harder than normal.  Think only about those physical activities that you did for 
at least 10 minutes at a time. 
1. During a usual week, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling?  
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
2. How much time did you usually spend doing vigorous physical activities on one of 
those days? 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
Think about all the moderate activities that you did in a usual week.  Moderate 
activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal.  Think only about those physical activities that you did 
for at least 10 minutes at a time. 
3. During a usual week, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles tennis?  
Do not include walking. 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
4. How much time did you usually spend doing moderate physical activities on one of 
those days? 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
Think about the time you spent walking in a usual week.  This includes at work and 
at home, walking to travel from place to place, and any other walking that you might 
do solely for recreation, sport, exercise, or leisure. 
5. During a usual week, on how many days did you walk for at least 10 minutes 
at a time?   
_____ days per week 
  
   No walking     Skip to question 7 
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6. How much time did you usually spend walking on one of those days? 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
The last question is about the time you spent sitting on weekdays during a usual week.  
Include time spent at work, at home, while doing course work and during leisure time.  This 
may include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to 
watch television. 
7. During a usual week, how much time did you spend sitting on a week day? 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
This is the end of the questionnaire, thank you for participating. 
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13.6. APPENDIX 6: Physical activity readiness questionnaire 
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13.7. APPENDIX 7: Representative photographic film images of UCP1 protein 
expression quantification 
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13.8. APPENDIX 8: Publications 
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On a global scale, the most recent evidence indicates that over 400 million adults are obese while ∼20 million children and 1.6
billion adults are overweight.The World Health Organization reveals that, by the year 2015, ∼2.3 billion adults will be overweight
and more than 700 million will be obese. In this review paper we summarized the current evidence to elucidate the impact of
exercise training on biological and psychological health indices in overweight and obese individuals. Endocrine function indices
that are discussed herein include leptin, adiponectin, growth hormone, and ghrelin levels. Psychological factors include anxiety and
depression, body image, and motivation for exercise. Overall, exercise promotes physical and psychological health in overweight
and obese individuals particularly because exercise-induced adaptations occur across a multitude of systems within the active
human. The impact of exercise on specific biological and psychological health indices contributes to overall health in overweight
and obese individuals.
1. Introduction
Increased adiposity and physical inactivity have been identi-
fied as harmful health indices [1]. It has been widely acknowl-
edged that obesity leads to health problems such as cardiovas-
cular disease, type 2 diabetes, and hypertension [2, 3]. On a
global scale, the most recent evidence indicated that over 400
million adults are obese while ∼20 million children and 1.6
billion adults are overweight [2]. An unpleasant estimation by
theWorld Health Organization revealed that by the year 2015∼2.3 billion adults will be overweight and more than 700
million will be obese [2]. Thus, it is necessary to establish
practical/cost effective strategies as well as update and renew
current health initiatives, such as physical activity participa-
tion, that will lessen the risk of weight gain and disease in
overweight and obese populations.
It is well known that physical activity contributes, at least
in part, to a healthy quality of life [4]. Indeed, compelling
evidence supports that cardiorespiratory fitness (an objective
measure of habitual physical activity) is an independent pre-
dictor of all-cause and cardiovascular disease mortality [5].
Specifically, recent evidence indicates that individuals with
the highest level of physical activity had a greater total life
expectancy compared to individuals with low physical activ-
ity participation [6, 7]. Conversely, physical inactivity has
been linked to a plethora of health conditions such as type
2 diabetes [2] and has been identified as a greater risk for
morbidity and mortality than a large adipose tissue mass [8].
In this light, it is essential to constantly monitor rele-
vant research, which continues to provide nascent exercise-
induced adaptations that are invaluable for weight manage-
ment, disease prevention, and to establish a high quality of
life.
The aim of this paper was to review and summarize
the current biological and psychological evidence to further
understand the relationship between exercise and health in
overweight and obese individuals.
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